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Chapter 1 
Introduction 
The nephrotic syndrome is a clinical syndrome consisting of proteinuria of at least 3.5 g/day, 
low serum albumin and edema, which is often the presenting symptom. A nephrotic syndrome 
is always caused by a renal disease with glomerular injury. As the presenting features and 
laboratory investigations are not distinctive enough to permit a diagnosis, a renal biopsy is 
necessary to elucidate the underlying glomerular disease. Membranous nephropathy 
(membranous glomerulonephritis) is the most common cause of the nephrotic syndrome in 
adults,1 accounting for about one third of cases. Other causes are minimal change disease, the 
most common cause of a nephrotic syndrome in children, focal segmental glomerulosclerosis 
and membranoproliferative glomerulonephritis. 
 
Membranous nephropathy can be secondary to other diseases, like immune diseases as 
systemic lupus erythematosus (SLE), can be associated with infections, like hepatitis B, can 
be induced by drugs like gold, penicillamine and nonsteroidal anti-inflammatory drugs 
(NSAIDs) or can occur in relation to a malignancy. In about two-thirds of cases, however, no 
obvious etiologic agent or condition can be identified and the disease is called idiopathic. 
 
Most patients with idiopathic membranous nephropathy present with a nephrotic syndrome, 
although proteinuria can be less severe. The natural history of patients with idiopathic 
membranous nephropathy is variable. In general, about half of the patients will develop a 
spontaneous remission of proteinuria, 10% will have persistent (mild) proteinuria and 40% 
will progress to renal insufficiency.2-4  
Multiple risk factors associated with future renal function deterioration have been defined.5 It 
is evident, that a steady rise in serum creatinine is the best predictor of future development of 
end-stage renal disease.3;6;7 Furthermore, the persistence of severe proteinuria has been shown 
to be a prominent risk factor for disease progression,8;9 requiring however a certain time of 
observation. We have previously presented the urinary excretion of the low molecular weight 
protein β2-microglobulin10 and the urinary excretion of IgG11 as promising markers for 
disease progression. 
 
Treatment of patients with membranous nephropathy consists of supportive treatment directed 
at proteinuria or the nephrotic syndrome and specific immunosuppressive therapy. 
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There is little discussion about the so-called conservative treatment of a patient with a 
nephrotic syndrome. This comprises reduction of edema with diuretics and aggressive 
lowering of blood pressure to values below 125/75 mm Hg with the preferential use of ACE-
inhibitors or Angiotensin II type I receptor blockers, because of their additional 
antiproteinuric effects. In addition, lipid lowering agents (statins) are advised for the often 
prominent hypercholesterolemia. In case of a severe nephrotic syndrome one should consider 
the prescription of anticoagulant drugs to prevent thrombo-embolic complications. 
In contrast to the generally accepted conservative treatment policy, there is much debate on 
the need for immunosuppressive agents as well as on which agent should be used in which 
patient at what time point. Some investigators argue against the use of any 
immunosuppressive drug, referring to the benign natural course in most patients.4;12 Others 
have advised treatment of all patients with a membranous nephropathy with 
immunosuppressive agents, like chlorambucil and cyclophosphamide in combination with 
steroids.13-15 Ponticelli and colleagues were the first to document improved renal survival in 
patients with idiopathic membranous nephropathy, treated with a regimen consisting of a six-
months course of alternating cycles of steroids and chlorambucil. In this study, the probability 
of surviving without developing end-stage renal disease was 92% at 10 years in patients 
treated with immunosuppression versus 60% in untreated controls.14 Routine use of this 
treatment, however, would expose 40% of patients unnecessarily to toxic immunosuppressive 
drugs. 
 
 
Outline of the thesis 
The studies presented in this thesis were aimed at defining the optimal treatment strategy for 
patients with idiopathic membranous nephropathy. The studies were designed to demonstrate 
the efficacy and safety of restricting immunosuppressive therapy to patients with idiopathic 
membranous nephropathy at the highest risk for disease progression. Additionally, we have 
validated the value of measuring the urinary excretion of β2-microglobulin and IgG in patients 
with idiopathic membranous nephropathy in predicting prognosis.  
 
We have studied the efficacy and side effects of a 12-months course of oral 
cyclophosphamide with steroids for the treatment of patients with idiopathic membranous 
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nephropathy and deteriorating renal function, thus patients at highest risk for disease 
progression (Chapter 2). Some patients do not respond or relapse after the treatment. In 
Chapter 3, we have documented the efficacy of treating non-responders and relapsing patients 
with repeated courses of immunosuppression and have calculated the time gained before the 
onset of end-stage renal disease. Given the frequent and severe side effects associated with the 
treatment with cyclophosphamide, we have started a pilot study, in 2002, to assess the 
efficacy of mycophenolate mofetil for the treatment of patients with idiopathic membranous 
nephropathy and deteriorating renal function. We report the short-term efficacy and side 
effects, based on the experience in thirteen patients (Chapter 4). 
 
Since 1988, we have advised to restrict immunosuppressive therapy to patients with a 
debilitating persistent nephrotic syndrome or renal function deterioration. To support the 
safety of our restrictive treatment policy we have performed a prospective cohort study which 
included all patients biopsied in the period 1988-2002 with normal renal function at the time 
of renal biopsy. The results of this study are presented in Chapter 5. 
 
To allow starting immunosuppressive therapy before the onset of renal failure, it is essential 
to be able to predict prognosis early in the course of the disease. In Chapter 6 we have 
evaluated the accuracy of the urinary excretion of β2-microglobulin and IgG as parameters 
predicting disease progression in patients with normal renal function. Unfortunately, β2-
microglobulin can only be measured in urine if urinary pH exceeds 6.0. Since this is not the 
case in about 7% of patients, despite the use of sodium bicarbonate, we investigated the value 
of acetazolamide to alkalinize urine in Chapter 7. 
In view of the high predictive value of the urinary excretion of β2-microglobulin and IgG in 
patients with idiopathic membranous nephropathy and normal renal function, we questioned 
the value of measuring these parameters during and at the end of therapy in patients who 
received cyclophosphamide and steroids because of renal function deterioration (Chapter 8). 
 
Based upon our experience and a review of the literature we propose a rational treatment 
strategy for patients with idiopathic membranous nephropathy in Chapter 9. 
 
 
  13 
Introduction and outline of the thesis
References 
 
1.  Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic 
syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 
30: 621-631 
2.  MacTier R, Boulton Jones JM, Payton CD, McLay A. The natural history of membranous nephropathy in 
the West of Scotland. Q J Med 1986; 60: 793-802 
3.  Donadio JV, Jr, Torres VE, Velosa JA, et al. Idiopathic membranous nephropathy: the natural history of 
untreated patients. Kidney Int 1988; 33: 708-715 
4.  Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous 
nephropathy. N Engl J Med 1993; 329: 85-89 
5.  Reichert LJ, Koene RA, Wetzels JF. Prognostic factors in idiopathic membranous nephropathy. Am J 
Kidney Dis 1998; 31: 1-11 
6.  Honkanen E, Tornroth T, Gronhagen-Riska C, Sankila R. Long-term survival in idiopathic membranous 
glomerulonephritis: can the course be clinically predicted? Clin Nephrol 1994; 41, 127-134  
7.  Torres A, Dominguez-Gil B, Carreno A, et al. Conservative versus immunosuppressive treatment of 
patients with idiopathic membranous nephropathy. Kidney Int 2002; 61: 219-227 
8.  Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous 
glomerulonephritis. Kidney Int 1992; 42: 960-966 
9.  Cattran DC, Pei Y, Greenwood CM, et al. Validation of a predictive model of idiopathic membranous 
nephropathy: its clinical and research implications. Kidney Int 1997; 51: 901-907 
10.  Reichert LJ, Koene RA, Wetzels JF. Urinary excretion of β2-microglobulin predicts renal outcome in 
patients with idiopathic membranous nephropathy. J Am Soc Nephrol 1995; 6: 1666-1669 
11.  Reichert LJ, Koene RA, Wetzels JF. Urinary IgG excretion as a prognostic factor in idiopathic 
membranous nephropathy. Clin Nephrol 1997; 48: 79-84 
12.  Schieppati A, Ruggenenti P, Perna A, Remuzzi G. Nonimmunosuppressive therapy of membranous 
nephropathy. Semin Nephrol 2003; 23: 333-339 
13.  Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil 
in idiopathic membranous nephropathy. N Engl J Med 1989; 320: 8-13 
14.  Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with 
methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604 
15.  Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus 
chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. 
J Am Soc Nephrol 1998; 9: 444-450 
 
 
 
  
  
 
Chapter 2 
Cytotoxic therapy for membranous nephropathy and  
renal insufficiency: 
improved renal survival but high relapse rate 
 
 
 
 
 
Peggy W.G. du Buf-Vereijken, Amanda J.W. Branten and Jack F.M. Wetzels 
for the Membranous Nephropathy Study Group 
 
Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, 
The Netherlands 
 
Nephrol Dial Transplant 2004; 19(5): 1142-8 
 
 
 
 
16 
Chapter 2 
Abstract 
Background. Patients with idiopathic membranous nephropathy (iMN) and renal 
insufficiency have a high risk for progression to end-stage renal disease (ESRD). In the short 
term, treatment with oral cyclophosphamide and steroids attenuates the deterioration of renal 
function in these patients; however, the long-term efficacy is unknown. 
Methods. We have studied prospectively 65 patients with iMN and renal insufficiency (serum 
creatinine  > 135 μmol/l) who were treated with oral cyclophosphamide (1.5-2.0 mg/kg/day 
for 12 months) and steroids (methylprednisolone pulses 3x1 g, i.v. at months 0, 2 and 4 and 
oral prednisone 0.5 mg/kg/48h for 6 months).  
Results. Follow-up was 51 (5-132) months. Renal function temporarily improved or 
stabilized in all patients. A partial remission (PR) occurred in 56 patients followed by a 
complete remission (CR) in 17. During follow-up, 11 patients had relapsed (28% relapse rate 
after 5 years), of whom nine were re-treated because of renal function deterioration. At the 
end of follow-up, 16 patients were in CR, 31 in PR, eight had a persistent nephrotic 
syndrome, one had mild proteinuria, four had progressed to ESRD and five had died. Overall 
renal survival was 86% after 5 years and 74% after 7 years, compared with 32% after 5 and 7 
years in a historical control group. Treatment-related complications occurred in two-thirds of 
patients, mainly consisting of bone marrow depression and infections. One patient has 
developed bladder cancer, another patient prostate cancer. 
Conclusions. Renal survival is good if patients with iMN and renal insufficiency are treated 
with oral cyclophosphamide. However, side effects occur frequently and relapse rate is high 
during longer follow-up. 
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Introduction 
Idiopathic membranous nephropathy remains the most common cause of the nephrotic 
syndrome in adults.1 Studies on the natural history of the disease show that up to 40% of 
untreated patients will progress to end-stage renal disease (ESRD).2-5 
The immunosuppressive treatment of idiopathic membranous nephropathy is still a matter of 
debate. Some authors advocate immunosuppressive treatment for all patients with idiopathic 
membranous nephropathy and nephrotic syndrome, based on a randomized controlled trial 
conducted in Italy, clearly demonstrating that treatment with a combination of chlorambucil 
and prednisone improves renal survival in patients with idiopathic membranous nephropathy.4 
However, other authors argue rather strongly against the need for immunosuppressive 
treatment in view of the observed benign course in  > 50% of patients.3 Therefore, we and 
others are in favour of restricting immunosuppressive therapy to patients at highest risk of 
developing ESRD. (reviewed in6)5;7-11 
In patients with idiopathic membranous nephropathy, various risk factors for the development 
of renal failure have been identified (reviewed by Reichert et al.12). However, the sensitivity 
and specificity of most factors is too low to justify their use to guide decisions on the start of 
immunosuppressive therapy.12 It is evident, however, that an established deterioration of renal 
function is a powerful predictor of ESRD.2;8;10;12 Therefore, most would agree that a trial of 
immunosuppressive therapy is warranted in such patients with idiopathic membranous 
nephropathy and renal function deterioration. We previously have shown that 
immunosuppressive treatment can attenuate the deterioration of renal function in these 
patients.6;7 In this group of patients, treatment with oral cyclophosphamide and steroids 
seemed more effective and less toxic than the combination of chlorambucil and steroids 
(overview of the literature data in6). Admittedly, there are no controlled trials that document 
the efficacy of immunosuppressive therapy in patients with idiopathic membranous 
nephropathy and established renal insufficiency. Furthermore, most data are derived from 
small studies with short follow-up (overview of the literature in6).5;7;10 A recent study 
demonstrated that the renal outcome was better in patients with idiopathic membranous 
nephropathy and renal failure who were treated with the combination of chlorambucil and 
prednisone when compared with historical controls.10  
Since June 1991, we have prospectively studied patients with idiopathic membranous 
nephropathy and renal insufficiency. The data of these patients, who have been treated with 
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oral cyclophosphamide and steroids, form the basis of this report. Our study comprises the 
largest patient cohort described so far. 
 
 
Subjects and Methods 
We included only adult patients (age  > 18 years) with a biopsy-proven membranous 
nephropathy in whom a secondary cause of membranous nephropathy was excluded on 
clinical and/or laboratory grounds. Patients were recruited in our University Hospital or in one 
of the 19 referring hospitals. Eligible patients had to have evidence of renal insufficiency 
(defined as a serum creatinine  > 135 μmol/l, a calculated endogenous creatinine clearance     
< 70 ml/min or a rise in serum creatinine of  > 50%) and a proteinuria of at least                  
2.0 g/10 mmol creatinine. Exclusion criteria were systemic diseases, malignancies, active 
infection, pregnancy or inadequate contraconception, unstable angina pectoris, diabetes 
mellitus type I or long-lasting diabetes mellitus type II, clinical evidence of renal vein 
thrombosis, liver test abnormalities ( > 2x upper limit of normal), active peptic ulcer disease 
or gastro-intestinal diseases that could impair the resorption of oral medication. Patients who 
used immunosuppressive therapy in the previous 6 months were not eligible, except in the 
case of evident failure of treatment. 
Details of the immunosuppressive treatment have been described.7 In brief, treatment 
consisted of 1.5-2.0 mg/kg/day of oral cyclophosphamide, for 1 year, 1 g of 
methylprednisolone i.v. for three consecutive days at the beginning of the first, third and fifth 
month, and 0.5 mg/kg of oral prednisone every other day for 6 months with subsequent 
tapering. For the prevention of gastric complaints, famotidine was added, and to prevent 
Pneumocystis carinii pneumonia, most patients received 480 mg of trimethoprim-
sulfamethoxazole daily in the first 4-6 months. All patients were advised to follow a 
moderately salt-restricted diet. Conservative treatment was not standardized; however, 
physicians were instructed to lower blood pressure aggressively. More recently, it has become 
practice to use angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor 
blockers for all patients with proteinuria, and to add cholesterol-lowering therapy. 
Anticoagulant drugs were not prescribed routinely.  
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For survival analysis, the time of follow-up started at the beginning of treatment with 
cyclophosphamide and steroids. Follow-up continued until September 2002, or ended at the 
time of death or the onset of ESRD. 
Patients were seen regularly during follow-up, every 4-8 weeks during treatment and every   
3-4 months thereafter, but less frequently in cases where complete remission (CR) occurred. 
Blood pressure, complications of the nephrotic syndrome, side effects of the therapy and 
laboratory data were registered. To correct for inappropriate 24 h urine collections, the 
amount of proteinuria was expressed as a protein-creatinine index (g/10 mmol creatinine).     
A CR of proteinuria, partial remission (PR), persistent proteinuria and nephrotic range 
proteinuria were defined as a protein-creatinine index of ≤ 0.2, 0.21-2.0, 2.1-3.4 and ≥ 3.5 
g/10 mmol creatinine, respectively, where in the case of remission, renal function should have 
improved or at least stabilized. All patients who entered a CR were also registered as having a 
partial remission. Relapses were defined as nephrotic range proteinuria after a PR or CR of 
the proteinuria or a rise in proteinuria of  > 50% in patients in whom proteinuria had 
improved initially with  > 50%, without reaching values ≤ 2.0 g/10 mmol creatinine. 
A second course of immunosuppressive therapy was offered to patients who relapsed to 
nephrotic range proteinuria together with a rise in serum creatinine of  > 50% over the lowest 
value attained during or after the first course of cyclophosphamide treatment. 
The historical controls (n=24) consisted of patients with an idiopathic membranous 
nephropathy and renal insufficiency (serum creatinine  > 135 μmol/l) referred to our 
University Hospital for therapeutic advise or inclusion in therapeutic trials, and thus came to 
our attention in the same way as the patients included in this cohort study. Several of these 
historical control patients were included in former trials and treated with prednisone 
monotherapy (n=7), i.v. cyclophosphamide (n=1) or both (n=3). Because these treatment 
modalities have proved ineffective,9;13 these patients can be considered historical controls. 
Most of the historical control patients were not treated with immunosuppressive therapy at all 
(n=13), mainly because we were not used to do so before June 1991. 
 
Calculations and statistics 
For descriptive statistics, results are given as means ± SD, or medians with range when 
appropriate. Mean arterial blood pressure (MAP) was calculated using de formula MAP = 
diastolic blood pressure + 1/3 x (systolic blood pressure - diastolic blood pressure). For 
calculations of renal survival, the time of renal death was defined as the start of renal 
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replacement therapy or the time of death. The cumulative probabilities of a clinical event 
(death, ESRD, PR, CR or relapse of nephrotic syndrome) were estimated according to Kaplan 
and Meier. The log rank test was used to compare survival curves. To demonstrate further an 
effect of the immunosuppressive therapy on the rate of deterioration of renal function, we 
have calculated the slope of 1000/serum creatinine vs time before and after the start of the 
treatment for the treated patients and overall for the historical controls. The Mann-Whitney 
test was used for comparison between groups, and Wilcoxon signed rank test for comparisons 
within the group of treated patients. A P-value of < 0.01 was considered significant. All 
statistical procedures were done using SPSS software (SPSS version 10.0, Chicago, IL, USA). 
 
 
Results 
Baseline characteristics of the treated patients are given in Table 1. 
 
Table 1. Baseline characteristics 
Number of patients 65  
Male : female      55 : 10 
Age at clinical onset of disease (years) 50 (15-77) 
Age at time of biopsy (years) 51 (15-77) 
Interval between biopsy and start of 
cyclophosphamide (months) 13 
 
(0-280) 
Serum creatinine (μmol/l) 171 (106-512) 
Serum albumin (g/l) 23 (9-43) 
Proteinuria (g/10 mmol creatinine) 10.0 (2.0-23.0) 
Creatinine clearance (ml/min/1.73 m2) 42 (13-109) 
Mean arterial pressure (mm Hg) 102 (80-133) 
Follow-up (months) 51 (5-132) 
Values are medians with range. 
 
Most patients (n=59) started immunosuppressive therapy because of a serum creatinine > 135 
μmol/l, and six patients started immunosuppressive therapy because of a 50% increase in 
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serum creatinine. Calculated endogenous creatinine clearance (Cockcroft formula) in the latter 
group was 86 (51-109) ml/min/1.73 m2, proteinuria 10.2 (4.5-16.0) g/10 mmol creatinine and 
serum albumin 23 (17-30) g/l. Inclusion of these patients did not influence the results. 
Nineteen patients (29%) had received previous immunosuppressive therapy, mainly 
consisting of short-term high-dose prednisone (n=7), prednisone followed by a combination 
of prednisone and chlorambucil (n=3) or only a combination of prednisone and chlorambucil 
(n=6). Four patients had received immunosuppressive therapy < 6 months before the start of 
cyclophosphamide treatment, but this previous treatment had failed as evidenced by 
progressive renal insufficiency. Follow-up after the start of therapy averaged 51 months (SD 
30 months, range 5-132 months). Twenty-one patients have been followed for  > 5 years.  
Median values of MAP, serum creatinine, serum albumin, serum cholesterol, proteinuria and 
creatinine clearance, before, at regular intervals after the start of therapy and at the end of 
follow-up, are given in Table 2.  
 
Table 2. Laboratory parameters and blood pressure during treatment and follow-up 
 -6 months 
 
(n =50) 
Start 
therapy 
(n =65) 
3 months 
 
(n =65) 
12 months 
 
(n =60) 
24 months 
 
(n =51) 
End 
follow-up 
(n =65) 
Screatinine 
(μmol/l) 
129** 
(68-376) 
171 
(106-512) 
130** 
(73-642) 
120** 
(74-337) 
123** 
(85-370) 
128** 
(69-1000) 
Salbumin 
(g/l) 
22 
(13-42) 
23 
(9-43) 
29** 
(11-42) 
38** 
(25-47) 
40** 
(23-50) 
39** 
(22-46) 
Scholesterol 
(mmol/l) 
7.7 
(5.0-28.8) 
7.6 
(4.6-23.2) 
6.9** 
(4.4-14.0) 
5.5** 
(3.8-8.5) 
5.4** 
(3.1-7.1) 
5.2** 
(3.1-10.3) 
Proteinuria 
(g/10 mmol creat) 
8.9* 
(3.4-17.9) 
10.0 
(2.0-23.0) 
4.8** 
(0-34.2) 
1.3** 
(0-13.0) 
0.8** 
(0-8.5) 
0.8** 
(0-11.1) 
Creatinine clearance 
(ml/min/1.73 m2) 
61** 
(22-170) 
42 
(13-109) 
59** 
(15-143) 
62** 
(17-136) 
60** 
(16-138) 
61** 
(7-155) 
MAP 
(mm Hg) 
92 
(69-118) 
102 
(80-133) 
94** 
(65-125) 
95** 
(75-124) 
97* 
(77-122) 
93* 
(71-118) 
Values are medians with range. 
S, serum; MAP, mean arterial pressure. 
* P < 0.01, ** P < 0.001, compared with values at the start of treatment. 
 
At the start of cyclophosphamide treatment blood pressure was reasonably well controlled, 
and 78% of patients was treated with an ACE-inhibitor and/or angiotensin receptor blocker. 
 
 
22 
Chapter 2 
Blood pressure further improved during follow-up, although antihypertensive treatment was 
not intensified.  
Serum creatinine improved by  > 10% in 91% of patients during the first year. In only three 
patients (4.6%) was serum creatinine increased by  > 10% during the treatment year. The 
lowest serum creatinine value attained after the start of treatment was 107 (70-489) μmol/l 
and this nadir was reached after a median of 6 months. Immunosuppressive therapy attenuated 
the deterioration of renal function as indicated by the change in the median slope of 
1000/serum creatinine from –3.0  l/μmol/yr before to 0.12  l/μmol/yr after the start of therapy 
(P < 0.001).  
Proteinuria also decreased in the majority of patients. This decrease in proteinuria was 
gradual, and continued even after the end of the immunosuppressive treatment (Table 2). As 
can be expected, serum albumin improved and cholesterol declined after the start of treatment 
(Table 2). 
Overall, 56 patients have developed a PR of proteinuria after an average of 10.6 months. In 17 
patients, proteinuria further decreased to values ≤ 0.2 g, and this CR was reached 12 (0-38) 
months after the onset of the PR. The cumulative incidence of PR is 92% after 5 years and of 
CR is 36% after 5 years (Figure 1).  
 
 
Figure 1. Cumulative incidence of partial and complete remissions of proteinuria. 
 
Not all patients have remained in stable remission. Of the 17 patients who developed a CR, 
one relapsed to nephrotic range proteinuria. Of the 39 patients who have developed only a PR 
of proteinuria, 10 relapsed to nephrotic range proteinuria. Relapsing patients had been in 
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remission for 27 (7-66) months. The cumulative incidence of relapses is 28% at 5 years after 
onset of the remission (Figure 2).  
 
 
Figure 2. Cumulative incidence of relapses after remission. 
 
In most relapsing patients, serum creatinine eventually has increased by  > 50%. The 
occurrence of a relapse could not be predicted by the serum creatinine, the amount of 
proteinuria or MAP at the start of therapy. 
The overall course in our patient group and the status at the end of follow-up are depicted in 
Figure 3. Thus far, nine patients have been retreated because of a relapse and again 
deteriorating renal function. At the end of the follow-up, 16 patients were in CR, 31 patients 
in PR, eight patients have a persistent nephrotic syndrome and one patient has mild persistent 
proteinuria. Four patients have reached ESRD; in three of these, serum creatinine was ≥ 400 
μmol/l at the start of treatment. Five patients have died at a median of 2.7 years after the start 
of therapy.  
Of the group of patients that started immunosuppressive therapy because of a 50% rise in 
serum creatinine (n=6) two patients were in CR (33%), three in PR (50%) and one had a 
persistent nephrotic syndrome (17%).  
Outcome was similar in patients who had received immunosuppressive therapy prior to 
starting cyclophosphamide (n=19) and patients who had not been treated before. Also, when 
analysing the data separately for patients with a serum creatinine below or above the median 
value of 171 μmol/l at start of therapy, no differences in outcome were noted. 
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Figure 3. Flow-chart of treatment results. 
CR, Complete Remission = proteinuria ≤ 0.2 g/10 mmol creatinine; 
PR, Partial Remission = proteinuria 0.21-2.0 g/10 mmol creatinine; 
PP, Persisting Proteinuria = proteinuria 2.1-3.4 g/10 mmol creatinine; 
(R)NS, (Recurrent) Nephrotic Syndrome = proteinuria ≥ 3.5 g/10 mmol creatinine; 
ESRD, end-stage renal disease. 
Status at the end of follow-up is given in the gray rectangles.  
 
A PR or CR of proteinuria developed in 43 out of 51 patients using an ACE inhibitor or 
angiotensin receptor antagonist as compared with 13 out of 14 patients who did not use these 
agents (P = NS). The use of an ACE inhibitor or angiotensin receptor antagonist also did not 
influence renal survival rate or death (7/51 vs 2/14; P = NS). We also did not observe an 
effect of blood pressure values on remission rate or renal outcome. 
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In our study, renal survival without censoring for death is 86% at 5 years and 74% at 7 years 
after the start of treatment. We have compared renal survival in our treated patients with renal 
survival in a group of 24 historical controls. In these historical controls, renal survival was 
32% at 5 years, a highly significant difference (P < 0.001; Figure 4). Results are similar if 
only untreated control patients are included in the analysis. 
 
 
Figure 4. Renal Survival. 
Renal survival for treated patients (n=65) was 86% after 5 years and 74% after 7 years;  
for historic controls (n=24), it was 32% after 5 years, the difference being significant ( P < 0.0001).  
 
The beneficial effect of cyclophosphamide therapy in attenuating deterioration of renal 
function is also obvious if we compare the slopes of 1000/serum creatinine: 0.12  l/μmol/year 
with cyclophosphamide compared with –1.21  l/μmol/year in the historical controls (P < 
0.001).  
Five patients have died, at a median age of 63 (43-79) years. Two patients died suddenly, at 
home of unknown causes while in CR or PR. One patient died from cardiovascular disease 
while being re-treated. One patient died due to sepsis, in CR 7 months after the completion of 
immunosuppressive treatment. The fifth patient died of a disseminated bladder carcinoma, 
which he developed 21 months after the start of therapy. This patient had received a 
cumulative dose of 20 g of cyclophosphamide. Patient survival is 91% after 5 years and 84% 
after 7 years.  
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Side effects were frequent. Of 65 patients, 43 experienced one or more side effects during the 
treatment year. Bone marrow depression and infectious complications were most frequent 
(Table 3). In most patients, the dose of cyclophosphamide was temporarily reduced (Table 3). 
Only four patients (6%) had to stop cyclophosphamide within 6 months after the start of 
treatment; in two patients, azathioprine was used as replacement.  
 
Table 3. Treatment-related complications 
Complication / side effect Number  
of patients 
(%) 
Temporary dose 
reduction 
(%) 
Treatment ended
 < 6 months 
(%) 
Bone marrow depression 
  Leucocytopenia 
  Anaemia 
  Thrombocytopenia 
27 
10 
3 
 
(42%) 
(15%) 
(4.6%) 
19 
6 
2 
 
(29%) 
(9%) 
(3%) 
 
1  
1  
0  
 
(1.5%) 
(1.5%) 
(0%) 
Infections 
  All infections 
  Respiratory infections 
17 
11 
 
(26%) 
(17%) 
6 
3 
 
(9%) 
(4.6) 
 
1  
0  
 
(1.5%) 
(0%) 
Malaise 8 (12%) 5 (7.7%) 2  (3%) 
Liver test abnormalities 2 (3%) 2 (3%) 1  (1.5%) 
Steroid-induced diabetes mellitus  1 (1.5%) 0 (0%) 0  (0%) 
Total number of patients 43 (66%) 30 (46%) 4  (6%) 
The numbers do not add up, as one patient can have more than one complication.  
Definitions: leucocytopenia: leucocyte count < 3.0 x 109/l; anaemia: haemoglobin < 6.0 mmol/l; 
thrombocytopenia: thrombocyte count < 100 x 109/l. 
 
Thromboembolic complications occurred in three patients after the start of treatment. Two 
patients have developed a malignancy after treatment: one patient developed a bladder 
carcinoma (see above) and one patient a prostate carcinoma.  
 
 
Discussion 
Our study clearly demonstrates that treatment with oral cyclophosphamide and prednisone 
improves renal survival in patients with idiopathic membranous nephropathy and renal 
insufficiency. Admittedly, we have not performed a randomized, controlled trial.  
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However, our study represents the largest cohort of treated patients studied prospectively over 
a long time period. If we compare renal survival in our treated patients with that in a group of 
historical controls from our centre, there is a clear survival difference (5 year renal survival 
86% vs 32%). We have also compared our results with data reported by other investigators. In 
untreated patients with idiopathic membranous nephropathy and renal insufficiency, reported 
renal survival rates range from 20 to 30% after 7 years.8;10 Moreover, our renal survival rate is 
even higher than those reported for untreated patients with idiopathic membranous 
nephropathy and normal renal function.2;4 Our study thus supports the conclusions from 
recent smaller studies that immunosuppressive therapy improves outcome in patients with 
idiopathic membranous nephropathy and renal failure.8;10 Apparently, these conclusions do 
not hold for all immunosuppressive regimens containing cytotoxic drugs. Falk et al. have 
reported that i.v. cyclophosphamide did not offer additional benefits.9 In a randomized study, 
we also demonstrated that i.v. cyclophosphamide was not effective.13 Azathioprine with oral 
prednisone, without methylprednisolone infusions, has also been used without success, as 
reported in a retrospective study.14 In contrast, chlorambucil has been used with apparent 
success.5;6;10 However, in our experience, chlorambucil may be less effective than 
cyclophosphamide and causes more side effects.6 
Based on the findings of the randomized trials conducted by Ponticelli et al.4 and our present 
and previous observations, we feel that it is no longer justified to withhold treatment from 
patients with idiopathic membranous nephropathy and renal failure. Therefore, it might be 
impossible to perform a placebo-controlled trial. Although the results of our study seem 
favourable, we cannot definitively answer the question of whether the start of 
immunosuppressive therapy can be delayed until renal insufficiency develops. In the study of 
Ponticelli et al., 10 year renal survival was 92%, a value which is better than our 74% renal 
survival after 7 years. However, patients were not comparable at all since we included only 
high-risk patients whereas in the Italian randomized study patients were included with a lower 
predicted risk, as indicated by the short duration of disease and the almost normal renal 
function at the start of therapy. Furthermore, we have calculated renal survival from the time 
of starting immunosuppressive therapy, which evidently causes an underestimation of 
survival rate. If we calculate renal survival from the time of renal biopsy, estimated 5, 7 and 
10 year renal survival rates are 93%, 90% and 81% respectively. 
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Thus far, five patients have died. No patient died of renal failure. In one patient, who died 
from bladder carcinoma, death may have been related to treatment. The other patients died 
long after the end of treatment, most frequently from cardiovascular causes. Patient survival 
of 91% at 5 years and 84% at 7 years is comparable with or better than reported data.2;4;5;10 
Our study also illustrates some major drawbacks of our immunosuppressive protocol, i.e. a 
relatively high rate of relapses, frequent side effects, and lack of effectiveness in some 
patients.  
Overall, a quarter of the patients entered a CR during follow-up. It is of note that in most 
patients, the time of onset of CR was  > 12 months after the start of treatment, i.e. well after 
stopping immunosuppressive therapy. Prognosis is excellent in patients who have developed a 
CR, since thus far only one of these patients (6%) has relapsed. In contrast, relapses have 
occurred frequently in patients who responded to treatment with a PR (10 out of 39 patients, 
26%) or a  > 50% reduction in proteinuria, and may even increase with longer follow-up. 
Cumulative incidence of relapses after the occurrence of a PR or CR is 28% after 5 years. We 
find this relapse rate rather high; however, similar figures (30% after 2 years) have been 
reported by Ponticelli et al. for patients with membranous nephropathy and preserved renal 
function treated with either cyclophosphamide or chlorambucil.15 In most of our patients who 
relapsed, renal function has deteriorated, necessitating a new course of immunosuppression.  
Many patients experienced complications from the immunosuppressive therapy, especially 
bone marrow depression and infectious complications. This high incidence of side effects may 
be partly related to the decreased renal function of our patients.5-7 In only 6% of patients did 
the severity of side effects necessitate a premature termination of therapy ( < 6 months). One 
feared side effect of cyclophosphamide therapy is the development of neoplasias, in particular 
bladder cancer.16;17 It has been shown that the risk of cyclophosphamide-related bladder 
cancer increases with the duration (especially  > 2.7 years) and the cumulative dosage (mainly  
> 100g) of cyclophosphamide treatment. Bladder carcinoma can become manifest even after a 
latency period of more than a decade.16;18  
The side effects of alkylating agents increases the urgency of the search for less toxic 
therapies. Recently, reports have become available regarding the treatment of patients with 
therapy-resistant or relapsing idiopathic membranous nephropathy with mycophenolate 
mofetil. Short-term results show substantial reductions of proteinuria, although remissions 
were scarce, mostly accompanied by preservation of renal function.  Furthermore, 
mycophenolate mofetil was well tolerated.19;20 Further results are awaited. 
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We feel that our data are sufficient to support the proposal of a formal comparison between 
early and late start of immunosuppressive therapy. Admittedly, an earlier start of 
immunosuppressive therapy poses a risk to some patients who would have developed a 
spontaneous remission of proteinuria. However, an earlier start of treatment might result in 
even better renal survival rates, may be associated with fewer and less severe side effects, and 
might result in a lower rate of relapses. Patients to be included in such studies could be 
selected based on defined risk factors for progressive disease such as the duration and 
magnitude of proteinuria or the urinary excretion of IgG, β2-microglobulin or α1-
microglobulin.12 
 
In conclusion, treatment of patients with idiopathic membranous nephropathy and renal 
insufficiency with oral cyclophosphamide and steroids results in a high remission rate and 
good renal survival, suggesting that immunosuppressive treatment is still effective when 
started at a time point when renal insufficiency has developed. We cannot answer the question 
of whether an earlier start of treatment would have been more beneficial. A formal study is 
warranted. Our treatment schedule with cyclophosphamide and steroids is hampered by the 
frequent occurrence of side effects. Unfortunately, relapses are also frequent with longer 
follow-up. Therefore, we need to continue studies in search of safer and more effective 
therapeutic agents. 
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Abstract 
Background. A single course of immunosuppressive treatment improves renal survival in 
patients with idiopathic membranous nephropathy (iMN) and renal insufficiency. However, 
not all patients respond and relapses occur within 5 years in 30% of patients. It is unknown if 
a second course of immunosuppressive therapy is effective in such patients. 
Methods. We have prospectively studied and evaluated the clinical course in 15 patients (14  
male, one female; age 52 ±12 years) with iMN who have received a repeated course of 
immunosuppressive therapy because of deteriorating renal function associated with relapsing 
or persistent nephrotic syndrome. 
Results. The first course of immunosuppression was started 8 months (range: 0-143 months) 
after renal biopsy and consisted of chlorambucil (n=8) or cyclophosphamide (n=7); the 
second course consisted of cyclophosphamide in all patients. The interval between the first 
and second course was 40 months (range: 7-112 months). Total follow-up was 110 months 
(range: 46 –289 months). Renal function and proteinuria improved at least temporarily in all 
patients after the second course. During follow-up, an additional course of therapy was given 
in four patients. Status at the end of follow-up was complete remission (n=2), partial 
remission (n=8), persistent proteinuria (n=3), end-stage renal disease (n=1) and death (n=1, 
due to cardiovascular disease while nephrotic). Renal survival was 86% at 5 and 10 years of 
follow-up. The repeated courses of immunosuppression have resulted in a gain of dialysis-free 
survival time of  ≥ 93 months (range: 43-192 months). 
Conclusions. Our results indicate that patients with iMN who do not respond well or relapse 
after a first course of immunosuppressive therapy and have renal insufficiency should be 
offered a second course of immunosuppression. Such a strategy maintains renal function in 
the majority of patients. 
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Introduction 
Idiopathic membranous nephropathy is the most common cause of the nephrotic syndrome in 
adults.1 Studies on the natural history of the disease show that ≤ 50% of untreated patients 
will progress to end-stage renal disease (ESRD).2 A randomized controlled study has 
provided evidence that a 6 month course of alternating prednisone and chlorambucil improves 
renal survival in patients with idiopathic membranous nephropathy, a nephrotic syndrome, 
and normal renal function at the start of therapy.3 In view of the toxicity of 
immunosuppressive therapy, most nephrologists have argued that treatment should be 
restricted to patients with evidence of renal insufficiency or longstanding, severe nephrotic 
syndrome.4 Observational studies have, indeed, suggested that immunosuppressive therapy is 
effective when started in patients with renal insufficiency.5-8 Most treatment regimens 
consisted of a combination of prednisone and an alkylating agent, notably chlorambucil or 
cyclophosphamide, administered for a period of 6-12 months. 
Since 1986 we have also used a restrictive treatment policy in patients with idiopathic 
membranous nephropathy.  
We have initially used the so-called Ponticelli regimen, a 6 month course of alternating cycles 
of prednisone and chlorambucil.3 From 1991 onwards, we have regularly used a 
cyclophosphamide-based regimen. Although a single course of immunosuppressive therapy 
was effective in most patients, some did not respond.8;9 Furthermore, in ≤ 30% of patients the 
disease relapsed with recurrent proteinuria.8;10-12 It is uncertain if a repeated course of 
immunosuppression is effective in patients with idiopathic membranous nephropathy and 
persistent or relapsing nephrotic syndrome. We have regularly offered a second course of 
immunosuppressive therapy to such patients if there was evidence of deteriorating renal 
function. For the present study we have analysed the outcome in 15 prospectively followed 
patients who have received a second course of immunosuppressive therapy. Our data indicate 
that retreatment is effective and attenuates progressive renal failure. 
 
 
Subjects and Methods 
From 1986 onwards we have used immunosuppressive therapy in adult patients with 
membranous nephropathy. Treatment was restricted to patients with renal insufficiency 
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(defined as a serum creatinine  > 135 μmol/l, a calculated endogenous creatinine clearance     
< 70 ml/min or a rise in serum creatinine of  > 50%) and a proteinuria of  ≥ 2.0 g/10 mmol 
creatinine or to patients with a severe, intolerable nephrotic syndrome. Eligible patients were 
treated in our University Hospital or by nephrologists in referring hospitals. Details of our 
treatment protocols and of the outcome in treated patients have been described previously.5;8;9 
In brief, during the period 1986-1991, our immunosuppressive therapy consisted of a 6 month 
course of alternating cycles of prednisone (1 g methylprednisolone intravenously (i.v.) on 
three consecutive days, followed by oral prednisone 0.5 mg/kg/day at months 1, 3 and 5) and 
chlorambucil (0.15 mg/kg/day at months 2, 4 and 6). Thereafter, a regimen containing 
cyclophosphamide became our therapy of choice. This regimen consisted of corticosteroids   
(1 g methylprednisolone i.v. on three consecutive days at months 0, 2 and 4, followed by oral 
prednisone 0.5 mg/kg on alternate days for 6 months) and oral cyclophosphamide in a dose of 
1.5-2.0 mg/kg/day for 12 months. All treated patients have been followed prospectively and 
were regularly seen in the outpatient clinic. For the present study, we have selected all 
patients who have received a second course of immunosuppressive therapy because of 
relapsing or persistent nephrotic syndrome and deterioration of renal function.  
 
Calculations and Statistics 
For this study, the time of follow-up started at the time of biopsy. Follow-up ended with the 
last clinical visit or at the occurrence of ESRD or death. The interval between consecutive 
courses of immunosuppression was calculated from the beginning of the first course to the 
beginning of the second course. Mean arterial pressure (MAP) was calculated as diastolic 
blood pressure plus one-third of the pulse pressure (systolic blood pressure - diastolic blood 
pressure). Proteinuria was expressed as g/10 mmol creatinine (protein-creatinine index). A 
complete remission of proteinuria (CR), partial remission (PR), persistent proteinuria (PP) 
and nephrotic range proteinuria were defined as a protein-creatinine index of ≤ 0.2, 0.21-2.0, 
2.1-3.4 and ≥ 3.5 g/10 mmol creatinine, respectively, where in case of remission, renal 
function should have improved or at least stabilized compared with the value at the start of the 
immunosuppressive therapy. Relapses of proteinuria were defined as nephrotic range 
proteinuria after a PR or CR of the proteinuria or a rise in proteinuria of  > 50% in patients in 
whom proteinuria had improved initially by  > 50%, without reaching values ≤2.0 g/10 mmol 
creatinine. 
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For each individual we have estimated dialysis-free survival time gained by therapy. To this 
end we have plotted the course of 1000/serum creatinine (= glomerular filtration rate (GFR)) 
vs time for each individual patient. The decrease in GFR in the period before the start of 
immunosuppression was defined by the trend line and the estimated time of onset of ESRD 
was derived by extrapolation. A value of 1000/serum creatinine of 1 was used as the ESRD 
reference value. Next, we estimated the expected time of onset of ESRD after treatment by 
extrapolating a trend line drawn through the point of the last observation in parallel with the 
first line. The procedure is illustrated for one patient in Figure 1. It is evident that this 
procedure provides a minimum estimate of the gained dialysis-free survival time, since in 
most patients there is no apparent decrease in GFR at the moment of last observation. 
When considering concomitant drug treatment, special attention was given to the use of 
angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (AIIA), 
because of their favourable effects on blood pressure and protein excretion.  
0
1
2
3
4
5
6
7
8
9
10
0 24 48 72 96 120 144 168 192 216 240
Follow-up from renal biopsy (months)
10
00
/S
cr
ea
t
estimated gain of dialysis-free survival time 
ESRD
     1st therapy
    2nd therapy
 
Figure 1. Estimate of dialysis-free survival time gained by therapy. 
To estimate the gain of dialysis-free survival time, we have plotted 1000/serum creatinine 
(1000/Screat; Screat in μmol/l) vs time. A trend line was drawn to estimate the decline in renal 
function before the start of the first immunosuppressive therapy. The expected date of onset of ESRD 
(without therapy) was derived by extrapolating the trend line. A value of 1000/Screat of 1 was used as 
a marker of ESRD. The date of onset of ESRD after therapy was estimated from a parallel line, drawn 
through the point of last observation. The figure represents data from patient no. 3; in this patient the 
onset of ESRD was delayed by  ≥164 months. 
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Renal survival, defined as being alive without dialysis, was calculated from the time of renal 
biopsy. The cumulative probabilities of a clinical event (death or ESRD) were estimated 
according to Kaplan and Meier. Unless otherwise stated, values are given as medians with the 
range. The Wilcoxon signed rank test was used for comparisons of clinical data within the 
total group of treated patients at different time points. A P-value of < 0.05 was considered 
significant. All statistical procedures were done using SPSS software (SPSS version 10.0, 
Chicago, IL, USA). 
 
 
Results 
Fifteen patients (14 male, one female) were eligible for the study. Mean age at biopsy was 51 
years (range: 24-68 years). An overview of patient and treatment characteristics, laboratory 
values at biopsy, time intervals to first immunosuppressive course and between first and 
second course, and total time of follow-up are given in Table 1.  
In Table 2 we have provided detailed information for each patient on the given courses of 
immunosuppression, side effects, necessary dose reductions, concomitant use of ACEI and/or 
AIIA, cumulative dosage of cyclophosphamide and estimated gained dialysis-free survival 
time. Four patients had received prednisone monotherapy in the early disease period. The first 
course of effective immunosuppression was started at a median of 8 months (range: 0 – 143 
months) after renal biopsy and consisted of chlorambucil in eight patients and of 
cyclophosphamide in seven patients. The interval between the first and second course was 40 
months (range: 7 –112 months). All patients received cyclophosphamide as the second course. 
In three patients (all treated with chlorambucil), retreatment started within 6 months after the 
end of the first course. In all other patients, retreatment started  > 2 years after the end of the 
first course. Total follow-up was 110 months (range: 46 – 289 months). One patient was lost 
to follow-up due to non-compliance. 
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Table 1. Overview of demographic parameters, laboratory values at biopsy, time intervals to 
first immunosuppressive course and between first and second courses, and total time of 
follow-up 
Patient 
no. 
Sex Age at 
biopsy 
(years) 
Screat
at biopsy
Proteinuria
at biopsy
Interval
Bx –1st Th
(months)
Interval 
1st – 2nd Th 
(months) 
Total FU
from biopsy
(months)
  1 Male 54 104 6.5 45 66 257
  2 Male 24 307 5.0 120 38 289
  3 Male 56 109 6.7 13 40 181
  4 Male 46 83 3.9 15 112 165
  5 Male 42 85 15.0 1 35 130
  6 Male 66 110 5.7 6 7 133
  7 Male 66 103 7.0 8 59 110
  8 Male 51 68 6.5 6 74 96
  9 Male 45 75 15.9 21 10 99
10 Female 55 117 4.3 143 56 214
11 Male 59 151 7.7 7 12 72
12 Male 48 90 13.4 8 35 60
13 Male 31 125 9.8 16 40 65
14 Male 68 270 6.8 3 36 50
15 Male 39 272 8.9 0 42 46
Median 
(range) 
51 
(24-68) 
109
(68-307)
6.8
(3.9-15.9)
8
(0-143)
40 
(7-112) 
110
(46-289)
Screat, serum creatinine (μmol/l) and proteinuria (g/10 mmol creatinine) at the time of renal biopsy; 
interval Bx–1st Th, time interval between renal biopsy and beginning of first course of effective 
immunosuppressive therapy; interval 1st –2nd Th, time interval between beginning of first and 
beginning of second course of effective immunosuppressive therapy; total FU from biopsy, total 
follow-up time from time of biopsy. 
 
In Table 3 an overview is given of the course of serum creatinine and proteinuria during the 
two consecutive immunosuppressive courses. We have depicted serum creatinine and urinary 
protein excretion at the start of the first and second courses of therapy, the lowest value after 
the start of each course of therapy and the value at the end of follow-up. 
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Table 3. Efficacy of immunosuppressive courses and status at the end of follow-up  
First Treatment  Second Treatment  Status End FU 
Screat  Proteinuria  Screat  Proteinuria  Screat Proteinuria 
Patient. 
no. 
Start Min.  Start Min. Start Min. Start Min.    
  1 126 126  7.6 0.7 446 174 11.6 1.2  428 1.2
  2 408 211  9.6 5.4 313 201 8.7 0.3  228 0.5
  3 197 132  7.0 4.0 512 238 10.2 0.4  262 1.2
  4 161 82  15.8 0.4 171 132 3.9 0.5  157 0.7
  5 85 64  15.0 0.4 162 104 6.6 0.3  87 2.5
  6 182 135  10.2 9.4 182 101 9.4 0.7  139 0
  7 165 100  6.8 0 158 114 9.8 0.3  127 0.7
  8 106 91  4.5 0.9 232 91 5.6 1.3  93 1.3
  9 123 88  12.8 4.5 117 83 11.2 4.0  111 0.5
10 171 110  6.0 1.5 266 186 11.1 2.2  186 2.3
11 269 146  7.7 4.4 319 143 18.5 0  143 0
12 184 130  19.1 2.6 208 160 10.1 2.0  194 2.5
13 492 210  19.3 2.9 567 517 2.9 2.4  1000 2.4
14 353 186  5.3 0.5 265 163 9.3 0.8  163 0.8
15 315 135  8.9 1.5 516 235 7.3 6.9  309 6.9
Median 
Range 
182 
85-492 
130a 
64-211 
 8.9 
4.5-19.3 
1.5a 
0-9.4 
 265 
117-567 
160a 
83-517 
 9.4 
2.9-18.5 
0.8a 
0-6.9 
 163 
87-1000 
1.2 
0-6.9 
Screat, serum creatinine (μmol/l); Start, start of the immunosuppressive course; Min., lowest value 
attained after the respective course; Status End FU, status at the end of total follow-up.  
Proteinuria is measured in g/10 mmol creatinine. 
a Minimum value statistically lower than value at start of therapy. 
 
 
Efficacy of the first course of immunosuppression 
Data are presented in Table 3. Renal function improved in all but one patient, who showed 
stabilization of serum creatinine. Proteinuria improved in all patients, but CR (one) or PR 
(seven) was achieved in only eight patients. 
Nine out of the 15 patients used an ACEI and/or AIIA at the start of the first course of 
immunosuppression. Mean arterial blood pressure amounted 103 mm Hg (range: 97-123 mm 
Hg) at the start of the first immunosuppressive course and 101 mm Hg (range: 87-121 mm 
Hg) at 12 months (NS).  
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Efficacy of the second course of immunosuppression  
Data are presented in Table 3. At the start of the second course of immunosuppression, renal 
function was worse in 11 patients in comparison with renal function at the start of the first 
course and was, by definition, worse in all cases in comparison with the best renal function 
achieved after the first course. Renal function and proteinuria improved in all patients during 
the second course of immunosuppression. Ten patients achieved CR (one) or PR (nine). The 
efficacy of the repeated courses of immunosuppression is visualized in Figures 2 and 3, 
depicting the time course of the change in 1000/serum creatinine and proteinuria in relation to 
the start of the second course of therapy. Eleven patients used an ACEI and/or AIIA at the 
start of the second course of immunosuppression. Despite this, all but one patient had a 
nephrotic syndrome at this time point. Mean arterial blood pressure was 108 mm Hg (range: 
78-130 mm Hg) at the start of the second immunosuppressive course and 95 mm Hg (range: 
80-110 mm Hg) at 12 months (NS).  
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Figure 2. Efficacy of the second course of immunosuppressive therapy on change in renal 
function.  
The start of the second immunosuppressive course is indicated by t = 0. Follow-up is shown from 6 
months before to 60 months after the second course. The figure plots the change in 1000/serum 
creatinine value (μmol/l) compared with the value at the start of therapy, which was set at 0.  
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Figure 3. Efficacy of the second course of immunosuppressive therapy on proteinuria. 
The start of the second immunosuppressive course is indicated by t = 0. Follow-up is shown from 6 
months before to 60 months after the second course. Proteinuria is expressed as g/10 mmol creatinine. 
The reference line reflects a proteinuria of 2 g/10 mmol creatinine, the threshold for defining a partial 
remission. 
 
 
Follow-up after the second course 
Thus far, four patients have received a third (four) or even fourth (one) course of 
immunosuppression, because of new relapse (Table 2). At the end of follow-up, two patients 
were in CR, eight were in PR, three had persistent proteinuria, one had developed ESRD and 
one had died due to cardiovascular disease while nephrotic (Table 2). Renal survival (alive 
without dialysis) from the time of biopsy amounted 86% at 5 and 10 years. The repeated 
courses of immunosuppression have resulted in an estimated dialysis-free survival time 
gained by therapy of  ≥ 93 months (range: 43-192 months). This estimate is a minimum and 
underestimates the real gain, since in seven patients renal function was stable or even 
improving at the end of follow-up. 
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Immunosuppressive therapy-related complications 
The side effects of immunosuppressive treatment are detailed per patient in Table 2. Side 
effects were frequent and often necessitated dose reduction. The second course of 
immunosuppression was not more frequently associated with side effects. 
The cumulative dosage of cyclophosphamide was 48 g (range: 17-146 g) (Table 2). In only 
one patient did the dosage exceed 100 g. This particular patient received a high dose because 
of his body weight ( > 100 kg) and the absence of side effects. The cumulative dose is lower 
than expected, even in patients who received two courses of cyclophosphamide. This is 
explained by the fact that, in most patients, dose reduction was necessary because of 
haematological side effects. Furthermore, if the cumulative dose of cyclophosphamide tended 
to reach the 100 g threshold, we have favoured to replace cyclophosphamide by azathioprine 
or cyclosporine (third courses; Table 2). 
 
 
Discussion 
Our study indicates that a second course of immunosuppressive therapy is effective in patients 
with membranous nephropathy and deteriorating renal function who have not responded well 
or who have relapsed after a first course of immunosuppressive therapy. In the short-term, 
renal function improved and proteinuria decreased in all patients during the second course. 
Also, at the end of follow-up, renal function was maintained in the majority of patients. 
Admittedly, one-quarter of patients have needed an additional course of treatment. The 
overall good outcome is reflected in the renal survival rate of 86% at 5 and 10 years from 
renal biopsy. 
Most patients with membranous nephropathy and renal insufficiency will progress to ESRD if 
left untreated.7;8;13 Historical control studies have shown renal survival rates of only 20-32% 
after 7 years.7;8;13 We and others have provided evidence that a single course of 6-12 months 
of immunosuppressive therapy is effective and improves renal survival.7;8;13  
However, with prolonged follow-up it has become evident that many patients will relapse, 
with a relapse rate of 28% at 5 years follow-up8. It is evident that relapses still can occur after 
a second course of immunosuppressive therapy (in our present study, four out of 15 patients 
have needed a third course of immunosuppression). 
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Our study, thus, provides arguments for an active treatment policy in patients with 
membranous nephropathy, relapsing proteinuria and deterioration of renal function. Although 
our study cohort is relatively small, to date there are few data on this particular group of 
patients available in the literature.13;14 Most data on repeated courses of immunosuppressive 
therapy relate to patients with relapsing nephrotic syndrome without renal 
insufficiency.3;10;14;15  Ponticelli et al.10 reported on 169 patients with a variable degree of 
proteinuria and normal renal function, half of whom were treated with immunosuppression. 
Of 111 patients entering a PR or CR, 42 relapsed to nephrotic range proteinuria. Relapses 
occurred more frequently after a PR. Half of the relapsing patients entered a spontaneous 
remission again. Fifteen patients were treated again; nine of 11 patients treated with 
chlorambucil had a persistent remission on retreatment. Repeated cytotoxic therapy clearly 
increased the chance of a stable remission. Renal function deterioration occurred in a minority 
of patients (six out of 42), mainly in patients with persistent proteinuria.10 Positive responses 
to retreatment in low-risk populations have been reported by others as well.14;15 However, 
relapses after retreatment occur even in this low-risk population.3;10;15  
Blood pressure control in the early years of the study was not optimal when considering 
current guidelines. Treatment of blood pressure has become more aggressive in the recent 
decade. This is reflected by the fact that MAP amounted 103 mm Hg at the start of the first 
course and 95 mm Hg at 12 months after the second course of immunosuppressive therapy. 
The target MAP of 92 mm Hg is difficult to achieve in patients with renal failure and older 
age. However, most patients were using ACEI or AIIA and it is unlikely that a more 
aggressive antihypertensive strategy could have prevented the observed deterioration of renal 
function, thus, obviating the need for repeated immunosuppressive therapy. It is well 
established that renal function may deteriorate in many patients with membranous 
nephropathy despite well-controlled blood pressures and the use of ACEI or AIIA.8 
Two important questions must be addressed with respect to our treatment strategy. First, is it 
allowed to delay the start of immunosuppressive therapy until renal dysfunction is apparent? 
There is no support for this strategy from randomized trials. However, a recent analysis of our 
data has provided arguments that a restrictive treatment policy is justified. We have studied 
the outcome of a restrictive treatment strategy in a large cohort of adult patients with 
membranous nephropathy. Details of this study will be published elsewhere.16 Thus far, 
nearly half of the patients have received immunosuppressive therapy, mainly because of renal 
insufficiency. At the end of follow-up, 67% of patients were in CR or PR. Renal survival was 
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94% at 5 years and 88% at 7 years. From these data we concluded that restricted therapy is 
justified in view of the good overall outcome, whilst preventing immunosuppressive therapy 
in more than half of the patients. 
The second question is whether the advantages of a second (or even third or fourth) course of 
immunosuppressive therapy outweigh the short- and long-term side effects, particularly in 
patients with established moderate to severe renal insufficiency. To be able to balance the 
benefits and risks, we have estimated the dialysis-free survival time gained by therapy. It is 
evident that treatment-attributable survival time greatly exceeds the duration of the treatment 
courses. Furthermore, in the discussion of the side effects of treatment, it is important to 
realize that most patients who develop ESRD will receive a kidney transplant, thus, 
necessitating life-long immunosuppression with the related side effects. Our data indicate that 
the use of a second course of immunosuppressive therapy is not associated with more frequent 
or more severe side effects in the short-term. Of course, it is important to consider the long-
term side effects, the most important one being the potential of cyclophosphamide to induce 
(bladder) malignancies.17;18 For this reason, we have often replaced cyclophosphamide by 
azathioprine or cyclosporine whenever a third or fourth course of immunosuppressive therapy 
was needed. The risk of cyclophosphamide-related bladder cancer increases with the duration 
(especially  > 2.7 years) and the cumulative dosage (mainly  > 100g) of cyclophosphamide 
treatment.17 The cumulative duration of cyclophosphamide therapy and the administered 
dosage of cyclophosphamide are well below these values in most of our patients. 
It is evident that not all patients respond well to treatment and it is likely that non responsive 
patients may develop ESRD with longer follow-up. One could consider taking a renal biopsy 
to aid in treatment decisions, particularly to prevent that treatment is instituted in patients with 
chronic sclerotic lesions.  
It might be questioned whether it is possible to reduce the dose of cyclophosphamide. 
Ponticelli et al.11 have used cyclophosphamide in an alternating schedule, limiting the 
duration of cyclophosphamide therapy to 3 months. However, this short regimen has been 
studied extensively only in patients with normal renal function. We previously have reported 
a comparison of the Ponticelli regimen (with chlorambucil) and our 12 month 
cyclophosphamide regimen.5 We found the cyclophosphamide regimen more effective and 
less toxic than chlorambucil. It remains to be proved if these differences are related to the 
difference in duration of treatment or the type of agent. Future studies are needed to settle this 
issue; meanwhile we favour the 12 month regimen in patients with renal insufficiency. 
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Another strategy would be to use other immunosuppressive agents, such as mycophenolate 
mofetil or cyclosporine. To date, information on the efficacy of mycophenolate mofetil in 
patients with idiopathic membranous nephropathy and renal insufficiency is limited and 
inconclusive. Cyclosporine has been evaluated in a small randomized study, demonstrating an 
improvement in creatinine clearance and a decrease in proteinuria.19  Relapses occur, 
however, in about one-third of patients after cyclosporine withdrawal, thus, necessitating 
long-term administration of the drug.20;21 Furthermore, transient renal dysfunction and 
hypertension can occur in cyclosporine-treated patients. 19-21 
In conclusion, a repeated course of immunosuppressive therapy with cyclophosphamide and 
prednisone improves renal function and retards the progression of renal insufficiency in 
patients with idiopathic membranous nephropathy, relapsing proteinuria and deteriorating 
renal function. The advantage of a renewed course of immunosuppressive treatment (i.e. a 
delay of onset of ESRD) must be weighed against the side effects. We would like to argue in 
favour of a strategy of repeated immunosuppression, in particular in patients who would 
otherwise progress to ESRD, necessitating renal transplantation with its associated life-long 
immunosuppression. 
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Abstract 
Background. Patients with idiopathic membranous nephropathy (iMN), a nephrotic 
syndrome and renal insufficiency are at high risk for progression to ESRD. We have 
demonstrated that treatment with cyclophosphamide (CP, 1.5-2.0 mg/kg/day for 12 months) 
and steroids is effective, but associated with frequent and severe side effects. 
Methods. From May 2002 we have used a treatment schedule consisting of mycophenolate 
mofetil (MMF, 1000 mg twice daily for 12 months) and steroids. Efficacy and side effects of 
this schedule are compared with the results of treatment with CP in historical control patients, 
matched for serum creatinine, proteinuria, age and previous immunosuppressive treatment. 
Results. Thirteen patients (9 M, 4 F; median age 53 years) have completed the treatment 
protocol with MMF. For comparison we have selected 13 patients treated with CP. All 
patients but one (CP-group) used an ACE-inhibitor and/or an angiotensin receptor blocker. 
Blood pressures were comparable. Treatment with MMF was as effective as CP in improving 
renal function: serum creatinine at start of therapy and at 12 months was 162 [98-378] and 
123 [90-454] µmol/l (MMF) vs 158 [117-386] and 113 [88-289] µmol/l (CP)(NS). MMF was 
as effective as CP in reducing proteinuria: proteinuria at start and at 12 months was 13.2 [3.6-
30.8] and 2.0 [0.0-12.2] g/day (MMF) vs 11.6 [4.3-23.0] and 0.9 [0.1-13.0] g/day (CP)(NS). 
Eight (MMF) resp. 7 (CP) patients developed a partial remission of proteinuria. Side effects 
were reported in 9 out of 13 patients treated with MMF (69%), and 10 out of 13 (77%) treated 
with CP (NS). In the MMF-treated patients side effects were less severe, and necessitated 
dose reduction or interruption of therapy in 3 patients as compared with 9 patients treated with 
CP (P < 0.05) Treatment failure occurred in two MMF- and none of the CP-treated patients.  
Conclusion. MMF was better tolerated than CP. In the short-term MMF is as effective as CP 
in improving renal function, reducing proteinuria and achieving an initial remission of 
proteinuria in patients with idiopathic membranous nephropathy and renal insufficiency. Thus 
far, treatment failure occurred in two patients in the MMF-treated group en in none in the CP-
treated group. A larger group of patients and longer follow-up is needed to confirm the long-
term efficacy of MMF therapy. 
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Introduction 
Idiopathic membranous nephropathy remains the most common cause of the nephrotic 
syndrome in adults.1 Studies on the natural history of the disease show that up to 40% of 
untreated patients will progress to end-stage renal disease (ESRD).2-5 We, and others, are in 
favour of restricting immunosuppressive therapy to patients at highest risk to develop    
ESRD.5-13 Besides a sustained high amount of proteinuria, deterioration of renal function is an 
important prognostic factor predicting chronic renal insufficiency in this patient group.14-16 
We have demonstrated that treatment with cyclophosphamide (1.5-2.0 mg/kg/day for 12 
months) and steroids (methylprednisolone 1 g i.v. on 3 consecutive days on months 0, 2 and 4 
and prednisone 0.5 mg/kg/48 hours for 6 months) in patients with idiopathic membranous 
nephropathy and renal failure is effective, with a remission rate of 86%.8 Renal prognosis 
improved from a 7 year renal survival of 32% in untreated historical controls to 74% in 
cyclophosphamide treated patients.8 A comparable improvement in renal survival was shown 
for similar high-risk patients treated with chlorambucil.12 
However, treatment with cyclophosphamide or chlorambucil is associated with frequent and 
severe side effects, especially in patients with renal insufficiency.7;8 Mycophenolate mofetil is 
a new immunosuppressive agent, with fewer side effects and proven efficacy in transplant 
patients. Therefore, we have started a pilot-study to evaluate mycophenolate mofetil as 
treatment agent in patients with idiopathic membranous nephropathy, a nephrotic syndrome 
and renal insufficiency. We have compared the efficacy and side effects with results obtained 
in historical control patients treated with cyclophosphamide. 
 
 
Subjects and Methods 
In our pilot study with MMF we included only adult patients (age  > 18 years) with a biopsy 
proven membranous nephropathy. A secondary cause of membranous nephropathy was 
excluded on clinical and/or laboratory grounds. Patients were recruited in our University 
Hospital or in one of 9 referring hospitals. Eligible patients had to have evidence of renal 
insufficiency (defined as a serum creatinine > 135 μmol/l, a calculated endogenous creatinine 
clearance < 70 ml/min or a rise in serum creatinine of  > 50%) and a proteinuria of at least 2.0 
g/10 mmol creatinine. Exclusion criteria were systemic diseases, malignancies, active 
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infection, pregnancy or inadequate contra-conception, unstable angina pectoris, diabetes 
mellitus type I or long-lasting diabetes mellitus type II (unless renal biopsy proved the 
absence of diabetic nephropathy), clinical evidence of renal vein thrombosis, liver test 
abnormalities ( > 2x upper limit of normal), active peptic ulcer disease or gastro-intestinal 
diseases that could impair the resorption of oral medication. Patients who had used 
immunosuppressive therapy in the previous six months were not eligible, except in case of 
evident treatment failure. These inclusion and exclusion criteria also were used to determine 
the eligibility of patients for treatment with cyclophosphamide in the period 1995-2002. 
Treatment consisted of methylprednisolone 1 g i.v. for three consecutive days at the beginning 
of months 0, 2 and 4, and oral prednisone 0.5 mg/kg every other day for 6 months with 
subsequent tapering. The patients treated with MMF were treated with oral MMF 1000 mg 
twice daily for 12 months. In case of anemia (Hb < 6.0 mmol/l) or diarrhoea, the dose was 
initially reduced with 50% and subsequently up titrated to the highest tolerated dose. 
Historical controls were treated with oral cyclophosphamide, 1.5-2.0 mg/kg/day for 12 
months, with dose reductions in case of side effects.8 All patients were advised a moderately 
salt restricted diet. Concomitant treatment was not standardized, however physicians were 
instructed to lower blood pressure aggressively, primarily by using ACE-inhibitors and/or 
angiotensin receptor blockers for all patients with proteinuria, in the maximum tolerated dose, 
and to titrate on blood pressure (target mean arterial pressure (MAP) 92 mm Hg) and 
proteinuria. HMG-CoA reductase inhibitors were used to lower serum cholesterol. 
Anticoagulant drugs were not routinely prescribed. For the prevention of gastric complaints, 
famotidine was added. We advised to add trimethoprim-sulfamethoxazole 480 mg daily in the 
first 4-6 months in patients treated with cyclophosphamide to prevent Pneumocystis carinii 
pneumonia. Such preventive treatment was not used during MMF treatment.  
The time of follow-up started at the beginning of treatment with either MMF or CP. Efficacy 
and side effects of both treatment regimens were compared during the treatment year. Patients 
were seen at least every 4-8 weeks during the treatment year. Blood pressure, side effects of 
the therapy and laboratory data were registered. 
From our database, we selected 13 patients treated with cyclophosphamide as historic controls 
for the 13 patients treated with MMF. For matching, we used the following criteria in 
descending order of relevance: serum creatinine and proteinuria at the start of therapy, age, 
previous immunosuppressive therapy, serum albumin at start of therapy and sex.  
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In most MMF-treated patients, the urinary excretion of IgG, β2-microglobulin and α1-
microglobulin were measured at 0, 2, 6 and 12 months in a standardized way.17 These 
parameters of glomerular perm selectivity and tubular proteinuria respectively, are well 
known prognostic markers in patients with idiopathic membranous nephropathy and normal 
renal function.17-20 We previously have validated the following threshold values: for IgG 250 
mg/24 hour, for β2-microglobulin 0.5 μg/min and for α1-microglobulin 40 μg/min. We have 
compared the results with data obtained in patients treated with CP. However, since such 
measurements were only recently introduced data for comparison were not available for all 
matched CP-treated controls. Therefore, for the comparison data of 11 less well-matched CP-
treated patients were used. 
 
Calculations and Statistics 
For descriptive statistics, results are given as means ± standard deviation or medians with 
range when appropriate. To correct for inappropriate 24-hour urine collections, the amount of 
proteinuria was expressed as a protein-creatinine index (g/10 mmol creatinine). A complete 
remission of proteinuria, partial remission, persistent proteinuria and nephrotic range 
proteinuria were defined as a protein-creatinine index of ≤ 0.2, 0.21-2.0, 2.1-3.4 and ≥ 3.5 
g/10 mmol creatinine respectively, where in case of remission renal function should have 
improved or at least stabilized. All patients who entered a complete remission were also 
registered as having a partial remission. A relapse was defined as nephrotic range proteinuria 
after a partial or complete remission of proteinuria or a rise in proteinuria of  > 50% in 
patients in whom proteinuria had improved initially with  > 50%, without reaching values      
≤ 2.0 g/10 mmol creatinine. Treatment failure was defined as a relapse of nephrotic range 
proteinuria with renal function deterioration, defined as a rise in serum creatinine of at least 
25% over the best value achieved in the treatment year. 
In case of treatment failure before the end of the treatment year, the last laboratory values 
before the start of rescue therapy were carried forward to determine the 12 months values. 
Mean arterial blood pressure (MAP) was calculated using de formula MAP = diastolic blood 
pressure + 1/3 x (systolic blood pressure - diastolic blood pressure).  
The Mann-Whitney test was used for comparison between groups, and the Wilcoxon signed 
rank test for comparisons within the groups of treated patients. A P-value of < 0.05 was 
considered significant. All statistical procedures were done using SPSS software (SPSS 
version 11.5, Chicago, IL, USA). 
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Results 
From May 2002 until May 2004 22 patients have been included in the MMF study. Thirteen 
patients have completed the 12-months treatment protocol or had a treatment failure within 
the treatment year. 
The patient characteristics of the 13 MMF-treated patients and 13 matched, historical control 
CP-treated patients are given in Table 1. The groups were well matched for previous 
immunosuppression, sex, age, serum creatinine, serum albumin, proteinuria and MAP at the 
start of therapy. The time between renal biopsy and the start of the currently evaluated 
immunosuppressive therapy was shorter in the MMF-treated group (P < 0.05). This is 
explained by the fact that serum creatinine at the time of biopsy was numerically higher in 
MMF treated patients (130 [76-301] vs 98 [75-118] μmol/l), and in 6 exceeded 135 μmol/l, 
the threshold for starting immunosuppressive therapy. In the MMF-treated group, all patients 
used ACE-inhibitors and/or angiotensin receptor blockers, in the CP-treated group one patient 
did not receive such therapy. Six CP-treated individuals received trimethoprim-
sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis, whereas, per protocol, 
none of the MMF-treated patients did. 
 
Table 1. Baseline characteristics 
 MMF (n=13)  CP (n=13) 
Previous immunosuppression Prednisone, n=1 
Prednisone, CP, n=2
CP, n=1 
 Prednisone, n=1 
Chlorambucil, n=1 
Chlorambucil, CP, n=1 
CP, n=1 
Sex (M:F) 9 : 4   11 : 2 
Age at start of study (years)   53 [38-69]    60 [47-78] 
Time between renal biopsy 
and start of study (months) 
    3* [1-96]    14 [7-77] 
Serum creatinine (μmol/l) 162 [98-378]  158 [117-386] 
Serum albumin (g/l)   21 [6-36]    22 [14-31] 
Proteinuria (g/10 mmol creatinine)   13.2 [3.6-30.8]    11.6 [4.3-23.0] 
Mean Arterial Pressure (mm Hg)   99 [76-117]    93 [80-132] 
Values are medians with range. 
* P < 0.05, MMF vs CP 
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In Table 2, serum creatinine, serum albumin, serum cholesterol, proteinuria and MAP at start 
of therapy, at 6 months and at the end of the treatment are given. Treatment with MMF was as 
effective as CP in improving renal function and lowering proteinuria. In the MMF-treated 
group, 7 patients developed an initial partial remission, as compared with 8 patients in the CP-
treated group (NS). In both groups one patient achieved a complete remission within the 
treatment year. Cumulative (partial) remission rate at 12 months was 54%±14% on MMF and 
62%±13% on CP. The onset of partial remissions was at a median of 6.4 and 6.8 months, 
MMF vs CP (NS). 
 
Table 2. Laboratory parameters and blood pressure during the treatment-year 
 MMF (n=13) CP (n=13) 
 start 6 months 12 months start 6 months 12 months 
Screatinine 
(μmol/l) 
162 
[98-378] 
112**
[86-268]
123
[90-454]
158
[117-386]
113**
[76-356]
113** 
[88-289] 
Salbumin 
(g/l) 
21 
[6-36] 
32**
[21-45]
35**
[27-43]
22
[14-31]
34**
[22-38]
39** 
[25-44] 
Scholesterol 
(mmol/l) 
7.1 
[4.9-15.0] 
6.7
[4.1-9.8]
4.7**
[3.2-8.6]
7.0
[5.4-9.7]
6.1*
[4.7-8.6]
5.2** 
[3.8-7.5] 
Proteinuria  
(g/10 mmol creat) 
13.2 
[3.6-30.8] 
3.4**
[0.0-10.0]
2.0**
[0.0-12.2]
11.6
[4.3-23.0]
2.4**
[0.2-10.0]
0.9** 
[0.1-13.0] 
MAP 
(mm Hg) 
99 
[76-117] 
99
[85-113]
95
[75-110]
93
[80-132]
89**,#
[75-120]
93 
[83-124] 
Abbreviations: S, serum; MAP, mean arterial pressure. Values are medians with range. 
* P < 0.05, ** P < 0.01 for comparison with laboratory values at start of therapy. 
# P < 0.05, for comparison of MMF vs CP 
 
In the MMF-treated group, two patients developed a relapse of the nephrotic syndrome at 8 
months. One of these had an initial improvement in proteinuria from 13 to 3 g/day, the other 
experienced a short lasting PR at 7 months. In the CP-treated group no patient relapsed during 
the treatment year. As both relapsing patients experienced deterioration in renal function, after 
an initial improvement in renal function on MMF-therapy, they have started rescue therapy 
with cyclophosphamide and are recorded as treatment failures.  
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The results at the end of the treatment year are given in Table 3. There are no major 
differences, although treatment failure only was observed in the MMF group. 
 
Table 3. Status at end follow-up 
 MMF  
(n=13) 
CP  
(n=13) 
Complete remission ( < 0.2 g/day) 1 ( 8%) 1 ( 8%) 
Partial remission (0.21-2.0 g/day) 5 (38%) 7 (54%) 
Nephrotic syndrome 5 (38%) 5 (38%) 
Treatment failure 2 (15%) 0 (  0%) 
 
 
In Table 4, the results of the urinary measurements of IgG, β2-microglobulin and α1-
microglobulin are shown. Although the treatment groups were comparable with respect to 
renal function, proteinuria was higher in the MMF-treated group. In both groups a similar 
decline in the urinary excretions of IgG, β2-microglobulin and α1-microglobulin was noted. 
At 12 months urinary IgG was below the threshold of 250 mg/24 hours in 8 MMF and all 11 
CP-treated patients. The urinary excretion of β2-microglobulin was below the threshold of   
0.5 μg/min in 4 out of 11 MMF-treated and 4 out of 10 CP-treated patients; in one CP-treated 
patient urinary pH was not  > 6.0 at 12 months thus unabling correct determination of urinary 
β2-microglobulin.The urinary excretion of α1-microglobulin was below the threshold of 40 
μg/min in 6 MMF- as well as 6 CP-treated patients. Therefore, on the parameters for 
glomerular permeability and tubular proteinuria, no difference in the efficacy of both 
treatment agents existed.  
In Table 5, side effects in both groups are shown. In the 13 patients treated with MMF, 
therapy-related side effects occurred in 9 patients (69% of patients): anemia (n=4), respiratory 
tract infections (n=2; 1 with tuberculosis), steroid diabetes (n=2) and diarrhoea (n=1). 
Furthermore, one patient with longstanding diabetes mellitus type II without signs of diabetic 
nephropathy in the renal biopsy, experienced a diabetic foot. Another MMF-treated patient 
developed severe angio-edema, necessitating even mechanical ventilation, probably related to 
the use of RAAS-blockers; re-challenge with MMF was uneventful. 
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In the CP-treated patients, 10 patients experienced side effects, mainly consisting of 
leucocytopenia (n=7), anemia (n=2) and infections (n=6). One patient developed a 
pancytopenia with severe sepsis. Two patients experienced general malaise. 
In general, side effects were less severe with MMF. This is reflected by the fact that side 
effects necessitated dose reduction in only 3 MMF patients vs 9 CP patients (P < 0.05). Most 
important, leucocytopenia, quite common in CP-treated patients, was not seen in MMF-
treated patients. Infections were more frequent with CP-use, compatible with the increased 
incidence of leucocytopenia, but especially noteworthy in view of the use of trimethoprim-
sulfamethoxazole in half of the patients treated with CP. 
 
Table 5. Treatment-related complications 
Side effect MMF (n=13) CP (n=13) 
 Number of pts 
(%)
Dose 
reduction
Number of pts 
(%)
Dose 
reduction 
Bone marrow depression
  Leucocytopenia 
  Anemia  
0 (  0%)
4 (31%)
  0*
2
7 (54%)
2 (15%)
 
7 
1 
Infections 
   All together 
   Respiratory 
2 (15%)
2 (15%)
0
0
6 (46%)
3 (23%)
 
3 
1 
Diarrhoea 1 (  8%) 0 (  0%) 0 
Malaise 0 (  0%) 0 2 (15%) 0 
Steroid induced  
  diabetes mellitus 
2 (15%) 0 0 (  0%) 0 
Other 2 (15%) 0 1 (  8%) 1 
Total 9 (69%)   3* 10 (77%) 9 
The numbers don’t add up; one patient can have more than one complication.  
Definitions: leucocytopenia: leucocyte count < 3.0*109/l; anemia: Hb < 6.0 mmol/l or erythropoietin 
use to prevent Hb < 6.0 mmol/l; thrombocytopenia: thrombocyte count < 100*109/l.  
* P < 0.05, MMF vs CP 
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Discussion 
Immunosuppressive therapy is effective in patients with idiopathic membranous nephropathy 
and renal insufficiency. However, side effects are a major limitation of the use of 
immunosuppressive agents such as CP or chlorambucil in the treatment of patients with 
idiopathic membranous nephropathy. Therefore, MMF may offer benefits. 
Our data indicate that, in the short-term, MMF is as effective as CP in the treatment of 
patients with idiopathic membranous nephropathy and renal insufficiency. Of course, since 
this was only a pilot study in a limited number of patients, firm conclusions cannot be drawn. 
However, we feel that our data support the conception of controlled studies using MMF. 
Literature data on the efficacy of MMF in patients with idiopathic membranous nephropathy 
are scarce and preliminary. 
Briggs described the first results in three patients with membranous nephropathy, a nephrotic 
syndrome and normal renal function, relapsing after therapy consisting of corticosteroids and 
cyclosporine.21 MMF was given in a dose of  ≥ 750 mg twice daily, initially with low dose 
steroids, which were subsequently withdrawn. With a short course of MMF, significant 
reductions in proteinuria were demonstrated to levels below 2g/day, with preservation of 
normal renal function. Side effects were absent.21 Follow-up of these patients suggests that 
relapse may occur after a six month course, with partial remission after the resumption of 
MMF in one patient.22 In a later report, the experience was extended into 17 patients with 
idiopathic membranous nephropathy, 15 of them nephrotic and six with renal insufficiency.23 
Indications for MMF treatment included steroid and/or cyclosporine dependency, resistance 
or intolerance. There was no predefined treatment protocol. The duration of MMF-therapy 
was highly variable: 4-25 months and the dosage varied from 0.5 to 1.0 g twice daily, with 10 
patients receiving 2.0 g/day. Most patients received low dose steroids. Of the 15 nephrotic 
patients, two achieved a complete and five a partial remission (remission rate 41%). The 
median percent reduction in proteinuria was 61%. There was no change in median serum 
creatinine. Two patients relapsed after MMF was stopped. In the majority of patients, 
progressive steroid and cyclosporine withdrawal was achieved. Side effects consisted of mild 
reversible leucocytopenia (n=1) and discontinuation of MMF was needed in three patients 
due to severe gastritis, pneumonia and squamous cell cancer of the arm. A striking 
observation in these studies was a threshold dose of 1.5 g/day for efficacy, unless there was 
severe renal insufficiency.23  
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Miller reported on 16 patients with membranous nephropathy and a nephrotic syndrome, of 
whom 15, 6 and 5 had failed on therapy with steroids, cytotoxic agents or cyclosporine A, 
respectively.24 All patients were at high risk for progressive renal failure, given their 
persistent high level of proteinuria and eleven patients had renal insufficiency (serum 
creatinine  > 135 μmol/l). The administered dose of MMF was low (500 –2000 mg/day, only 
7 patients achieved the target dose of 2 g/day). MMF was given for a mean period of 8 
months, and was discontinued in patients with no response at 6 months. Additional low dose 
steroid therapy ( < 15 mg/day) was given in only five patients. Most patients used RAAS-
blockers and HMG-CoA reductase inhibitors. Six patients (38%) experienced a halving of 
proteinuria, which occurred after a mean duration of 6 months of therapy. A partial remission 
of proteinuria ( < 3 g/day) occurred in only two patients; both patients were treated for about 
one year and with doses of 1.0-1.5 g/day of MMF. No significant change in serum creatinine 
level was seen. Again, side effects were infrequent and mild with transient leucocytopenia in 
one patient, Varicella Zoster infection in another patient and severe diarrhoea in one patient, 
necessitating discontinuation of the drug in these last two patients.24 
Polenakovic described the effect of MMF-treatment in eight patients with membranous 
nephropathy, in whom previous treatment failed in five patients (previous treatment consisted 
of steroids with cyclosporine, chlorambucil or cyclophosphamide) and three patients were 
treated with MMF as first choice drug.25 All patients were nephrotic, three had slight 
elevations of serum creatinine. Treatment consisted of MMF 2g/day during nine months. 
Proteinuria decreased significantly from 4.4 g/day to 1.9 g/day after nine months. Renal 
function did not improve significantly. Side effects were noted in one patient, who 
experienced joint and muscle aches.25  
Our study demonstrates the short-term efficacy of mycophenolate mofetil (MMF) with 
steroids in a quite homogeneous group of patients with idiopathic membranous nephropathy 
and renal insufficiency, thus patients at high risk for progressive renal insufficiency. Efficacy 
of MMF may seem better than expected based on the literature data. We feel that our data are 
rather robust, since we have been able to compare the efficacy of MMF with the efficacy of 
cyclophosphamide (CP) and steroids in a group of well-matched historical control patients. 
Both patient groups were comparable at the start of treatment with respect to those parameters 
that are most important predictors of renal insufficiency: serum creatinine and amount of 
proteinuria at the start of treatment. Furthermore, they were comparable on other 
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characteristics, like previous immunosuppression, age, serum albumin, MAP and the use of 
RAAS-blockers.  
Our results may be explained by the treatment protocol. We have treated almost all patients 
with MMF 2 g/day for 12 months and (initial high dose) steroids for 6 months in a predefined 
treatment protocol. Thus, our treatment schedule clearly outweighs the schedules given by 
other investigators. 
In the short-term, MMF was as effective as CP in improving renal function and reducing 
proteinuria. An equal substantial number of patients developed a remission of proteinuria. 
Most patients experienced an improvement in renal function, in contrast to literature results 
hitherto reported. 
We must caution however, since we cannot comment on the long-term efficacy. Thus far, two 
patients have already experienced treatment failure and have needed additional therapy with 
CP. This might suggest that MMF is less able to induce sustained remissions. We know, from 
our previous study, that the rate of relapse increases with the duration of follow-up.8 We have 
shown a relapse rate of 28% after 5 years in a large group of 65 patients treated with 
cyclophosphamide for idiopathic membranous nephropathy, nephrotic syndrome and renal 
insufficiency.8 Ponticelli found an even higher relapse rate of 30% after 2 years in patients 
with normal renal function treated with chlorambucil.26 Therefore, especially regarding the 
efficacy in maintaining a remission of proteinuria, a larger group of patients and longer 
follow-up are needed. It will be relevant to determine if relapses occurring after MMF 
treatment respond to a second course of immunosuppression. We have shown before, that 
repeated treatment with cyclophosphamide is effective in patient who had received previous 
therapy with chlorambucil or cyclophosphamide.27 In such case, it might always be 
worthwhile to use the less toxic drug as first line therapy.  
Side effects were almost equally frequent but less severe with the use of MMF. Especially 
leucocytopenia was more frequent with CP-use and indeed the number of infections was less 
with the use of MMF. This is even more remarkable since half of the patients in the CP-
treated group have used trimethoprim-sulfamethoxazole prophylactically. Cyclophosphamide 
is associated with bladder toxicity and malignancies28;29, and these problems do not occur 
with MMF. As the risks of these serious side effects of cyclophosphamide increase with 
increasing cumulative dose, this could be an extra argument for starting with a less toxic drug 
like MMF, reserving CP for patients not responding on or relapsing after treatment with 
MMF. 
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In conclusion, the short-term efficacy of MMF and steroids for the treatment of patients with 
idiopathic membranous nephropathy, nephrotic syndrome and renal insufficiency seems 
comparable with the efficacy of cyclophosphamide and steroids. Our predefined treatment 
schedule with a longer duration of therapy (12 months), a higher dose of MMF (2 g/day) and 
the addition of steroids, seems to result in substantial reductions of proteinuria and 
improvement in renal function. Relapse rate is of serious concern. Results of larger groups of 
patients with longer follow-up and head to head comparisons between MMF and current 
immunosuppressive therapies for this group of patients have to be awaited. 
 
Appendix 
The following colleagues have actively participated in this study of the Membranous 
Nephropathy Study Group: 
Dr. J. Broekroelofs, Medical Center Leeuwarden, Leeuwarden; Dr. P.G.G. Gerlag, Máxima 
Medical Center, Veldhoven and Dr. A.G. Lieverse, Máxima Medical Center, Eindhoven; Dr. 
W. Grave, Laurentius Hospital, Roermond; Dr. E.C. Hagen and Dr. C.A.J.M. Gaillard, 
Meander Medical Center, Amersfoort; Mrs. Dr. M.I. Koolen, Jeroen Bosch Hospital, ’s 
Hertogenbosch; Dr. L.J.M. Reichert, Rijnstate Hospital, Arnhem and Dr. A.L. Zanen, 
Deventer Hospital, Deventer. 
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Summary 
Background. Immunosuppressive treatment initiated at an early stage in patients with 
idiopathic membranous nephropathy (iMN) improves renal survival. Treatment should ideally 
be restricted to high-risk patients. 
Aim. To evaluate the efficacy of a restrictive immunosuppressive treatment strategy for 
patients with iMN. 
Design. Prospective cohort study evaluating a pre-defined treatment protocol. 
Methods. From 1988, we adopted a restrictive treatment strategy: immunosuppressive 
treatment, mainly consisting of cyclophosphamide and steroids, was advised only in patients 
with renal insufficiency or severe intolerable nephrotic syndrome. We evaluated this strategy 
in a large patient cohort. To exclude any bias, we included all adult patients with iMN 
biopsied in the study period with a serum creatinine (Scr) < 135 μmol/l, a proteinuria ≥ 3.0 
g/day and/or a serum albumin (Salb) ≤ 30 g/l at the time of biopsy. Analysis was according to 
the intention-to-treat principle.  
Results. We studied 69 patients. At the time of biopsy, mean age was 51 years, Scr 90 μmol/l, 
Salb 23 g/l and proteinuria 6.7 g/day. Average follow-up was 5.5 years. Thus far 33 (48%) 
patients have received immunosuppressive therapy, mainly because of renal insufficiency 
(n=24). Status at the end of follow-up was: complete remission n=22 (32%), partial remission 
n=24 (35%), nephrotic syndrome n=15 (22%), persistent proteinuria n=1 (1.4%), ESRD n=6 
(8.7%), death n=1 (1.4%; due to bladder carcinoma after cyclophosphamide therapy). Patient 
survival was 100% at 5 and 7 years. Renal survival was 94% at 5 years and 88% at 7 years. 
Conclusion. In patients with iMN, a restrictive treatment policy assures a favourable 
prognosis, while preventing exposure to immunosuppressive therapy in  > 50% of the 
patients. 
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Introduction 
The treatment of patients with idiopathic membranous nephropathy is still a matter of debate. 
Some authors have argued against the use of immunosuppressive drugs.1 A meta-analysis of 
randomized studies found no prove for a beneficial effect of immunosuppressive therapy on 
renal survival.2 However, the recent publication of the long-term follow-up data of the 
randomized, controlled trial conducted by Ponticelli and his collaborators has provided hard 
evidence that immunosuppressive therapy is effective and improves renal survival.3,4 In the 
latter study, treatment, which consisted of a combination of chlorambucil and steroids, was 
started at an early stage, i.e. before significant deterioration of renal function had occurred. 
Since only up to 40-50% of untreated patients will progress to end-stage renal disease 
(ESRD), such a strategy of early treatment start will expose many patients unnecessarily to 
immunosuppressive treatment.1,4-10 In view of the potential side effects of therapy, many 
investigators have been reluctant to adopt the Ponticelli treatment strategy, although the 
efficacy of their regimen is not debated. Uncontrolled studies have suggested that 
immunosuppressive therapy is effective even when started in patients with established renal 
insufficiency.11-21 We and others have shown that immunosuppressive treatment offers a clear 
renal survival benefit over untreated historic control patients.21,22 However, thus far there are 
no data to suggest that such a restrictive treatment policy is safe and assures an outcome 
which is comparable to that obtained by Ponticelli et al. 
The present report summarizes the efficacy of such a restrictive treatment strategy applied to a 
large cohort of patients with idiopathic membranous nephropathy, a nephrotic syndrome and 
normal renal function at the time of renal biopsy. 
 
 
Methods 
Treatment Strategy 
For more than two decades, we have been actively recruiting patients with idiopathic 
membranous nephropathy for participation in ongoing studies directed at the identification of 
prognostic risk factors.23,24 Treatment guidelines have been developed for the follow-up of 
these patients. Until 1988, most patients were treated with alternate-day high-dose prednisone 
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monotherapy.25 From 1988 onwards, we used a more restrictive treatment strategy. 
Immunosuppressive therapy was advised only in patients with renal insufficiency (serum 
creatinine > 135 μmol/l and/or an increase in serum creatinine of  > 50%) or severe 
intolerable nephrotic syndrome (prolonged proteinuria ≥ 8 g/day). Details of our 
immunosuppressive treatment regimens have been described.11-13,26 Initially, 
immunosuppressive therapy consisted of the combination of chlorambucil and corticosteroids, 
or a combination of i.v. cyclophosphamide and i.v. methylprednisolone. The latter 
combination was ineffective.26 In 1991, we started to use a combination of oral 
cyclophosphamide and steroids, and this treatment has been the treatment of choice after an 
analysis of our data suggested that cyclophosphamide was more effective and better tolerated 
than chlorambucil.12 Cyclophosphamide treatment consisted of oral cyclophosphamide in a 
dose of 1.5-2 mg/kg bodyweight/day for 12 months. In most patients, the corticosteroid 
regimen consisted of three consecutive i.v. pulses of 1 g of methylprednisolone at the 
beginning of the first, third and fifth month of therapy, and oral prednisone in a dose of       
0.5 mg/kg bodyweight on alternate days for six months. Repeated courses of 
immunosuppressive therapy were offered to patients in whom previous therapy showed no 
effect, or who relapsed to nephrotic range proteinuria, together with a rise in serum creatinine 
of more than 50% over the lowest value attained during or after the previous course of 
immunosuppressive treatment. The study protocol, on the treatment of patients with 
membranous nephropathy, has been approved by the University Hospital Ethics Committee.  
 
Patient Selection 
To exclude any bias, we have identified all patients with membranous nephropathy from the 
pathology registries of our university hospital and five referring hospitals. We have included 
only patients with a first renal biopsy in the study period, age ≥ 18 years, and with a serum 
creatinine < 135 μmol/l, a proteinuria ≥ 3.0 g/10 mmol creatinine and/or a serum albumin      
≤ 30 g/l at the time of biopsy.  Follow-up should have lasted at least 6 months. We excluded 
patients with a secondary membranous nephropathy on clinical and laboratory grounds. 
Patients were followed prospectively at their local hospitals at regular intervals. For this 
study, we have evaluated the patient records, retrieved relevant laboratory data and when 
applicable, we have specified the time of start, the type and the duration of 
immunosuppressive therapy. The indication for starting immunosuppression was noted. 
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Follow-up started at the time of renal biopsy and continued until December 2002, or ended at 
the time of death or onset of ESRD. 
 
Calculations and Statistics 
For descriptive statistics, results are given as means ± SD or medians with range when 
appropriate. Creatinine clearance was calculated according to Cockcroft and Gault.27 
Proteinuria was expressed per 10 mmol creatinine (protein-creatinine index). Complete 
remission of proteinuria (CR), partial remission (PR), persistent proteinuria (PP) and 
nephrotic range proteinuria (NS) were defined as protein-creatinine indices of ≤ 0.2, 0.21-2.0, 
2.1-3.4 and ≥ 3.5 g/10 mmol creatinine, respectively, where in case of remission, renal 
function should have improved or at least stabilized. Mean arterial pressure (MAP) was 
calculated as diastolic blood pressure plus one third of the pulse pressure (systolic minus 
diastolic blood pressure). For calculations of renal survival, the time of renal death was 
defined as the start of renal replacement therapy. The cumulative probabilities of death and 
ESRD were estimated according to Kaplan and Meier. 
 
 
Results 
In the period from 1988 to 2002, idiopathic membranous nephropathy was diagnosed in 87 
patients. For this study, we excluded 18 patients because of renal insufficiency (n=8; median 
serum creatinine at time of biopsy 218 [149-324] μmol/l) or non-nephrotic proteinuria (n=5) 
at the time of renal biopsy, age < 18 years (n=2) or follow-up < 6 months (n=3). Thus the 
study cohort comprised 69 patients. 
Patient characteristics at the time of renal biopsy are given in Table 1.  
Mean follow-up after renal biopsy was 5.4 (range 0.5-14.1) years, 37 patients have been 
followed for  > 5 years, nine for  > 10 years. Four patients were lost to follow-up: two because 
they moved (one in CR, one with persistent proteinuria), one because of non-compliance (in 
PR) and one for unknown reason (with persistent nephrotic syndrome). 
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Table 1.  Characteristics of the patients at the time of biopsy 
Characteristic Value 
Number of patients 69 
Male : female 43 :  26 
Age (years) 51 ± 15 
Serum creatinine (μmol/l) 90 ± 20 
Serum albumin (g/l) 23 ± 5 
Serum cholesterol (mmol/l) 10.4 ± 3.1 
Proteinuria (g/10 mmol creatinine) 6.7 ± 3.0 
Creatinine Clearance (ml/min/1.73 m2) 99 ± 33 
Mean Arterial Pressure (mm Hg) 103 ± 13 
Data are means ± SD where appropriate. 
 
Follow-up, with emphasis on the use of immunosuppressive therapy, is detailed in Figure 1.  
Thus far, 33 patients have been treated with immunosuppressive drugs. In 24 patients, 
immunosuppressive therapy was started because of renal insufficiency. For these patients, the 
mean time between renal biopsy and start of the immunosuppressive therapy amounted to 11 
(range 0.5-103) months and total follow-up time from renal biopsy was 65 (range 16-169) 
months. If we analyse the data according the intention-to-treat principle, patient survival was 
100% at 5 and 7 years, and renal survival 94% at 5 years and 88% at 7 years (Figures 2 and 
3). At the end of follow-up, 22 patients were in complete remission (32%), 24 in partial 
remission (35%), one patient had persistent proteinuria (1.4%) and 15 patients had a nephrotic 
syndrome (22%). Six patients had progressed to ESRD (8.7%) and one patient had died 
(1.4%), due to disseminated bladder carcinoma, occurring after a cumulative dose of only    
20 g cyclophosphamide. 
It is evident from Figure 1 that the advised treatment protocol has not been adhered to by 13 
patients (white boxes in Figure 1). In three patients with established renal insufficiency, no 
immunosuppressive therapy was given because of old age (n=2; 73 and 83 years old, 
respectively) or patient refusal (n=1). Two patients with proteinuria < 8 g/day were treated 
with prednisone. 
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Figure 1. Flow-chart of  treatment regimen. 
Immunosuppressive therapies: P, prednisone; CP, cyclophosphamide with steroids;  
CA, chlorambucil with steroids; Aza, azathioprine; oth, others.  
CR, complete remission; PR, partial remission; NS, nephrotic syndrome; PP, persistent proteinuria; 
ESRD, end-stage renal disease.  
Dotted rectangles represent status at end of follow-up.  
Gray rectangles indicate patients in whom the optimal treatment regimen was followed. 
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Figure 2. Patient survival. 
Numbers of patients at risk are given in parentheses. 
 
 
Figure 3. Renal survival. 
Numbers of patients at risk are given in parentheses. 
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Furthermore, eight patients with severe nephrotic syndrome (n=5) or renal insufficiency 
(n=3) were treated initially with prednisone monotherapy, reflecting the reluctance of patients 
and/or doctors to use alkylating agents, especially in patients with preserved renal function. 
As expected, prednisone monotherapy proved ineffective in seven out of eight patients, thus 
necessitating a second, more aggressive course of immunosuppressive therapy. In four of 
these patients, serum creatinine exceeded 200 μmol/l at the time that the second course of 
therapy was started. To determine the potential influence of these protocol violations on 
patient outcome, we have analysed our data for the subgroup of patients who were treated 
according to the predefined protocol (n=56; 82%) thus including untreated patients with 
preserved renal function (n=33) and patients treated with a combination of steroids and 
cyclophosphamide or chlorambucil because of renal insufficiency (n=21) or a severe 
nephrotic syndrome (n=2). These patients are indicated in Figure 1 with gray boxes. In this 
subgroup analysis, patient survival was 100% at 5 and 7 years and 89% at 10 years, whereas 
renal survival was 97% at 5 and 7 years and 86% at 10 years follow-up. 
Seven patients were initially treated with prednisone (n=5) or cyclophosphamide (n=2) 
because of severe proteinuria with normal renal function. Five of them progressed to renal 
insufficiency necessitating a second course of immunosuppression; four had a persistent 
proteinuria  > 5.3 g/10 mmol creatinine after the start of the first course. In these five 
progressors, serum creatinine at the start of the first and at the start of the second 
immunosuppressive course was 85 (range 79-115) and 189 (range 162-489) μmol/l (P < 0.01) 
and proteinuria 9.1 (range 8.1-46.0) and 6.6 (range 5.3-13.0) g/10 mmol creatinine (P = NS), 
respectively. 
 
 
Discussion 
Our data clearly show that a restrictive treatment strategy applied to nephrotic patients with 
idiopathic membranous nephropathy results in high patient and renal survival. We feel that 
our study thus provides some arguments against the unrestrictive use of immunosuppressive 
therapy in patients with idiopathic membranous nephropathy.  
Admittedly, our study is not a randomized, controlled trial, but a cohort study. We feel that 
the data are representative. Our patient cohort is large, and included only patients who were 
nephrotic at the time of biopsy. To exclude any referral bias, we have retrieved all patients 
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who were diagnosed with idiopathic membranous nephropathy in the study period, using the 
pathology registries. Furthermore, in our analysis we have included the data of all patients, 
irrespective of their course and given treatment (intention-to-treat principle). Our data must be 
compared with those reported by Ponticelli et al.3,4 The Italian investigators have conducted a 
randomized, controlled study in patients with idiopathic membranous nephropathy and 
nephrotic syndrome, who were randomized for either no treatment or treatment with a 
combination of chlorambucil and steroids. This study provided hard evidence that unrestricted 
immunosuppressive treatment improves renal survival. The baseline characteristics of the 
patients in Ponticelli’s and our study were quite similar with respect to proteinuria and renal 
function (Table 2).  
 
Table 2. Results of different treatment strategies in patients with idiopathic membranous 
nephropathy and nephrotic syndrome 
 This Study Ponticelli 
untreated3,4 
Ponticelli 
treated3,4 
Stirling19 
 
n  69 39 42 53 
Treated with immunosuppressives 48% 0% 100% 36% 
Immunosuppressive drug Mainly 
cyclophosphamide
- Chlorambucil Chlorambucil 
Serum creatinine (μmol/l) 
  At biopsy 
  At start immunosuppressive therapy 
 
  90 ± 20 
150 ± 54 
 
93 ± 25 
 
94 ± 22 
94 ± 22 
 
130 
267 
Proteinuria at biopsy 
  (g/10 mmol creatinine) 
  6.7 ± 3.0   5.3 ± 2.8   6.2 ± 3.0   8.3 
Follow-up (years)   5.4 [0.5-14.1]   7.3*  > 10*   5.9 
Remissions: CR 
  PR 
22 (32%) 
24 (35%) 
  2 (5.1%) 
11 (28%) 
17 (40%) 
  9 (21%) 
13 (24%) 
12 (23%) 
NS / Renal dysfunction 16 (23%) 14 (36%) 13 (31%) 13 (25%) 
ESRD   6 (8.7%)   9 (23%)   2 (4.8%)   7 (13%) 
Death (non-renal)   1 (1.4%)   3 (8%)   1 (2.4%)   8 (15%) 
Renal survival 
  5 years 
  7 years 
10 years 
 
94% 
88% 
78% 
 
84%* 
79%* 
60% 
 
97%* 
94%* 
92% 
 
84% 
72%* 
54% 
CR, complete remission; PR, partial remission; NS, nephrotic syndrome; ESRD, end-stage renal 
disease. *Approximate values derived from graphs.  Values are means ± SD, or medians [range]. 
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It is evident from Table 2 that the outcome in our patient cohort was better than in the 
untreated group of patients from Ponticelli’s study, thus supporting the efficacy of 
immunosuppressive therapy. Most importantly, however, our patient cohort fared almost as 
well as the treated patients with respect to remission rate and development of renal failure. 
Admittedly, follow-up in our study was less than the 10-year follow-up reported by Ponticelli 
et al. The estimated 10-year renal survival in our patients is 78% (95% CI 58-98%), clearly 
lower than the 92% survival rate reported by Ponticelli et al. (95% CI not provided). These 
differences in renal survival can be attributed to the fact that, especially in the initial study 
period, some of our patients received the less effective prednisone monotherapy. If we 
analysed our data ‘per protocol’, renal survival was 97% at 7 years and 86% at 10 years. In 
our treated patients, serum creatinine at the start of immunosuppressive therapy averaged 150 
± 54 μmol/l. 
The outcome in our patient cohort is clearly better than that reported by Stirling et al.19 These 
authors reported the outcome in a group of patients with idiopathic membranous nephropathy, 
in whom immunosuppressive treatment, which consisted of a combination of chlorambucil 
and steroids, was restricted to patients with renal insufficiency. Although the number of 
remissions was higher and the percentage of patients reaching ESRD lower than in a historical 
control group of untreated patients, the differences did not reach statistical significance. We 
feel that these seemingly discordant results can be explained (Table 2). Stirling et al. initiated 
immunosuppressive therapy at a late stage, serum creatinine averaging 267 μmol/l at start of 
treatment. Furthermore, they did not use intravenous methylprednisolone in all their patients, 
and in earlier publications they have indicated that the outcome in patients not receiving i.v. 
methylprednisolone is not as good.28 Last but not least, the type of immunosuppression is 
important. We have previously demonstrated that in patients with renal insufficiency 
chlorambucil is less well tolerated and less effective than cyclophosphamide.12  
Our data thus indicate that it is unnecessary to use immunosuppressive treatment in all 
patients with membranous nephropathy. On the other hand, it is evident from the data 
presented in Table 2, that the treatment should be started before severe renal insufficiency has 
developed. We feel that the good renal survival in our patients who were treated per protocol 
suggests that treatment should be started as soon as deterioration of renal function becomes 
apparent, as reflected by a rise of serum creatinine  > 50% or a value of serum creatinine  > 
135 μmol/l. It might well be that starting therapy at an earlier time point might even prove 
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slightly more effective. In this respect it could be advantageous to identify patients at high 
risk for renal insufficiency at an earlier stage, using prognostic markers such as urinary 
excretion of IgG, β2-microglobulin or α1-microglobulin.23,24,29 
When comparing our treatment schedule, consisting of 12 months of cyclophosphamide with 
the Ponticelli regimen (3 months of chlorambucil or cyclophosphamide), safety issues are a 
concern. If cyclophosphamide is given for  > 3 months, there is an increasing risk of persistent 
amenorrhea and azoospermia. Therefore, in patients who wish to become pregnancy, we 
currently replace cyclophosphamide by azathioprine after 3 months. Bladder cancer is also a 
serious complication of long-term cyclophosphamide therapy, although bladder cancer is 
particularly observed if duration of treatment exceeds 2 years and the cumulative dosage 
exceeds 100 g.30,31 Our current regimen contains approximately 40 g of cyclophosphamide. 
Although it would be tempting to use the 3 months regimen, we are somewhat concerned 
about the efficacy. In fact, we have demonstrated that 12 months of cyclophosphamide is 
more effective (and less toxic) than 3 months of chlorambucil.12 Thus, it is quite possible that 
the efficacy of a drug regimen is dependent on the duration of treatment. Furthermore, the 
efficacy of the Ponticelli regimen has only been demonstrated in low-risk patients.3,4,32 The 
optimal timing and dosage of cyclophosphamide therapy is an important topic for future 
studies. Until these issues are resolved, we favour a 12-month regimen as initial treatment in 
patients with membranous nephropathy and renal insufficiency. 
 
Conclusions 
In patients with idiopathic membranous nephropathy and nephrotic syndrome, a restrictive 
use of immunosuppressive therapy assures a favourable prognosis while preventing exposure 
to immunosuppression in over half of the patients. The optimal time of start of 
immunosuppressive therapy needs to be further defined.  
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Abstract 
An accurate prediction of the prognosis of patients with idiopathic membranous nephropathy 
(iMN) should allow restriction of immunosuppressive treatment to patients who are at highest 
risk for ESRD. On the basis of retrospective studies, it has previously been suggested that the 
urinary excretions of β2-microglobulin (Uβ2m) and IgG (UIgG) are useful predictors of renal 
insufficiency in patients with iMN. The threshold values of 0.5 µg/min (Uβ2m) and 250 
mg/24 h (UIgG) have been validated in a new and larger patient cohort. From 1995 onward, 
57 patients with iMN (38 men, 19 women; age 48 ± 16 yr), a nephrotic syndrome, and a 
serum creatinine level ≤ 1.5 mg/dl were studied prospectively. At baseline, a standardized 
measurement was carried out to determine renal function and protein excretion. The end point 
renal death was defined as a serum creatinine exceeding 1.5 mg/dl or a rise of serum 
creatinine of  > 50%. Mean (±SD) follow-up was 53 ± 23 months. Thus far, 25 (44%) of the 
patients have reached the end point renal death. Multivariate analysis confirmed Uβ2m as the 
strongest independent predictor for the development of renal insufficiency. Sensitivity and 
specificity were 88% and 91%, respectively, for Uβ2m, and both were 88% for UIgG. When 
the excretions of both proteins were combined, specificity improved to 97%. It is concluded 
that the present data validate the accuracy of Uβ2m and of UIgG in predicting renal outcome 
in patients with iMN. These markers can be used to guide decisions on the start of 
immunosuppressive treatment. 
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Introduction 
Idiopathic membranous nephropathy (iMN) is one of the most frequent causes of the 
nephrotic syndrome in adults.1 If left untreated, up to 40% of patients will progress to 
ESRD.2-4 The efficacy of immunosuppressive therapy has been demonstrated in a 
randomized, controlled trial.4 Although this study provided arguments to treat all patients with 
iMN and a nephrotic syndrome, most authors advocate restricting immunosuppressive 
treatment to patients who are at highest risk for developing ESRD.5,6 It is well established that 
deterioration of renal function is a powerful predictor of ESRD.7,8 Therefore, a trial of 
immunosuppressive therapy is warranted in patients with iMN and established renal 
insufficiency. However, it is evident that immunosuppressive treatment started at a relatively 
late time point may be less effective in attaining normal renal function.9 Moreover, we and 
others have noted that the use of immunosuppressive agents in patients with renal 
insufficiency was associated with more frequent and more severe side effects than in patients 
who are treated in an earlier phase of their disease.10-12 Therefore, it would be ideal if 
treatment could be optimized by identifying high-risk patients at an earlier time point. In 
patients with iMN, various risk factors for the development of renal failure have been 
identified.13 However, the sensitivity and specificity of most of these factors (e.g., age, 
gender, glomerular injury, tubular interstitial fibrosis) are too low to justify their use to guide 
decisions on the start of immunosuppressive therapy. Thus far, the level and the duration of 
proteinuria are the best predictive factor in a model introduced by the Toronto 
Glomerulonephritic Registry.14 This model requires a minimal observation period of 6 to 18 
months.  
On the basis of data derived from small patient cohorts, we demonstrated previously that the 
urinary excretion of β2-microglobulin (Uβ2m) and IgG (UIgG), assessed in a single urine 
sample, independently predicted the development of renal insufficiency in patients with 
iMN.15,16 Our data suggested high sensitivities and specificities, which ranged from 80 to 
90%. We now have validated these results in a prospectively studied, new and larger patient 
cohort.  
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Materials and Methods 
In our center, patients with proteinuria are evaluated using a standard protocol. In all of these 
patients, standardized urine and blood measurements are carried out as described below.  For 
the validation study, we prospectively studied patients with biopsy-proven iMN, evaluated 
from 1995 onward. In the analysis, we included only patients with a baseline serum creatinine 
≤ 1.5 mg/dl* and proteinuria ≥ 2.7 g/g creatinine and/or serum albumin ≤ 3.0 g/dl. We 
excluded patients who had been treated with immunosuppressive drugs other than oral 
prednisone. Patients were also excluded when the interval between renal biopsy and the 
baseline measurement exceeded 3 years.  
 
Standardized Measurement of Urinary Proteins 
Patients come to the ward after an overnight fast. Patients are instructed to take 4000 mg of 
sodium bicarbonate on the evening before to ensure that urinary pH exceeds 6.0, which is 
mandatory for the measurement of Uβ2m. On the morning of the measurement, patients are 
not allowed to take diuretics. Upon arrival, 375 to 500 ml of tap water is given to enforce 
diuresis. The patients remain supine during 2 h except for voiding. Blood pressure 
measurements are done using an automatic device, and 10 consecutive readings are registered 
with an interval of 5 minutes (DINAMAP, Criticon, Tampa FL). Timed urine samples are 
collected, and in the middle of the collection period, a blood sample is drawn. In addition, two 
24-h urine samples are collected for assessment of daily excretion of total protein and 
creatinine. 
 
Laboratory Measurements 
In the blood samples, we assessed the following parameters: creatinine, cholesterol, β2m, 
albumin, IgG, and transferrin. In the timed urine samples, we measured creatinine, β2m, α1-
microglobulin, albumin, IgG, and transferrin. The concentrations of serum creatinine, serum 
cholesterol, urinary total protein, and urinary creatinine were measured with standard 
automated techniques.  
 
 
* Note: To convert serum creatinine in mg/dl to µmol/l, multiply by 88.4. 
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The concentrations of albumin, transferrin, α1-microglobulin, and IgG in serum and urine 
were measured by immunonephelometry on a BNII nephelometer (Behring, Marburg, 
Germany) using antibodies whose specificity was checked by Ouchterlony double 
immunodiffusion and immunoelectrophoresis (Dako, Glostrup, Denmark). Urinary and serum 
β2m were measured by ELISA as described before.17 
 
Calculations 
Endogenous creatinine clearance (ECC) was calculated according to the formula Ucr x V / 
Pcr, where Ucr is the concentration of creatinine in the urine, V is the urine flow, and Pcr is 
the plasma concentration of creatinine, and was corrected for body surface area. Because 24-h 
urine samples were not collected regularly during follow-up, we estimated creatinine 
clearances using the Cockcroft and Gault formula. In addition, we calculated GFR for patients 
who reached the end point renal death by applying the recently developed Modification of 
Diet in Renal Disease (MDRD) formula using serum creatinine, age, gender, race, serum 
albumin and serum urea.18 The mean arterial pressure was the average of the last six of 10 
registered measurements.  
The amounts of β2m, α1-microglobulin, IgG, transferrin, and albumin in the timed urine 
samples are expressed as excretion per unit time (minute or 24 h). Protein selectivity index 
was calculated as the clearance of IgG divided by the clearance of transferrin. The total 
protein excretion in the 24-h urine samples was expressed as g/g creatinine to correct for 
sampling errors. 
 
Statistical Analysis 
For the validation study, we calculated renal survival using Kaplan-Meier statistics. Renal 
death was defined as an increase of serum creatinine  > 50 % or an increase of serum 
creatinine  > 1.5 mg/dl. Survival was calculated using the date of the baseline study at t = 0. 
We compared renal survival using log-rank test for patients with low and high Uβ2m and 
UIgG. We used the threshold values established in our previous studies.15,16 The threshold 
level for β2m excretion was 0.5 µg/min and for IgG was 250 mg/24 h. Using these threshold 
levels, we calculated sensitivity, specificity, true positive predictive value, and true negative 
predictive value. 
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Because the use of a fixed serum creatinine value as end point, irrespective of the baseline 
value, might have introduced a bias (a subtle increase in serum creatinine could have been 
defined as failure), we performed a subanalysis in a group of patients with a baseline serum 
creatinine < 1.2 mg/dl. 
Using the data of the present patient cohort, we also studied the effect of other parameters in 
predicting renal outcome. Univariate analysis and multivariate analysis using the Cox 
proportional hazard model with a forward stepwise procedure was performed to identify 
independent predictive parameters. Receiver operating characteristics (ROC) curves were 
made to determine the area under the curve (AUC) and to calculate the sensitivity and the 
specificity using the most discriminative thresholds. The following parameters were plotted 
into ROC curves: β2m excretion, IgG excretion, α1-microglobulin excretion, transferrin 
excretion, albumin excretion, selectivity index, ECC, serum creatinine, serum albumin, and 
total proteinuria per 24 h. The parameters with the highest AUC were selected and used as 
covariates in the Cox regression analysis. All values are given as means (±SD) or medians 
(range) when appropriate. All statistics were performed using SPSS software (SPSS version 
11.0, Chicago, IL, USA). P < 0.05 was considered significant. 
 
 
Results 
From 1995 to 2002, we studied 57 patients who had iMN and fulfilled the inclusion criteria. 
In 90% of the patients, the baseline measurement was performed within 1 year after renal 
biopsy. Baseline characteristics are given in Table 1.  
Two patients had been treated with prednisone. Patients have been followed for 53 ± 23 
months. Thus far, 25 (44 %) patients have reached the predefined end point of renal death. 
The reason for renal death was a serum creatinine  > 1.5 mg/dl in 21 patients and a rise of      
> 50% of serum creatinine in 4 patients. Overall renal survival was 81% at 6 months, 68% at 
1 year, and 54% at 3 years. Thus, in most patients, progressive disease was apparent within 3 
years after the baseline study. In this new patient cohort, the use of the previously established 
threshold values of Uβ2m and UIgG excretion allowed an accurate prediction of renal 
outcome. Renal survival curves are depicted in Figures 1 and 2. 
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Table 1.  Baseline characteristics of patients with iMN (n=57)  
Gender   (M / F)     38 / 19 
Age   (years)    48 ± 16 
MAP   (mmHg)    98 ± 16 
ECC - 24 h  (ml/min per 1.73 m2)    88 ± 26 
Serum creatinine   (mg/dl) 1.00 ± 0.23 
Serum β2m  (mg/l)   2.8 ± 1.1 
Serum albumin  (g/dl)   2.4 ± 0.5 
Cholesterol  (mg/dl) 329  ±  76 
Interval Bx–measurement (months)   2 (0–33) 
Follow-upa  (months)    53 ± 23 
 
Timed urine sample: 
 
 albumin excretion  (mg/min)  3.8  (0.3–16) 
 IgG excretion  (mg/24 h) 197  (18–3597) 
 β2m excretion  (µg/min)b 0.38  (0.05–68.4) 
 α1m excretion  (µg/min)   29  (4–418) 
 transferrin excretion  (µg/min) 283  (17–1455 ) 
 Selectivity Index 0.18  (0.06–0.39) 
 proteinuria  (g/g creatinine) 5.8  (1.7–13.3) 
Data are means ± SD or medians (range). 
iMN, idiopathic membranous nephropathy; MAP, mean arterial pressure; ECC - 24 h, creatinine 
clearance calculated from 24 h urine; β2m, β2-microglobulin; α1m, α1-microglobuline; Bx, renal biopsy. 
aFrom baseline measurement until end of follow-up.  
bIn case of β2m excretion: n=56; in one patient, β2m was not measurable because pH urine was too  
low ( < 6.0). 
 
Our calculations confirmed the high sensitivity and specificity (Table 2).  
We evaluated the possible bias of using the fixed serum creatinine value of 1.5 mg/dl as end 
point. To this end, we assessed the extent of the deterioration of renal function. In the 25 
patients who reached the predefined end point of renal death, serum creatinine had increased 
by an average of 46% from 1.15 ± 0.2 to 1.65 ± 0.24 mg/dl. Calculated creatinine clearance 
(Cockcroft and Gault formula) was 76 ± 22 ml/min per 1.73 m2 at baseline and 52 ± 13 
ml/min per 1.73 m2 at the end point. The absolute decrease in creatinine clearance averaged 
45 ml/min per 1.73 m2/year. For comparison, in the nonfailure group, the average change of 
calculated creatinine clearance was 1.7 ml/min per 1.73 m2/year. 
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Figure 1. Renal survival in patients with idiopathic membranous nephropathy (iMN) with 
urinary β2-microglobulin excretion (Uβ2m) < 0.5 µg/min and ≥ 0.5 µg/min.  
Renal death was defined as an increase of serum creatinine to values  > 1.5 mg/dl or an increase of 
serum creatinine  > 50%. 
 
When we estimate GFR using the recently developed MDRD formula, the severity of renal 
dysfunction is even more manifest: The MDRD GFR at the predefined end point (and thus at 
the start of immunosuppressive therapy) was 37 ± 9 ml/min per 1.73 m2. Of note, because we 
did not calibrate serum creatinine values against the standard of the MDRD reference 
laboratory, our calculated MDRD GFR may underestimate true GFR by 5 ml/min per         
1.73 m2.  
The difference in course of renal function between patients with high and low Uβ2m can be 
appreciated by comparing the slopes of 1/serum creatinine: In patients with low Uβ2m, the 
slope was –0.012 dl/mg per year (interquartile range, –0.04 to 0.014); in patients with high 
Uβ2m, the slope was –0.42 dl/mg per year (interquartile range, -0.91 to -0.16; P < 0.01).  
A subgroup analysis limited to 44 patients with an initial serum creatinine < 1.2 mg/dl 
resulted in similar conclusions: Renal survival was 93% at 6 months, 79% at 1 year, and 67% 
at 3 years. In this subgroup, 14 (32%) patients reached the end point of renal death; at 
baseline, their serum creatinine was 1.00 ± 0.14 mg/dl and increased by 63% to 1.64 ± 0.31 
mg/dl before start of immunosuppressive therapy. In this subgroup analysis, both Uβ2m and 
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UIgG predicted prognosis. Renal survival was 33% at 1 year in patients with high Uβ2m and 
97% in patients with low Uβ2m. Calculated sensitivity and specificity were 79 and 97% for 
the Uβ2m and 79 and 90% for the IgG excretion. The specificity improved to 100% when the 
β2m and IgG excretion were combined.  
We also explored our data using all available parameters. In the initial multivariate analysis, 
α1-microglobulin was not included in view of the very high correlation between Uβ2m and 
urinary α1-microglobulin. In univariate analysis, the following parameters were significantly 
related to renal outcome: serum creatinine (P < 0.001), serum albumin (P < 0.001), ECC (P < 
0.01), proteinuria (P < 0.001), selectivity index (P < 0.001), and urinary excretion of albumin, 
β2m, α1-microglobulin, transferrin and IgG (all P < 0 .001). Multivariate analysis revealed that 
Uβ2m was the strongest independent predictive factor (relative risk, 1.030; 95% confidence 
interval, 1.017 to 1.043; P < 0.001), indicating that the risk for renal insufficiency increased 
by  3.0% for every 0.1 µg/min increase of Uβ2m. After Uβ2m, serum albumin was identified 
as the second independent predictive factor (relative risk, 0.786; 95% confidence interval, 
0.691 to 0.894; P < 0.01). We calculated sensitivity and specificity for the various parameters 
(Table 2). When combining parameters, specificity can be somewhat increased (Table 2). 
ROC curves, as depicted in Figure 3, confirmed the best performance of Uβ2m, as reflected by 
the AUC. 
 
Figure 2. Renal survival in patients with idiopathic membranous nephropathy (iMN) and an 
IgG excretion < 250 mg/24 h versus patients with an IgG excretion ≥250 mg/24 h. 
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Table 2. Sensitivity, specificity, PPV, and NPV of the most discriminative threshold levels of 
urinary proteins and creatinine clearance in the prediction of renal failure 
Parameter AUC  Threshold Sensitivity Specificity PPV NPV 
Uβ2m 0.947   0.5  µg/min  88%  91%  88%  91% 
UIgG 0.876   250  mg/24 h  88%  88%  85%  90% 
Uα1m 0.956   40  µg/min  84%  94%  91%  88% 
Uexc albumin 0.896   2.8  mg/min  92%  69%  70% 92% 
Uexc transferrin 0.906   350  µg/min  80%  84%  80%  84% 
Proteinuria 0.898   8  g/24 h  88%  72%  71%  89% 
SI 0.687   0.16  76%  50%  54%  73% 
ECC 24 h 0.741   80  ml/min per 1.73 m2  64%  81%  73%  74% 
Serum creatinine 0.833   1  mg/dl  76%  81%  76%  81% 
Serum albumin 0.913   2.2  g/dl  80%  97%  95%  86% 
 
Combinations: 
      
  high Uβ2m  
 +  high UIgG 
 0.5  µg/min  
   +  250  mg/24 h 
 83%   97%   95%  89% 
  high Uβ2m  
 +  low serum albumin 
 0.5  µg/min  
   +  2.2  g/dl 
 75% 100% 100%  84% 
  high Uα1m 
 +  high UIgG 
 40  µg/min  
   +  250  mg/24 h 
 76%   94%   91%  83% 
  high Uα1m 
 +  low serum albumin 
 40  µg/min  
   +  2.2  g/dl 
 72% 100% 100%  82% 
Uexc, urinary excretion; β2m, β2-microglobulin; α1m, α1-microglobulin; SI, selectivity index;  
PPV, positive predictive value; NPV, negative predictive value. 
 
We specifically evaluated urinary α1-microglobulin excretion in comparison with β2m 
excretion. There was a high correlation between these parameters (r = 0.80, P < 0.001). In 
fact, it is evident from Table 2 and Figure 3 that urinary α1-microglobulin excretion and Uβ2m 
give comparable results. 
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Figure 3. Comparative efficacy of serum creatinine and the urinary excretion of several 
proteins for predicting renal death in patients with iMN (n=57). 
Receiver operating characteristics curves of β2m excretion (β2m-exc; area under the curve [AUC], 
0.947), α1-microglobulin excretion (α1m-exc; AUC, 0.956), IgG excretion (IgG-exc; AUC, 0.876), 
proteinuria per day (AUC, 0.898), and serum creatinine concentration (Screatinine; AUC, 0.833). 
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Discussion 
We have validated the performance of Uβ2m and UIgG as predictors for renal insufficiency in 
patients with iMN. To this end, we tested the threshold values developed in our previous 
studies in a new, prospectively studied patient cohort. Our data clearly demonstrate that Uβ2m 
and UIgG predict with high accuracy renal outcome in patients with iMN. In fact, the 
calculated sensitivities and specificities are nearly identical to the values obtained in our 
previous studies.13 Thus, our data indicate that the model parameters are robust. 
Our study may be criticized because we used a fixed value of serum creatinine of 1.5 mg/dl as 
end point for defining renal death. However, it is evident from calculated creatinine clearance 
and MDRD GFR that renal function was severely disturbed at the end point. The slope of 
1/serum creatinine proved that there was a clear loss of renal function. Adopting a doubling of 
serum creatinine or 50% decrease in GFR as end point would have resulted in even longer 
withholding of immunosuppressive treatment. 
We used a restrictive treatment policy in our patients, initiating immunosuppressive treatment 
as renal failure was evident. On the basis of the results of the randomized study conducted by 
Ponticelli et al.,4 one might ask whether delay of treatment is justified especially in patients 
with a nephrotic syndrome. Our treatment policy was based on our preliminary findings that 
immunosuppressive treatment with cyclophosphamide is effective in patients with established 
renal failure. We recently extended these observations and also demonstrated that a restrictive 
treatment policy results in excellent patient and renal survival rates.9,12 
In our previous study, we noted that the UIgG was the only variable that was independently 
associated with renal function deterioration. This superiority of UIgG over Uβ2m was 
explained by one patient in whom results of UIgG and Uβ2m did not concur. In this patient, 
who developed renal insufficiency, UIgG exceeded the threshold value of 250 mg/day 
whereas Uβ2m was below the threshold.16 In our present, larger study cohort, Uβ2m was the 
most significant independent predictive factor. It has been well established that Uβ2m reflects 
the severity of tubulointerstitial injury.19,20 Thus, our findings are in good agreement with 
studies that have unequivocally shown that in patients with glomerular diseases, renal 
outcome is more related to the presence and the extent of tubulointerstitial injury than to 
glomerular pathology. In general, there was a good agreement between Uβ2m and UIgG. 
When both parameters were combined, specificity even increased to a value of 97%.  
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How can we explain that UIgG and Uβ2m accurately predict renal failure? We propose that 
UIgG reflects the severity of glomerular damage, whereas Uβ2m is a marker of 
tubulointerstitial injury. It has been suggested that IgG or other high molecular weight 
proteins cause tubular cell activation or injury that results in tubulointerstitial inflammation, 
the final step toward renal insufficiency.  
Thus far, only one model for the identification of patients who have iMN and are at risk for 
the development of chronic renal failure has been validated. The model was developed with 
data derived from the Toronto Glomerulonephritis Registry. In the first study, the duration 
and the level of proteinuria proved to be fairly accurate predictive factors. The best 
performance was found using a level of proteinuria  > 8 g/day for  > 6 months. Calculated 
sensitivity was 66%, and specificity was 88%.13,14 In the validation study, roughly similar 
figures were reported with a sensitivity of 58% and a specificity of 93%.21 In addition, the 
Toronto group extended the model by calculating a risk score on the basis of the data of a 
selected 6-months interval with the worst sustained proteinuria. In this model are included the 
minimum amount of proteinuria in that 6-months interval, the initial creatinine clearance, and 
the slope of the creatinine clearance during the 6-months period. The risk score model was 
validated in three different populations and proved quite good with sensitivities varying from 
60 to 89%, specificities from 86 to 92%, and an overall accuracy of 79 to 87%.21 Obviously, 
this model has a very good performance. However, there are several disadvantages, 
particularly the need to have an observational period that exceeds a period of 6 months and 
the necessity of multiple, accurate 24-h urine collections. Our model is based on the collection 
of a single timed urine sample collected in the morning period. 
Furthermore, it is unproved whether the Toronto model can be applied to patients with newly 
diagnosed iMN. The model has been validated and applied to a group of patients with well-
defined follow-up. This suggests that a long observation period was used to define the 6-
months period with the worst sustained proteinuria. In more than one quarter of the patients, 
the 6-months period started  > 12 months after renal biopsy. Therefore, the model may not be 
applicable to patients with a follow-up after biopsy of < 12 to 18 months. 
In the present study, we specifically analysed the value of urinary α1-microglobulin, a low 
molecular weight protein like β2m. In routine clinical practice, measurement of urinary α1-
microglobulin is easier in view of its relative stability at pH < 6.0. We observed a very high 
correlation between Uβ2m and urinary α1-microglobulin. Sensitivities and specificities were 
also comparable, although, admittedly, the threshold values used for α1-microglobulin should 
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be validated in a second population. Our data confirm and strengthen the conclusion of Bazzi 
et al.22 In a small cohort of 19 untreated patients with iMN, a nephrotic syndrome, and normal 
renal function, these authors found that urinary α1-microglobulin predicted the development 
of chronic renal failure with a sensitivity and specificity of 100%. We have applied their 
threshold value of 33.5 mg/g creatinine to our study cohort of 57 patients and calculated a 
sensitivity of 88% and a specificity of 78%. Bazzi et al. also reported the predictive value of 
UIgG. Using a threshold value of 110 mg/g creatinine, sensitivity was 100% and specificity 
was 69%. Applying this threshold value to our study cohort, we calculated a sensitivity of 
92% and a specificity of 63 %. We used a higher cut-off value (250 mg/day, approximately 
180 mg/g creatinine), thereby increasing specificity. We believe that a high specificity should 
be pursued to be able to avoid unnecessary immunosuppressive therapy in patients with iMN. 
The data of our secondary analysis suggest that serum albumin may have added value as a 
prognostic marker. Admittedly, this needs confirmation in another patient cohort. Can we 
avoid unnecessary immunosuppressive treatment by using Uβ2m and UIgG as prognostic 
markers? From our data, it can be calculated that when used in the present population with a 
failure rate of 44% (which is in close agreement with literature data), our established 
threshold values would have resulted in the unnecessary treatment of one patient (1.8% 
overall, 4.8% of all treated patients), whereas 31 patients rightly would not have received 
treatment.  
 
Conclusion 
We have validated the performance of Uβ2m and UIgG as prognostic markers in patients with 
iMN. Urinary α1-microglobulin can replace Uβ2m. Use of these markers will allow 
identification of high-risk patients at an early stage. We propose that these markers may help 
to guide the time of start of immunosuppressive treatment in individual patients. 
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Abstract 
The urinary excretion of β2-microglobulin (β2m) is used as a marker of renal tubulo-interstitial 
injury. Unfortunately, β2m is rapidly degraded in acid urine (pH < 6.0). We questioned if the 
use of a single dose of the carbonic anhydrase inhibitor acetazolamide would allow valid 
measurement of urinary β2m without influencing its excretion rate.  
We have studied 10 healthy volunteers (4 male, 6 female) who received no drug (N), sodium 
bicarbonate (B) or acetazolamide (A) orally on three separate days. Timed 2 hour urine 
samples were collected. In addition, we have studied 11 patients (all male) with proteinuric 
renal disease, mean serum creatinine of 117 μmol/l and mean proteinuria of 3.3 g/10 mmol 
creatinine. After pretreatment with sodium bicarbonate and baseline measurements 
acetazolamide was given and another urine sample was collected. 
The use of acetazolamide increased urinary pH and allowed measurement of urinary β2m in 
all volunteers and patients. When compared with sodium bicarbonate, use of acetazolamide 
did not influence the urinary excretion of β2m. Side effects were frequent and included 
paresthesias, change in taste and dizziness. 
In conclusion, administration of a single dose of acetazolamide (with or without pretreatment 
with sodium bicarbonate) increases urinary pH and does not influence urinary excretion rate 
of β2m. Use of acetazolamide thus allows valid measurement of urinary β2m. 
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Introduction 
Beta-2-microglobulin (β2m) is a low-molecular-weight (LMW) protein (Molecular mass 11.8 
kD) that is readily filtered through the glomerulus and almost completely reabsorbed by the 
proximal tubules.1 An increased urinary excretion of β2m (UEβ2m) is a good marker of 
tubulo-interstitial injury.2-4 We have previously demonstrated that measurement of urinary 
excretion of β2m allows to predict prognosis in patients with membranous nephropathy with 
high sensitivity and specificity.5 Unfortunately, β2m is rapidly degraded in acid urine (pH < 
6.0),6-8 a process which already occurs during retention of the urine in the bladder.7;8 
As an alternative, the low molecular weight proteins α1-microglobulin (α1m) and Retinol 
Binding Protein (RBP) can be used. However, both α1m and RBP are somewhat unstable at 
urinary pH below 7.0, and for the measurement of these proteins also alkalinization of urine 
has been recommended.7 Furthermore, in serum both α1m and RBP are bound to proteins 
whereas β2m is only present in its free form, thus freely filterable. The fractional excretion of 
β2m thus quantitatively reflects tubular reabsorptive capacity. In contrast, the urinary 
excretion of α1m and RBP is not only dependent on tubular reabsorption but is also influenced 
by changes in glomerular permeability.9 Quantitatively, proximal tubular reabsorption can 
therefore best be assessed by measuring fractional excretion of β2m.10  
To ensure urine alkalinization we thus far have prescribed oral sodium bicarbonate, 4 g in the 
evening and 2 g in the morning before collection of a timed (two hours) urine sample. 
However, even with this dose of sodium bicarbonate, urinary pH (UpH) was below 6.0 in 7% 
of 944 consecutive urine samples collected in patients with proteinuria (unpublished data). 
Acetazolamide is a diuretic agent that inhibits carbonic anhydrase activity, thus increasing 
urinary bicarbonate excretion and UpH. We questioned if the administration of a single dose 
of acetazolamide (partly after pretreatment with sodium bicarbonate) would allow valid 
measurement of β2m in the urine, without influencing protein excretion rates. 
 
 
Materials and Methods 
We first have studied 10 healthy volunteers (4 male, 6 female) without proteinuria and with 
normal renal function (median serum creatinine 80 μmol/l, range 67-92 μmol/l). In these 
volunteers timed urine samples were collected in the morning at three consecutive days. In 
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random order the volunteers received nothing, sodium bicarbonate (4 g orally the evening 
before and 2 g in the morning about 4 hours before urine sampling) or acetazolamide (250-
500 mg orally 2 hours before urine sampling). Blood pressure was measured with an 
automatic device. 
We next studied eleven patients (11 male) with proteinuria. Mean serum creatinine was 117 
μmol/l (range 91-285 μmol/l) and proteinuria amounted 3.3 g/10 mmol creatinine (range 0.8-
18.7 g/10 mmol creatinine). These patients were studied according to our standard protocol 
for patients with proteinuria, i.e. timed urine samples were collected in the morning after an 
overnight fast and after pretreatment with sodium bicarbonate. At the end of the urine 
collection period, acetazolamide 250 mg orally (n=9) or i.v. (n=2) was given and a second 
urine sample was collected two hours later. Blood pressure was measured at regular intervals 
during the collection period with an automatic device (DINAMAP, Criticon, Tampa FI, 
USA). 
In the urine samples pH, creatinine, β2m, albumin and sodium were measured.  
Measurement of creatinine was done with the modified Jaffe technique on a Hitachi  747 auto 
analyser (Roche, Almere, The Netherlands), β2m and albumin were measured by ELISA11 and 
pH  with a Checker ®2 (Hanna Instruments, IJsselstein, The Netherlands). Urinary β2m 
excretion was not measured in samples with UpH < 6.0. 
For statistical analysis the Wilcoxon Signed Ranks Test was used for paired data.  Values are 
given as means ± SD or medians (range) when appropriate.  
 
 
Results 
Overall results are given in Table 1.  
Changes in the urinary excretion of β2m for each individual are depicted in Figure 1. 
 
In the healthy volunteers administration of acetazolamide resulted in significantly higher 
UpH. Use of acetazolamide enabled measurement of β2m in all urine samples. In contrast, 
measurement of β2m in urine was not possible in four urine samples without pretreatment and 
in two urine samples after sodium bicarbonate. Mean arterial blood pressure and urinary 
excretion of albumin were not different after acetazolamide when compared with no 
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pretreatment or sodium bicarbonate. We also observed no significant differences in the 
urinary excretion of β2m when comparing acetazolamide and sodium bicarbonate.  
In the patients acetazolamide likewise increased UpH. In these patients, who were on a 
sodium-restricted diet and were regularly using diuretics, acetazolamide induced a fall in 
mean arterial pressure (MAP). 
 
Table 1. Effects of acetazolamide on urinary pH and urinary excretion of β2m and albumin 
 Study I: 
Healthy volunteers (n=10) 
 Study II: 
Proteinuria patients (n=11) 
 No 
pretreatment 
 
Bicarbonate 
 
Acetazolamide
  
Bicarbonate 
Plus 
Acetazolamide
UpH 6.21 
(4.97-7.39) 
7.57 
(5.80-7.89) 
8.0** 
(7.91-8.26) 
 7.08 
(5.48-7.90) 
7.80** 
(6.38-8.40) 
Nr of subjects 
with UpH < 6.0 
 
4 
 
2 
 
0 
  
2 
 
0 
UEβ2m # 
(mg/10 mmol 
creatinine) 
0.081 
(0.047-0.117) 
0.087 
(0.077-0.141) 
0.108 
(0.063-0.150) 
 1.63 
(0.47-7.67) 
1.36 
(0.26-6.87) 
UEalb 
(mg/10 mmol 
creatinine) 
7.31 
(3.96-13.60) 
8.67 
(4.33-20.83) 
8.28 
(4.13-12.67) 
 2655 
(939-14,129) 
2047* 
(635-14,200) 
MAP 
(mm Hg) 
91 
(71-98) 
93 
(82-109) 
93 
(74-106) 
 101 
(88-116) 
87** 
(63-105) 
Values are given as medians with range. 
UpH, urinary pH; UEβ2m, urinary excretion of β2-microglobulin; UEalb, urinary excretion of albumin; 
MAP, mean arterial pressure. #For UEβ2m values are given for 8 controls and 9 patients respectively, 
for whom paired samples were available that allowed a comparison between sodium bicarbonate and 
acetazolamide.   
* P < 0.05; ** P < 0.01 for acetazolamide compared with bicarbonate. 
 
Overall, urinary excretion of β2m was not significantly different. In contrast, we observed a 
significant decrease in urinary albumin excretion after acetazolamide (P = 0.033). This 
decrease in albuminuria correlated with the change in MAP (r = 0.594, P = 0.05). 
If we compare the values of urinary excretion of β2m after acetazolamide and after sodium 
bicarbonate it is evident that there is no significant difference (Figure 1). The percentage 
difference between UEβ2m after acetazolamide and sodium bicarbonate amounted median      
-4% (-20 – 56%) for the volunteers and -17% (-82 – 20%) for the patients. 
After the administration of acetazolamide side effects occurred frequently, mainly consisting 
of paresthesias (58%), changes in taste (32%) and dizziness (29%). Although these side 
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effects were not severe, some individuals expressed their reluctance to use acetazolamide 
again. 
 
 
Figure 1. Correlation between the urinary excretion of β2m (β2m, in mg/10 mmol creatinine, 
logarithmic scale) after sodium bicarbonate and acetazolamide in volunteers and patients.  
The reference line is the line of identity. 
 
 
Discussion 
Administration of acetazolamide adequately increased urinary pH, thus allowing 
measurement of urinary β2m. Acetazolamide did not itself influence the urinary excretion of 
β2m. One might have expected an increased urinary excretion of albumin and/or β2m since 
acetazolamide increases proximal tubular flow rate. In the healthy volunteers, no changes in 
urinary excretion of β2m or albumin occurred. In the patients, we observed a numerical 
decrease in urinary β2m excretion and a significant decrease in albuminuria. This however 
could readily be explained by the decrease in blood pressure that we observed, a likely 
consequence of the administration of acetazolamide to sodium-restricted patients who were 
using diuretics and ACE-inhibitors. 
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We observed frequent side effects even with the use of only a single dose of acetazolamide. 
These side effects are well known and may limit the frequent use of acetazolamide in clinical 
practice. 
A reasonable strategy would be to use acetazolamide only in those patients in whom a urinary 
pH above 6.0 cannot be achieved with the administration of sodium bicarbonate. 
 
 
References 
 
1.  D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003; 63: 809-825 
2.  Portman RJ, Kissane JM, Robson AM. Use of β2-microglobulin to diagnose tubulo-interstitial renal 
lesions in children. Kidney Int 1986; 30: 91-98 
3.  Tomlinson PA, Dalton RN, Hartley B, et al. Low molecular weight protein excretion in glomerular 
disease: a comparative analysis. Pediatr Nephrol 1997; 11: 285-290 
4.  Guder WG, Ivandic M, Hofmann W. Physiopathology of proteinuria and laboratory diagnostic strategy 
based on single protein analysis. Clin Chem Lab Med 1998; 36: 935-939 
5.  Reichert LJ, Koene RA, Wetzels JF. Urinary excretion of β2-microglobulin predicts renal outcome in 
patients with idiopathic membranous nephropathy. J Am Soc Nephrol 1995; 6: 1666-1669 
6.  Davey PG, Gosling P. β2-Microglobulin instability in pathological urine. Clin Chem 1982; 28: 1330-1333 
7.  Donaldson MD, Chambers RE, Woolridge MW, Whicher JT. Stability of α1-microglobulin, β2-
microglobulin and retinol binding protein in urine. Clin Chim Acta 1989; 179: 73-77 
8.  Blumsohn A, Morris BW, Griffiths H, Ramsey CF. Stability of β2-microglobulin and retinol binding 
protein at different values of pH and temperature in normal and pathological urine. Clin Chim Acta 1991; 
195: 133-137 
9.  Hofmann W, Edel H, Guder WG. A mathematical equation to differentiate overload proteinuria from 
tubulo-interstitial involvement in glomerular diseases. Clin Nephrol 1995; 44: 28-31 
10.  Ten Dam MA, Branten AJ, Klasen IS, Wetzels JF. The gelatin-derived plasma substitute Gelofusine 
causes low-molecular-weight proteinuria by decreasing tubular protein reabsorption. J Crit Care 2001; 
16: 115-120 
11.  Jacobs EM, Vervoort G, Branten AJ, et al. Atrial natriuretic peptide increases albuminuria in type I 
diabetic patients: evidence for blockade of tubular protein reabsorption. Eur J Clin Invest 1999; 29: 109-
115 
 
 
  
 
  
Chapter 8 
 
Treatment related changes in urinary excretion of 
 high and low molecular weight proteins  
in patients with idiopathic membranous nephropathy  
and renal insufficiency 
 
 
 
Peggy W.G. du Buf-Vereijken1,2, Jack F.M. Wetzels2 
 
1Department of Internal Medicine, Amphia Hospital, Breda, 
2 Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands 
 
Nephrol Dial Transplant 2005; in press in revised form  
 
 
 
104 
Chapter 8 
Abstract 
Background. In patients with idiopathic membranous nephropathy (iMN) an increased 
urinary excretion of high (IgG) and low (β2-microglobulin (β2m), α1-microglobulin (α1m)) 
molecular weight proteins predicts prognosis and precedes renal insufficiency. We have 
studied the changes in the urinary excretion of these proteins in patients with iMN and renal 
insufficiency during and after treatment with cyclophosphamide and steroids and investigated 
their value in predicting long-term outcome. 
Methods. Standardized measurements of urinary IgG, albumin, β2m, and α1m were performed 
at 0, 2, 6 and 12 months in 11 patients, at 12 months in 25 patients and in 17 of these last 
patients after 2-5 years. 
Results. We observed a rapid improvement in glomerular permselectivity and tubular protein 
reabsorption within 2 months after start of therapy. Despite a partial remission of proteinuria 
within 12 months in most patients, evidence of tubulo-interstitial injury remained apparent. 
Levels of urinary IgG, β2m or α1m neither at baseline nor at 12 months clearly predicted the 
occurrence of a remission or a relapse to nephrotic range proteinuria. In case of a persistent 
stable remission we observed a gradual decrease in urinary β2m towards normal values.  
Conclusions. In patients with iMN and renal insufficiency treatment with cyclophosphamide 
and steroids resulted in an improvement in glomerular permeability and tubular proteinuria. 
Tubular proteinuria remained present for many years, even in patients with stable remission of 
proteinuria. Measurements of urinary proteins at 12 months after treatment start lacked 
predictive accuracy. 
 
 
 
  105 
Treatment related changes in proteinuria in membranous nephropathy
Introduction 
Idiopathic membranous nephropathy is the most common cause of the nephrotic syndrome in 
adults.1 Approximately 40% of patients with idiopathic membranous nephropathy and a 
nephrotic syndrome will progress to renal insufficiency.2-4 We and others have demonstrated, 
that the urinary excretion of the high molecular weight protein IgG and of the low molecular 
weight proteins β2-microglobulin (β2m) and α1-microglobulin (α1m) accurately predict 
prognosis in patients with idiopathic membranous nephropathy and normal renal function.5-8 
The reported data support the following sequence of events that lead to renal failure: severe 
alterations in glomerular permselectivity (identified by non-selective proteinuria9 and high 
levels of urinary IgG) are followed by tubulo-interstitial injury (identified by high levels of 
urinary β2m and α1m), which ultimately causes renal insufficiency.10-12 In our study7 in 
multivariate analysis urinary β2m excretion proved the strongest independent predictor for the 
development of renal failure, which is in agreement with the observations that (development 
of) renal insufficiency correlates better with tubulo-interstitial damage than with glomerular 
injury.11 
We recently have reported that immunosuppressive therapy consisting of cyclophosphamide 
and steroids is effective in patients with idiopathic membranous nephropathy and renal 
insufficiency. In most patients renal function improved, and over 80% of patients developed a 
partial remission of proteinuria. Unfortunately, relapses occurred in 28% of patients after five 
years follow-up.13;14 
Over the last years we have quantitated urinary high and low molecular weight proteins 
during and after treatment. We have analysed the data, specifically evaluating the response of 
glomerular permselectivity characteristics and tubulo-interstitial injury in time. We also 
questioned if measurement of these proteins at the end of the treatment year allows predicting 
prognosis. 
 
 
Subjects and Methods 
We recently evaluated the efficacy of treatment with oral cyclophosphamide and steroids in 
patients with idiopathic membranous nephropathy, nephrotic syndrome and renal 
insufficiency.14 Treatment consisted of oral cyclophosphamide in a dose of 1.5-2.0 mg/kg 
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bodyweight/day for 12 months and steroids. The corticosteroid regimen consisted of three 
consecutive i.v. pulses of 1 g of methylprednisolone at months 0, 2 and 4 and oral prednisone, 
in a dose of 0.5 mg/kg bodyweight on alternate days for six months. In patients treated most 
recently, standardized measurements of urinary proteins and renal function were performed at 
indicated time intervals after start of therapy. Twenty-five patients were studied at the end of 
treatment (12 months). In addition, the time course of changes in proteinuria was studied 
more closely in 11 patients who were evaluated at 0, 2, 6 and 12 months. Measurements were 
repeated after longer follow-up in 17 patients.  
 
Standardized measurement of urinary proteins  
and renal function 
All patients collected two 24-hour urine samples for measurement of creatinine and total 
protein. The excretion of the low and high molecular weight proteins was measured under 
standardized conditions. In brief, patients came to the ward after an overnight fast. They 
received 4 g of oral sodium bicarbonate in the evening before, and additionally 2-4 g at arrival 
in the ward to achieve an urinary pH  > 6.0, which is necessary to allow reliable 
measurements of urinary β2m. Two hours before arrival in the hospital, patients had taken 
1200 mg of cimetidine orally. Cimetidine was given to inhibit tubular secretion of creatinine, 
but has been shown not to influence the glomerular permeability and tubular reabsorption of 
proteins.15 At arrival at the ward, up to 500 ml tap water was given to enforce diuresis. The 
patients remained supine during two hours except for voiding. Blood pressure measurements 
were done using an automated device (DINAMAP, Criticon, Tampa FI, USA), with 6 
consecutive readings registered every 5 minutes after 10 minutes rest; these readings were 
used to calculate the average MAP. The timed urine sample, collected after two hours, was 
used for the measurement of urinary pH, β2m, α1m, IgG, transferrin, albumin, total protein 
and creatinine. Only in urine with a urinary pH  > 6.0 β2m excretion was measured. 
Laboratory parameters were measured in blood samples collected in the mid of the urine 
collection period. 
The use of angiotensin converting enzyme inhibitors and/or angiotensin-II-type 1 receptor 
antagonist as well as of HMG-CoA-reductase inhibitors (statins) during the treatment year 
was noted. 
 
 
  107 
Treatment related changes in proteinuria in membranous nephropathy
Laboratory measurements  
Serum creatinine and cholesterol, and urinary total protein and creatinine were measured with 
standard automated techniques. The concentrations of α1m, albumin, transferrin and IgG in 
serum and urine were measured by immunonephelometry on a BNII nephelometer (Behring, 
Marburg, Germany) using antibodies, whose specificity was checked by Ouchterlony double 
immunodiffusion and immunoelectrophoresis (Dako, Gloostrup, Denmark). Serum and 
urinary β2m were measured by ELISA, as described before.16 
 
Calculations and statistics 
Creatinine clearance (ECC) was calculated according to the formula Ucr x V / Pcr, where Ucr 
and Pcr are the concentration of creatinine in urine and plasma respectively, and V is the urine 
flow.  
Proteinuria (urinary total protein) is expressed as g/10 mmol creatinine. The excretion of the 
low and high molecular weight proteins is expressed per unit of time (min or 24 hours) to 
allow comparison with our previously reported threshold values: for UIgG 250 mg/24 hr5;7 for 
Uβ2m 500 ng/min (=0.5 μg/min)6;7 and for α1m 40 μg/min.7;8  
The Selectivity index (SI) of proteinuria was calculated using the formula: SI = (UIgG/SIgG) 
* (STransf/UTransf), where U = urine, S = serum, Transf = transferrin. Non-selective 
proteinuria was defined as a SI ≥ 0.21. The tubular reabsorption of β2m was calculated using 
the formula: reabsorption = 1 - fractional excretion (FE), and expressed as a percentage. FE of 
β2m = (Uβ2m/Sβ2m) / (Ucr *1000 / Scr). 
Values are given as medians with range. The Wilcoxon Signed Rank Test was used for 
comparison of paired data on different time points. The Mann-Whitney test was used for 
comparison of data between different groups of subjects. A P-value < 0.05 was considered 
significant. All statistical procedures were done using SPSS software (SPSS version 11.5, 
Chicago, IL, USA). 
 
Definitions  
A complete remission of proteinuria (CR), partial remission (PR), persistent proteinuria (PP) 
and nephrotic range proteinuria (NS) were defined as a protein-creatinine index of ≤ 0.2, 0.21-
2.0, 2.1-3.4 and ≥ 3.5 g/10 mmol creatinine respectively, where in case of remission renal 
function should have improved or at least stabilized. Relapses of proteinuria were defined as 
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nephrotic range proteinuria after a partial or complete remission of the proteinuria or a rise in 
proteinuria of  > 50% in patients in whom proteinuria had improved initially with  > 50%, 
without reaching values ≤ 2.0 g/10 mmol creatinine. 
 
 
Results 
Time course of changes in glomerular permselectivity and tubular proteinuria 
during treatment (Tables 1 and 2). 
Eleven patients were studied at the indicated time points (0, 2, 6 and 12 months) during the 
treatment year. Patients were all male, with a median age of 61 (45-75) years. 
 
Table 1. Serum measurements and calculated creatinine clearances in 11 patients with 
measurements at all time points (0, 2, 6 and 12 months) during the treatment year  
 t = 0 months t = 2 months t = 6 months t = 12 months 
Serum values     
Screatinine 
(μmol/l) 
152 
(132-278) 
137* 
(108-221) 
126** 
(83-168) 
128** 
(89-215) 
Sβ2m 
(mg/l) 
5.32 
(3.13-7.52) 
3.45** 
(2.38-5.72) 
2.80** 
(2.20-4.60) 
2.91** 
(1.90-6.46) 
Salbumin 
(g/l) 
26 
(18-35) 
30** 
(20-38) 
36** 
(32-39) 
41** 
(34-44) 
SIgG 
(g/l) 
4.6 
(2.4-13.2) 
2.6** 
(1.0-4.8) 
3.6** 
(2.1-10.6) 
6.1* 
(3.3-10.2) 
Scholesterol 
(mmol/l) 
6.7 
(4.8-18.0) 
6.4 
(4.1-10.0) 
5.3* 
(4.0-6.3) 
4.8** 
(3.4-6.4) 
 
Calculated creatinine clearances 
  
24-hours urine 
(ml/min) 
53 
(25-68) 
59* 
(29-100) 
68** 
(45-108) 
62* 
(33-113) 
2-hours urine 
(ml/min) 
39 
(5-52) 
52** 
(21-68) 
50** 
(33-81) 
51** 
(33-87) 
* P < 0.05, ** P < 0.01 of values compared with baseline values 
S, serum; β2m, β2-microglobulin 
 
All patients used an ACE-inhibitor (n=10) or an angiotensin-II-type1 receptor antagonist 
(n=1) at the start and during the treatment year and six patients used a statin. Mean arterial 
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pressure was 90 (69 – 112) mm Hg at baseline and did not change significantly during the 
treatment year. Data are given in Tables 1 and 2.  
 
Table 2. Urine measurements in 11 patients with measurements at all time points (0, 2, 6 and 
12 months) during the treatment year 
 t = 0 months t = 2 months t = 6 months t = 12 months
Proteinuria 
(g/10 mmol creatinine) 
11.7 
(6.3-31.3) 
5.0** 
(1.4-9.4) 
1.7** 
(0.7-5.9) 
1.0** 
(0.3-3.9) 
Albuminuria 
(g/10 mmol creatinine) 
7.9 
(4.9-16.6) 
3.4** 
(0.9-6.4) 
1.2** 
(0.5-3.8) 
0.7** 
(0.1-3.8) 
UEβ2m (n=7)# 
(μg/min) 
15.1 
(2.5-46.9) 
3.2 
(0.3-56.8) 
1.8 
(0.2-37.6) 
2.4 
(0.2-47.3) 
UEα1m ## 
(μg/min) 
69.0 
(17.0-306.7) 
55.1 
(17.0-182.2) 
30.4* 
(7.3-126.1) 
16.4* 
(8.2-137.7) 
UEIgG 
(mg/24 hour) 
348 
(188-787) 
61** 
(5-253) 
16** 
(4-105) 
16** 
(12-124) 
Fractional excretion of IgG 0.22 
(0.08-0.43) 
0.03** 
(0.00-0.24) 
0.006** 
(0.00-0.08) 
0.004** 
(0.00-0.03) 
SI (IgG/Transferrin) 
(n=6) 
0.35 
(0.27-0.53) 
0.20 
(0.12-0.74) 
0.22* 
(0.08-0.42) 
 
Number of patients 
in partial remission 
0 1 5 10 
# Normal urinary excretion of β2m < 0.2 μg/min ( < 200 ng/min) 
## Normal urinary excretion of α1m < 10 μg/min. 
* P < 0.05; ** P < 0.01 of values compared with baseline value 
UE, urinary excretion; β2m, β2-microglobulin; α1m, α1-microglobulin; SI, Selectivity Index 
 
All patients had renal insufficiency as reflected by serum creatinine and calculated creatinine 
clearances. Creatinine clearances calculated from the 2-hours urine, collected after cimetidine, 
are significantly lower than creatinine clearances calculated from 24-hours urine, reflecting 
the inhibition of creatinine secretion by cimetidine. All patients had nephrotic range 
proteinuria, ranging from 6.3 – 31.3 g/10 mmol creatinine. Renal function improved in all 
patients. We also observed a reduction of proteinuria in all patients (Table 2). All but one 
patient developed a partial remission, but no patient developed a complete remission within 
the first year of treatment. The decrease in proteinuria was paralleled by a significant rise in 
serum albumin and decrease in serum cholesterol (Table 1). From Table 1 it is evident that 
serum IgG did not rise in parallel with serum albumin. Compared with baseline, lower values 
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of serum IgG were observed at 2 and 6 months after start of therapy, most likely the result of 
the immunosuppressive lymphocytotoxic therapy. 
Changes in the urinary excretion of the various low- and high molecular weight proteins can 
be derived from Table 2. As expected, the urinary excretion of albumin decreased roughly in 
parallel with the decrease in urinary total protein. Urinary excretion of IgG decreased to a 
greater extent, partly explained by the initial decrease in serum IgG. However, the greater 
reduction of urinary IgG also reflected an improvement in glomerular size-selectivity as 
indicated by the lower selectivity index. The time course of the urinary excretion of β2m could 
only be fully assessed in 7 patients in whom urinary pH was above 6.0 in all measurements. 
Still, it is evident from Table 2 that we observed a rapid and large reduction in urinary 
excretion of β2m. A similar pattern was observed for urinary α1m, which was measurable in 
all patients. Although all patients but one attained a partial remission of proteinuria at 12 
months, urinary excretion of the low molecular weight proteins remained abnormal in all but 
one patient at this time point. 
The data of these repeated measurements have allowed us to study in more detail the 
possibility of blockade of tubular reabsorption of β2m by IgG. Based on animal experiments it 
has been suggested that an increased urinary excretion of β2m could result from competitive 
inhibition of tubular protein reabsorption. Previously we have provided evidence that albumin 
does not interfere with the tubular reabsorption of low molecular weight proteins,17 however 
in that study we could not exclude an effect of IgG. In Figure 1 we have plotted the 
reabsorption of β2m against the urinary excretion of IgG (mg/100 ml GFR). It is evident that 
there is only a weak correlation, and it can be calculated that variations in urinary IgG 
excretion cannot explain the changes in urinary β2m excretion (r2 = 0.14). Thus, the urinary 
excretion of β2m is a valuable marker of tubular dysfunction and not merely a reflection of 
glomerular permeability changes. 
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Figure 1. Relation between tubular reabsorption of β2-microglobulin and the urinary IgG-
content. 
r2 = 0.14. 
 
Predictive value of tubular proteinuria at the end of the treatment year  
(Table 3) 
 
Twenty-five patients (21 males, 4 females; age 58 (38-75) years) were studied at the end of 
the treatment year (12 months). Follow-up from the start of treatment amounted 36 (14-76) 
months. During follow-up 22 patients (88%) developed a partial remission of proteinuria after 
7 (1-42) months, in 19 of them the partial remission was evident within the treatment year. 
Four of these 22 patients have improved into a complete remission at 18 (9-22) months after 
the start of the treatment. In two patients proteinuria improved to values below 3.5 g/10 mmol 
creatinine (persistent proteinuria), whereas one patient had a persistent nephrotic syndrome. 
During follow-up five patients relapsed to nephrotic range proteinuria (1 out of a complete 
remission, 3 out of a partial remission and 1 out of persistent proteinuria), after 34 (23-45) 
months. Thus, at the end of follow-up, 18 patients were in remission (3 in complete remission, 
15 in partial remission), 1 had persistent proteinuria and 6 patients had a (relapse to) nephrotic 
syndrome. 
Renal function had improved in all patients, from a serum creatinine of 161 (112-444) μmol/l 
at the start of treatment to a lowest value of 114 (70-255) μmol/l (P < 0.01) after a median of 
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10 months. Serum creatinine amounted 120 (74-255) μmol/l at 12 months and 122 (79-267) 
μmol/l (NS) at the end of follow-up. A significant deterioration of renal function (defined as a 
50% increase of serum creatinine over the lowest value obtained after treatment start) has 
occurred in 2 patients during follow-up, both patients also had a relapse of proteinuria to a 
nephrotic syndrome. Thus far no patient has developed ESRD.  
Values of serum and urine parameters for the 25 patients at the end of the 12-month treatment 
period are given in Table 3. At this time point, urinary IgG excretion had decreased to values 
below the threshold value of 250 mg/24 h in all patients. In contrast, the urinary excretion of 
β2m and α1m reached values below the thresholds in eight out of 21 and 16 out of 25 patients 
respectively. 
 
Table 3. Laboratory parameters and calculated creatinine clearances in 25 patients with a 
measurement at 12 months 
Serum measurements  Urine measurements 
Screatinine 
(μmol/l) 
120 
(74-255) 
 Proteinuria 
(g/10 mmol creat) 
1.0 
(0.1-13.0) 
Sβ2m 
(mg/l) 
3.2 
(1.9-6.5) 
 UEβ2m # 
(μg/min) 
1.0 
(0.1-47.3) 
Salbumin 
(g/l) 
40 
(24-44) 
 Albuminuria 
(g/10 mmol creat) 
0.73 
(0.05-7.31) 
Scholesterol 
(mmol/l) 
4.8 
(3.3-6.7) 
 UEα1m 
(μg/min) 
18.6 
(6.8-137.7) 
SIgG 
(g/l) 
5.6 
(3.0-10.2) 
 UEIgG 
(mg/24 hour) 
16 
(4.9-216) 
 
Calculated creatinine clearances 
   
24-hours urine 
(ml/min) 
67 
(31-113) 
   
2-hours urine 
(ml/min) 
51 
(22-93) 
   
# n=21 patients 
S, serum; UE, urinary excretion; β2m, β2-microglobulin; α1m, α1-microglobulin 
 
We next evaluated if the urinary excretions of β2m, α1m and IgG at 12 months were useful 
predictors of outcome. Since only two patients had evidence of renal failure during follow-up, 
we have defined failure as the presence of a nephrotic syndrome at the end of follow-up 
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(n=6). Time to failure was either total follow-up time in case no failure occurred, time to 
relapse in case of a relapse to nephrotic syndrome or start of repeated immunosuppressive 
therapy in the one patient with a persistent nephrotic syndrome. For univariate analysis we 
have made Kaplan Meier curves comparing patients with levels of the parameter under study 
above or below the median. No significant differences were found for the following 
parameters: urinary excretions of IgG, β2m and α1m, serum creatinine and creatinine clearance 
and serum albumin. Thus, the measurements at 12 months do not allow to predict treatment 
failure or relapse. 
In a subgroup analysis we have investigated the possibility to predict failure defined as a 
relapse of proteinuria after an initial remission. We only considered those patients (n=12) 
with a partial remission of proteinuria (at 7 (1-15) months), a follow-up time of more than 24 
months after the occurrence of the remission, with a standardized urine measurement at 
baseline and 12 months. Three patients failed. Again, the values at 12-months did not predict 
the development of a relapse. Also the percentage improvement from baseline to 12-months 
was not predictive. All patients with a relapse had baseline values above the median for the 
total group. Although this suggested that baseline values could offer some clues about 
outcome after therapy, we could not confirm this in a larger group of treated patients who had 
baseline measurements at the start of therapy (n=24).  
 
Progressive improvement in tubular proteinuria in case of a stable remission 
Since urinary β2m excretion was still abnormal in most patients at 12 months, we have 
continued to study patients during longer follow-up. Thus far, repeated measurements were 
done in 17 patients (13 male, 4 female; age 58 (38-71) years at start of treatment). These later 
measurements were done a median of 34 (19-71) months after the start of treatment. Twelve 
patients with a stable remission were studied, whereas five patients were studied within four 
months after onset of a relapse. 
In patients with a stable remission we observed a gradual further decrease in urinary β2m-
excretion (Figure 2). In contrast, in patients with a relapse there was a sharp increase in 
urinary IgG excretion from 14 to 373 mg/24 hours (P < 0.05), in urinary β2m-excretion from 
0.7 to 4.9 μg/min (n=3; NS) and in urinary α1m-excretion from 25.9 to 63.1 μg/min  
(P < 0.05).  
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Figure 2. Progressive improvement in urinary β2-microglobulin-excretion in patients with a 
stable remission. 
Reference line represents threshold value. 
 
 
Discussion 
We previously have shown that the urinary excretion of the low molecular weight proteins 
β2m and α1m and the high molecular weight protein IgG accurately predicted renal outcome 
in patients with idiopathic membranous nephropathy.5-7 In multivariate analysis urinary β2m 
excretion proved the best independent predictive variable,7 in agreement with observations 
that renal function deterioration is better correlated with tubulo-interstitial injury, than with 
glomerular damage.11 Furthermore, we have reported that patients with idiopathic 
membranous nephropathy and renal insufficiency can be effectively treated with 
cyclophosphamide and steroids.14 We now evaluated the effect of this therapy on glomerular 
permeability and tubular proteinuria. Furthermore, we aimed at determining the predictive 
value of tubular and glomerular proteinuria at the end of the treatment year for long-term 
outcome. 
The study in 11 patients, measured on four different occasions during the treatment year, 
confirmed the marked improvement in renal function. During the treatment year serum 
albumin and serum cholesterol improved as a result of the reduction of proteinuria, with most 
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patients entering a partial remission of proteinuria. Although ACE-inhibitors and/or AT1-
receptor antagonists and more recently statins have been shown to lower proteinuria,18-20 it is 
unlikely that the reduction of proteinuria that we observed in our patients can be attributed to 
these drugs since the use of these medications did not change during the treatment year. Thus, 
the improvement in renal function and proteinuria must be attributed to the 
immunosuppressive therapy. 
In these 11 patients, immunosuppressive therapy resulted in a rapid improvement in 
glomerular permselectivity and tubulo-interstitial injury as reflected by the lower selectivity 
index and the decreased excretion of the low molecular weight proteins β2m and α1m. 
Although improvement was already noted at 2 months after start of therapy, and all but one 
patient were in partial remission at 12 months, some degree of tubulo-interstitial injury 
remained evident at 12 months. This latter finding was further confirmed by the 12 month 
data in the group of 25 patients. Urinary β2m was abnormal in 20 out of 21 evaluated patients, 
and above our previously established threshold of 0.5 μg/min in 13 patients. 
In view of the high accuracy of our parameters in predicting renal function deterioration in 
patients with idiopathic membranous nephropathy and normal renal function, we aimed at 
evaluating the predictive value of these parameters for long-term outcome after treatment. For 
this analysis we could not use renal insufficiency as end point, since only two patients had 
deterioration of renal function during follow-up. This confirms the efficacy of our treatment 
schedule. Therefore we have used persistence or relapse of the nephrotic syndrome as end 
point. Results of the analysis must be interpreted with some reluctance, since we have 
observed only 6 failures out of 25 treated patients and only 19 patients had a follow-up time 
of  > 24 months. However, the data suggest that values at the end of therapy do not predict 
prognosis. It is highly unlikely that even in a larger patient group and with longer follow-up, 
parameters will be found with high enough sensitivity and specificity. Thus, measurement of 
these various high and low molecular proteins has no value when patients have been treated. 
Our study does allow drawing conclusions on some other aspects of low molecular weight 
proteinuria. 
We have examined in more detail the possible effects of IgG on tubular reabsorption of β2m. 
It is clear that the urinary IgG has only a limited effect on tubular reabsorption of β2m, if at 
all. 
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Furthermore, we have studied tubular proteinuria in patients with a longstanding stable 
remission. A gradual further improvement was noted after many years of follow-up, 
suggesting that recovery of tubulo-interstitial injury is a slow, but continuous process. 
  
In conclusion, in patients with idiopathic membranous nephropathy, a nephrotic syndrome 
and renal insufficiency, treatment with cyclophosphamide and steroids not only is highly 
effective in inducing remissions, but also significantly improves the urinary excretions of IgG, 
β2m and α1m. However, levels of tubular proteinuria remain significantly abnormal at the end 
of treatment year. Unfortunately, values at the end of the treatment year do not allow 
predicting long-term prognosis. The increased urinary excretion of β2m in patients with a 
nephrotic syndrome is not the result of inhibition of tubular reabsorption by IgG. Thus, 
urinary β2m is an accurate marker of tubular damage. 
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Abstract 
Idiopathic membranous nephropathy (iMN) is a common cause of the nephrotic syndrome.  
The treatment of patients with iMN is heavily debated. Based upon literature data and our 
own experience we propose a rational treatment strategy. Patients with renal insufficiency are 
at highest risk for development of end-stage renal disease (ESRD) and should receive 
immunosuppressive therapy. In patients with normal renal function risk for developing ESRD 
can be estimated by measuring urinary excretion of β2-microglobulin or α1-microglobulin and 
IgG. For low-risk patients a wait and see policy is advised. High-risk patients likely benefit 
from immunosuppressive therapy. Currently, combinations of steroids with chlorambucil or 
cyclophosphamide are best studied. We prefer cyclophosphamide in view of the fewer side 
effects. Cyclosporine may be an alternative option in patients with well-preserved renal 
function, although long-term data are lacking. Other immunosuppressive agents such as 
mycophenolate mofetil or rituximab are currently under study, however there are insufficient 
data to support their routine use. 
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Introduction 
Idiopathic membranous nephropathy (iMN) is one of the most common causes of the 
nephrotic syndrome in adult patients.1 The natural history varies from a spontaneous complete 
remission of proteinuria to rapid progression to end-stage renal disease (ESRD). The 
treatment of iMN has been a regular theme for debate. The opinions of various investigators 
are as diverse as the reported data on the natural history. Some emphasize the high rate of 
spontaneous remissions and argue against the use of immunosuppressive drugs,2 whereas 
others point to the high rate of ESRD and favour immunosuppressive therapy.3 The titles of 
editorial reviews written during the past 25 years clearly reflect the uncertainty in this field, 
from Stewart Cameron’s “Membranous nephropathy: the treatment dilemma” in 1982 and 
“Membranous Nephropathy-still a treatment dilemma” in 1992 to Glassock’s “The treatment 
of idiopathic membranous nephropathy: a dilemma or a conundrum” in 2004.4-6 In the current 
era of evidence based medicine some might argue that the discussion can end with the 
publication of a recent meta-analysis on immunosuppressive therapy for iMN.7 Based on data 
derived from 18 randomized controlled trials (RCTs) including more than 1000 patients the 
investigators concluded that immunosuppressive treatment had no benefit in terms of patient 
and/or renal survival. There was weak evidence in favour of regimens containing alkylating 
agents in inducing a complete remission of proteinuria, however only when considering 
patients with relatively well preserved renal function. Since the use of immunosuppressive 
therapy in especially this latter group of patients is most questionable, also this finding seems 
to argue against the use of immunosuppressive therapy. However, the conclusions of the 
meta-analysis are debatable and must not lead to therapeutic nihilism. Specifically, the meta-
analysis has included RCTs of limited size and quality. Conclusions based on a systematic 
review, which includes many trials of limited quality are not necessarily better than 
conclusions based on the results of one large, carefully conducted randomized controlled trial. 
Furthermore, in view of the limited number of large, high-quality RCTs, we must not neglect 
important and relevant information that can be obtained from carefully conducted 
observational studies.8;9 
During the past two decades we have systematically studied patients with iMN, our database 
now includes 279 patients.8;10-18 These studies have enabled us to define risk factors and to 
develop a treatment strategy tailored to the individual patient. Our treatment strategy is 
depicted in Figure 1.  
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Schedule Immunosuppressive Therapy: 
Methylprednisolone 1 g i.v. days 1,2,3, 61,62,63,121,122,123 
Prednisone 0.5 mg/kg every other day 6 months 
Cyclophosphamide 1.5 mg/kg/day 12 months 
 
Figure 1. Outline of proposed treatment strategy in patients with idiopathic membranous 
nephropathy. 
 
In this review we discuss treatment modalities for patients with iMN and provide compelling 
arguments based on literature data and our experience in favour of our strategy. We  
specifically address the following questions.  
1. Has the natural history of iMN changed during the past decades? 
2. Is immunosuppressive therapy of proven benefit in patients with iMN when 
considering hard end-points? 
3. Should all patients with iMN and nephrotic syndrome be treated with 
immunosuppressive therapy? 
4. Are all immunosuppressive agents equally effective? 
5. Which parameters can be used to identify patients at risk for progressive renal 
insufficiency? 
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1. The natural history of idiopathic membranous nephropathy. 
It is important to define the natural history of iMN. In fact, most will probably agree that the 
overall prognosis determines if one would ever consider the (early) use of aggressive therapy. 
In this respect, descriptions of the natural history of iMN are quite divergent and thus have 
laid the ground for heavy disputes on the use of immunosuppressive therapy. Schieppati et al. 
have pointed to the relatively benign course of iMN in untreated patients, with 65% of 
patients who were followed for more than 5 years developing a spontaneous remission of 
proteinuria and an estimated renal survival rate of 88% at 5 years.2 In contrast, Ponticelli et al. 
have stressed the poor outcome observing a permanent remission in only 33% of untreated 
patients followed for more than 10 years and a renal survival rate of 60% at 10 years.3 It is no 
surprise that the first investigators claim that symptomatic treatment is still the best option for 
patients with iMN whereas the latter argue that all patients with iMN and a nephrotic 
syndrome should receive immunosuppressive therapy.  
 
The short-term outcome ( < five years) of membranous nephropathy already was reported 
extensively before 1980.19-26 However, it is difficult to compare results because most of these 
older studies have the handicap that they included not only patients with idiopathic and 
secondary membranous nephropathy, but also treated and untreated patients. In the above-
mentioned studies a complete remission of proteinuria occurred in about 16% to 29% of 
patients, whereas in about 40 – 60% of patients, there was evidence of progressive renal 
insufficiency.  
 
To better appreciate the natural history of patients with iMN we have analysed studies 
published during the past 25 years. An overview is given in Tables 1 and 2.2;3;27-36 Whenever 
possible we have used the data from untreated patients. The reported studies still vary 
considerably with respect to patient characteristics, time of follow-up and definition of renal 
failure. Therefore, it may be no surprise that reported outcomes are quite variable. However, 
we must take into account the fact that many studies have included patients with non-
nephrotic proteinuria. Outcome in never-nephrotic patients with iMN is invariably good, with 
reported 10-year renal survival rates approximating 100%.31;35;37-39  
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The confounding effect of including up to 37% of non-nephrotic patients in studies of the 
natural history of iMN is illustrated in Figure 2.  
 
Figure 2. Outcome in studies of patients with idiopathic membranous nephropathy is 
dependent on the prevalence of the nephrotic syndrome.  
Relation of the calculated percentage of patients with progressive renal insufficiency during 5 yr 
follow-up and the percentage of patients with a nephrotic syndrome in studies on membranous 
nephropathy. Data from references.27-29;31;32;36;61 
 
Therefore, we have recalculated the data of the studies in Table 1 by attributing a 100% renal 
survival rate to the non-nephrotic patients (Table 2). Furthermore, we have not only included 
the reported data on the percentage of patients with ESRD, since these figures are not always 
corrected for patient death and not quite informative for studies with follow-up of less than 5 
years. To circumvent this problem and to allow good comparisons between studies we have 
calculated the percentage of patients with evidence of renal function deterioration (RFD), 
which is a very specific predictor of ESRD.37 From Table 2 it is evident that the data become 
more homogeneous. Overall, nearly half of the patients with iMN and a nephrotic syndrome 
will develop renal failure. The validity of our assumptions is underlined by the good 
agreement between the calculated percentage of RFD and the reported overall renal survival 
rate (Table 2). 
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Table 2. Calculated outcome in patients with idiopathic membranous nephropathy and a 
nephrotic syndrome 
Author 
 
 
Yr 
 
 
Patients 
(n) 
 
Nephrotic
(%)
Treated
(%)
Follow-up
(Yr)
Corrected RFD 
(%) 
 
Corrected renal 
survival (%) 
(Yrs)
Davison28  1984 64 81 0 7 62 NA
MacTier29 1986 37 93 0 5.3 44 46
Zuchelli30 1987 49 100 0 9.5 45 52 (10 yr)
Donadio31 1988 89 83 0 6.1 39 49 (10 yr)
Cattran32 1989 77 73 0 4 34 88 (8 yr)*
Wehrmann33 1989 334 73 35 4 42 59 (4 yr)
Cameron34 1990 51 100 0 4.3 52 NA
Durin35 1990 82 68 0 8 56 63 (10 yr)
Schieppati2 1993 100 63 0 3.3 51 57 (8 yr)
Ponticelli3 1995 39 100 0  > 10 47 60 (10 yr)
RFD, renal function deterioration; we calculated percentage RFD and renal survival after correction 
for the percentage of patients without a nephrotic syndrome assuming a 100% survival in non-
nephrotics. The correction factor used = 100/(% Nephrotics).  
For this analysis we excluded studies with a follow-up < 3 yrs.27 NA, not available.  
* The projected eight years renal survival is not reliable, since 22% of patients were lost to follow-up 
and median follow-up time was only 4 years. 
 
Obviously, conservative treatment of patients with proteinuria has changed dramatically in the 
past decade. Nowadays all patients with proteinuria are treated with ACE-inhibitors (ACEi) or 
angiotensin II type 1 receptor antagonists (ARBs). These agents reduce proteinuria and 
attenuate the deterioration in renal function in patients with diabetic and non-diabetic 
proteinuric renal diseases.40-43 Therefore, one might question the relevance of the data 
presented in Tables 1 and 2, which are largely derived from studies that included many 
patients who did not receive ACEi or ARBs. We must consider if the natural history of iMN 
has changed with the venue of ACEi and ARBs. 
Indeed, the prospect of the use of ACEi as effective treatment in patients with iMN has 
stimulated the initiative of a randomized study in the early nineties. In this study, called 
ACIMEN (ACE inhibition versus Corticosteroids in Membranous Nephropathy) it was 
intended to compare the ACEi enalapril with a 6-month course of alternate day prednisone or 
supportive treatment.44 Unfortunately, this study has not been completed due to the low rate 
of patient accrual; however, an interim analysis did not reveal any particular benefit of ACEi 
over placebo.  
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To determine whether use of ACEi could have substantially changed the prognosis in patients 
with iMN we have analysed the outcome in patients with iMN entered in our database since 
1988. For this analysis we have included all patients with a biopsy proven idiopathic MN, a 
normal renal function (serum creatinine < 1.25 mg/dl*) at the time of biopsy, and treated with 
an ACEi or an ARB (start of treatment before or within 6 months after biopsy). There were 91 
patients (61M, 30F) who fulfilled the entry criteria. Median age was 49 years (range 18-78), 
serum creatinine 0.98 mg/dl (0.54 – 1.24), and proteinuria 6.1 g/10 mmol creatinine (0.7 – 
32). A nephrotic syndrome was present in 87% of patients. Median follow-up was 46 months 
(3-167). During follow-up 39 patients (43%) have developed renal death, defined by the 
criteria that we have regularly used to allow the start of immunosuppressive therapy.8;15 Thus, 
our data indicate that the use of ACEi or ARBs has not greatly improved the prognosis in 
patients with iMN. Our data support the findings of Troyanov et al., who assessed the role of 
ACEi as independent predictor of outcome in their cohort of patients with iMN.45 In 
multivariate analysis the use of ACEi was not related to outcome. The possible benefits of 
ACEi treatment in patients with iMN have also been challenged by the studies of Praga et al., 
who clearly demonstrated that the antiproteinuric effects of ACEi were particularly evident in 
patients with renal diseases characterized by secondary focal segmental glomerulosclerosis 
due to hyperfiltration.46 In these patients proteinuria decreased from 7.1 ± 1.7 g/day at 
baseline to 3.7 ± 1.7 g/day after 6 months of treatment with ACEi. In contrast, in patients with 
a nephrotic syndrome (the majority caused by iMN) proteinuria remained unchanged at 
approximately 8 g/day. In a subsequent study it was shown that this poorer antiproteinuric 
response in patients with primary glomerulopathies also heralded a worse outcome with 
respect to renal function.47 
  
From the studies that report on the natural history important information can be obtained on 
the time course of events in patients with iMN. This knowledge is pivotal to allow evaluation 
of the quality of RCTs conducted in patients with iMN, in particular, to determine whether 
suitable end-points have been used in relation to the time of follow-up. In general, 
development of ESRD will take more than 5 years, and as a consequence studies that use 
ESRD as end point need a follow-up of 7-10 years. In contrast, patients with evidence of RFD 
(a specific predictor of ESRD, see below) can be identified at an earlier time point. In various 
studies the median time to the development of renal insufficiency was 2-2.5 years, with no 
patient with a normal renal function at 5 year follow-up showing deterioration of renal 
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function thereafter.28;35 Thus, RFD can be used as an estimate of treatment efficacy in studies 
with a follow-up of 3-4 years. 
The remission rate cannot be evaluated at a much earlier time point. The median time to 
partial remission ranges from 11 to 23 months and to complete remission from 16 to 40 
months.8;38;45;48 Although remissions occurred somewhat earlier in treated patients, the median 
time to complete remission in Ponticelli’s and our studies was 18 and 22 months 
respectively.3;8 Thus, studies with a limited time of follow-up (less than 2-3 years) cannot be 
used to evaluate remission rate.  
Admittedly, it can be questioned whether RFD and remission rate can be used as reliable 
surrogate end points of studies in iMN. The use of RFD as end point is supported by studies 
showing low renal survival in untreated iMN patients with established renal insufficiency.8;9 
Furthermore, patients with evidence of RFD (an increase of serum creatinine) almost 
invariable progress to ESRD.28;37;49 Likewise, the development of a remission can be used as a 
surrogate end point of a study, because most studies have documented a good overall 
prognosis in patients who have entered a partial or complete remission of proteinuria, 
independent of treatment.38;45;48;50 In Troyanov’s study the hazard ratio for developing ESRD 
was zero for patients with a complete remission and 0.08 for patients with a partial 
remission.45  
 
2. Is immunosuppressive therapy of proven benefit? 
In the period 1960-1970 membranous nephropathy was considered a slowly progressive 
disease, that was totally unresponsive to steroid treatment (reviewed by Rastogi et al.).51 
However, several investigators thereafter have reported complete remissions of proteinuria in 
patients with iMN following steroid therapy. Rastogi et al. have summarized the data of 108 
patients who were treated with steroids, 29 patients developing a complete remission of 
proteinuria and 19 patients developing a partial remission. Since many of the treated patients 
had a normal renal function at the time of treatment start, these data didn’t provide hard 
evidence that treatment with prednisone improved outcome.  
A subsequent randomized controlled trial provided promising results.27 A treatment regimen 
consisting of high dose alternate day prednisone (125 mg every other day for 8 weeks) 
significantly reduced the rate of renal function deterioration. This study has been criticized 
because of the rather high rate of doubling of serum creatinine that occurred within two years 
of follow-up in the placebo group (29% vs 6%). Two subsequent RCTs unequivocally proved 
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that prednisone did not prevent deterioration of renal function.32;34 Apparently publication of 
these RCTs has settled the issue, and prednisone monotherapy since then is regarded 
ineffective in patients with iMN. However, it is important to realize that these conclusions 
only hold for the use of prednisone in limited dosage or during a limited time period. The 
above-mentioned studies have used either 125-150 mg prednisone on alternate days for 8 
weeks27;34 or 45 mg/m2 on alternate days for 6 months,32 thus providing cumulative doses of 
prednisone of 4.2 and 7.0 g respectively. It is quite possible that a higher dose of prednisone 
administered for a longer period of time may be more effective. Hopper et al. have used 
prednisone in a dose of 100-200 mg every other day for a period of 7.5 months, followed by a 
gradual dose reduction during another 6 months.52 The cumulative dose of prednisone 
averaged  > 25 g. They have reported on 15 patients with progressive disease during an 
observation period of 8-66 months before start of therapy. After treatment 7 patients have 
developed a complete remission and 4 a partial remission of proteinuria. Before start of 
therapy renal function was severely reduced in 9 patients (all with serum creatinine  > 1.8 
mg/dl). At the end of follow-up renal function had improved in 7 out of these 9 patients. 
Slightly less impressive results were reported by Short et al.53 These investigators have used 
pulses methylprednisolone (5x 1000 mg), followed by high dose oral prednisone in a starting 
dose of 100 mg every other day, with gradual reduction over 8 months (cumulative dose 
approximately 9.5 g). Fifteen patients with renal insufficiency were treated and an 
improvement in renal function was noted in all, mean serum creatinine decreasing from 4.6 to 
2.5 mg/dl, the average percentage reduction amounting 46% (21% to 65%). Although 
improvement was not sustained in all, still 8 patients were alive without renal failure after 6- 
48 months follow-up. Other uncontrolled studies that have reported some benefit from steroid 
therapy have used prednisone in cumulative dosages of 9-10 g.20;54 Admittedly, the high dose 
prednisone regimen as used by Hopper is quite toxic and its efficacy is not adequately proven. 
Therefore, it is realistic to consider alternative treatment options. 
Other immunosuppressive agents have been used in patients with iMN, although most 
regimens have contained prednisone. Most studies have used a combination of an alkylating 
agent and prednisone.3;8;9;14;15;55-64 The efficacy of combined immunosuppressive therapy in 
membranous nephropathy was illustrated in an interesting case report by Ford.65 The author 
described a patient with ESRD due to iMN who received a kidney transplant. Postoperatively 
a renal biopsy was done because of the slower than expected improvement in renal function. 
The biopsy contained only totally infarcted renal tissue, which was confirmed by transplant 
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nephrectomy. Renal function meanwhile had gradually improved to a creatinine clearance of 
25 ml/min, with proteinuria averaging 1.6 g/day. This patient needed no further dialysis 
during 2 years of follow-up. 
The best study on the efficacy of aggressive immunosuppressive therapy in patients with iMN 
undoubtedly is the randomized controlled trial conducted by Ponticelli and co-workers.3;61;62 
These Italian investigators have randomized patients with iMN with a nephrotic syndrome 
and normal renal function for treatment with alternating monthly cycles of prednisone and 
chlorambucil versus no treatment. Duration of treatment was 6 months. Patients have 
meanwhile been followed for more than 10 years.3 The data unambiguously have 
demonstrated the beneficial effect of immunosuppressive therapy. Treatment increased 
remission rate (at the end of follow-up 63% vs 33%) and improved renal survival (92% vs 
60%).  
Unfortunately, the results of one RCT cannot be used to draw conclusions with the highest 
level of evidence. In the recently published Cochrane meta-analysis the results provided by 
Ponticelli’s study are virtually annihilated by reports of three other RCTs. However, two 
RCTs were small sized and had a limited follow-up of 12 and 24 months respectively.66;67 In 
view of the above-mentioned characteristics of the natural course in iMN, these latter studies 
cannot be used to analyse the effect of treatment on renal function. Notably, even within the 
short period of follow-up both studies documented a significant lower proteinuria in the 
treated patients. The third RCT has only been published in abstract form.68 However, 
additional information is provided in the manuscript by Risler et al.69 The investigators 
specifically state that for statistical purposes retrospectively studied control patients were 
added, thus invalidating this study as RCT. Furthermore, no clinical data are provided, 
especially the percentage of nephrotic patients is unnoted. Moreover, chlorambucil and 
prednisone tended to be more effective in inducing remission of proteinuria in the severely 
nephrotic patients and were of limited effect in the absence of tubulo-interstitial lesions.  
The efficacy of alkylating agents in patients with iMN is supported by other studies. In a 
small RCT we have demonstrated that the Ponticelli regimen is more effective than i.v. 
cyclophosphamide and methylprednisolone.10 Furthermore, two cohort studies have 
demonstrated the efficacy of alkylating agents.8;9 In these studies historical controls were used 
for comparison. The data of these studies are strengthened by the fact that only patients with 
RFD were included, thus patients with a bad renal prognosis and a low likelihood of 
spontaneous remissions. Torres et al. have treated patients with iMN and renal insufficiency 
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with chlorambucil and prednisone. We have performed a similar study using a 
cyclophosphamide-based regimen. Results were quite similar, with a favourable renal survival 
in the treated patients when compared with the historical controls (Figure 3). 
 
Figure 3. Renal survival in patients with idiopathic membranous nephropathy and renal 
insufficiency treated with alkylating agents (treated) compared with historical controls 
(controls). 
Data adapted from Du Buf et al.8 (cyclophosphamide; straight lines) and Torres et al.9 (chlorambucil; 
dotted lines). Data of Torres et al. were recalculated to provide overall renal survival without 
censoring for death. 
 
In conclusion, a high-quality RCT and two cohort studies with historical controls, of adequate 
size and long follow-up provide evidence for the efficacy of immunosuppressive therapy 
consisting of alkylating agents and prednisone in patients with iMN. 
 
3. Should all patients with membranous nephropathy and a nephrotic syndrome 
be treated? 
Based on the results from their controlled trials Ponticelli et al. concluded that treatment with 
chlorambucil and prednisone improved survival in patients with iMN, a nephrotic syndrome 
and normal renal function.61 Although we fully appreciated their findings, we and others were 
not convinced that the data proved that all patients should receive immediate treatment. 
Adoption of such an approach would unnecessarily expose up to 40% of patients to toxic 
immunosuppressive agents.  
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From the late 1980s, we have adopted a restricted treatment policy in which 
immunosuppressive therapy was given to patients with iMN, a nephrotic syndrome, and 
evidence of renal function deterioration.13;14;70 We found support for this strategy in studies by 
Mathieson and Warwick who reported improvement in renal function in patients with renal 
insufficiency.60;64 We recently have reported our experience with a cyclophosphamide based 
treatment regimen in 65 patients with iMN and renal insufficiency.8 Renal function improved 
at least temporarily in  > 90% of patients, and the cumulative incidence of complete and 
partial remissions of proteinuria was 92% at 5 years. If we calculated renal survival from the 
time of biopsy renal survival rates were 93% and 81% at 5 and 10 years respectively. 
Although these results were quite favourable and supported the efficacy of 
immunosuppressive therapy when started in patients with renal insufficiency, these data could 
not answer the question if start of therapy can be safely delayed until renal insufficiency has 
developed. In fact, our survival data must be compared with the results obtained by Ponticelli 
et al. who reported a 10 years renal survival of 92% (Figure 4).  
It is obvious that the comparison is biased in view of the high-risk profile of our treated 
patients. Therefore we have formally analysed the results of our restrictive treatment policy in 
an unbiased cohort of patients with iMN, a nephrotic syndrome and normal renal function at 
the time of biopsy.16 We advised to restrict immunosuppressive treatment to patients with 
renal insufficiency. The cohort comprised 69 patients with a serum creatinine of 1.0 ± 0.2 
mg/dl and proteinuria 6.7 ± 3.0 g/day. Follow-up was 5.4 (0.5-14.1) years. Thus far 33 
patients (48%) have received immunosuppressive therapy, which confirms the general idea 
that approximately half the patients will not need therapy. 
If we calculated renal survival for the patients who were treated according to the protocol     
5-year renal survival was 97%, comparable to the results obtained by Ponticelli et al. when 
treating all patients from the onset of disease (Figure 4). There was a small survival difference 
at 10 years of follow-up. However, it is important to realize that the average serum creatinine 
in our treated patients was 1.7 ± 0.6 mg/dl at the time of start of therapy whereas in 
Ponticelli’s study serum creatinine was 1.05 ± 0.25 mg/dl. It is likely that our results had been 
even better if treatment in the high-risk patients had started at an earlier time point, which 
may become possible with the use of sensitive and specific predictors of progression (vide 
infra). 
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Figure 4. Renal survival in patients with iMN, a nephrotic syndrome and normal renal 
function using a restrictive treatment policy.16 
Overall, 48% of patients have needed immunosuppressive treatment during follow-up. For comparison 
renal survival is shown for patients included in the RCT of Ponticelli et al. comparing chlorambucil 
and steroids (treated) with no treatment (untreated).3 
 
4. Are all immunosuppressive agents equally effective? 
Various immunosuppressive agents have been used in the treatment of patients with iMN 
including chlorambucil, cyclophosphamide, azathioprine, cyclosporine, mycophenolate 
mofetil, tacrolimus, ACTH, and most recently the anti CD20 monoclonal antibody rituximab 
and the anti-C5a monoclonal antibody eculizumab.3;8;9;14;15;55-60;62;63;66;67;69;71-88 Relevant data 
from the most important studies are given in Tables 3 and 4. 
There are no randomized trials that have compared the various classes of agents. It therefore 
is difficult to draw hard conclusions. From reviewing the literature some conclusions emerge.  
Most studies have used oral chlorambucil or oral cyclophosphamide. Our experience with 
both agents has been reported previously.14 In our hands, a regimen based on chlorambucil 
was less effective and more toxic than a cyclophosphamide based regimen. An overview of 
the studies performed in patients with renal insufficiency supported this notion (Table 3). 
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Remission of proteinuria as well as an improvement in renal function was more frequently 
seen during cyclophosphamide treatment. Admittedly, we cannot exclude that the better 
efficacy of cyclophosphamide is explained by the fact that cyclophosphamide therapy usually 
is given for a more prolonged period of time (12 months cyclophosphamide as compared with 
6 months chlorambucil). However, despite this shorter treatment period side effects occurred 
more frequently with chlorambucil. It has been suggested that side effects of chlorambucil 
might be particular prominent in patients with renal insufficiency. However, a similar 
difference in side effects was noted by Ponticelli et al. who compared chlorambucil and 
cyclophosphamide, administered in monthly alternating cycles with prednisone, for 6 months 
in patients with normal renal function.89 Side effects occurred more frequently during 
chlorambucil: Herpes Zoster infections occurred in 8% of chlorambucil-treated patients and in 
0% of the cyclophosphamide-treated patients, other side effects necessitated withdrawal of 
therapy in 12% of patients on chlorambucil vs 4% on cyclophosphamide.  
Of note, the above-mentioned studies all have used orally administered cyclophosphamide. 
Thus far, treatment schedules that have used intravenous pulses of cyclophosphamide have 
been ineffective.10;58 
 
Azathioprine often is considered a good replacement of cyclophosphamide, and recent studies 
in patients with vasculitis have provided evidence that after the induction phase (3 months) 
cyclophosphamide can be replaced safely by azathioprine.90 
We are used to switch from cyclophosphamide to azathioprine after three months in patients 
of young age because of the infertility risks associated with the use of cyclophosphamide.91 
Although our experience is limited we have the impression that the few treatment failures that 
we have observed during the past 10 years were confined mainly to patients who had used 
cyclophosphamide for only three months. In the literature azathioprine has been used with 
variable success.71;73-75;84;85 The first study by the Western Canadian Glomerulonephritis 
Study Group was a controlled double blind randomized trial that included only 9 patients (5 
azathioprine, 4 placebo) followed for merely one year.84 Not surprisingly there was no proven 
benefit of azathioprine. A similar conclusion was reached in a retrospective study71 that 
compared 38 treated patients with 20 contemporary untreated patients. Unfortunately, 
treatment was left at the discretion of the physicians, which makes it likely that the baseline 
characteristics have been pivotal in making a treatment decision. Indeed, although not 
significantly different, serum creatinine and proteinuria were 17 – 23% higher in the treated 
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patients. Furthermore, the study has included many patients with a good prognosis as 
reflected by the high spontaneous remission rate of 65% in the untreated patients. In a 
population with a good outcome in the untreated patients, it is more difficult to prove the 
efficacy of treatment especially if only small numbers of patients are included. 
Other studies have focussed on patients with progressive renal failure and reported more 
promising results (Table 4).73-75;85 
Bone et al. have evaluated the outcome after start of azathioprine therapy in 21 patients with 
evidence of progressive renal insufficiency as reflected by a mean decrease in ECC of 23 
ml/min/yr.73 These patients have been followed for 10 yrs. Treatment resulted in an 
improvement or stabilisation of renal function in all but three patients and a reduction of 
proteinuria, although levels below 1 g/day were reached in only 6 patients. At the end of 
follow-up 4 patients had progressed to dialysis, still 14 were alive with functioning kidneys. 
Of note, treatment with low dose azathioprine and prednisone needed to be continued lifelong, 
with relapses occurring during reductions of the prednisone dose. Roughly similar results 
have been reported by Brown et al.75 These investigators have treated 13 patients with 
azathioprine and prednisone. All patients had evidence of renal failure (see Table 4). Overall 
treatment improved renal function with a decrease in serum creatinine  > 15% in 10 patients 
and resulted in a complete or partial remission in 7 patients. Continued treatment was needed 
to maintain efficacy during follow-up. Only 4 patients were able to successfully discontinue 
azathioprine and prednisone therapy at the end of follow-up. The latter studies at least suggest 
that a combination of azathioprine and prednisone exerts beneficial effects in patients with 
iMN and renal insufficiency. However, the data also indicate that azathioprine containing 
regimens may be effective only if treatment is continued for life, in contrast to the experience 
with cyclophosphamide. 
 
Cyclosporine was used with success in patients with minimal change disease. The efficacy of 
cyclosporine (CsA) was attributed to the ability of CsA to decrease the production of 
lymphokines or cytokines. Subsequently, it was noted that CsA also reduced proteinuria in 
patients with such non-immunological glomerular diseases as Alports syndrome.92 In these 
latter patients the reduction of proteinuria was considered the consequence of the 
hemodynamic effects of CsA, which decreased GFR. Animal studies clearly proved a direct 
effect of CsA on glomerular permeability,93;94 which was confirmed in humans. Zietse et al. 
studied patients with iMN and observed a decrease in proteinuria within 1-3 months. Because 
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the fractional excretion of albumin decreased, it was suggested that hemodynamic effects 
were not the only cause of the decrease in proteinuria. In subsequent studies, both Zietse and 
Ambalavanan, by using dextran sieving experiments confirmed that CsA improved 
glomerular permselectivity, with a reduction in shunt flow.95;96 Unfortunately, proteinuria 
returned to baseline values within 4-8 weeks after stopping CsA therapy.  
Many studies have demonstrated the short-term antiproteinuric effect of CsA in patients with 
iMN. Most investigators agree that the effect is evident within 3 months after start of therapy, 
and that continued use of CsA beyond 4 months is not useful in non-responders. It remained 
unclear if use of CsA could have long-term benefits. Rostoker et al. treated patients for a 
median of 15 months and observed that several patients remained in remission after 
discontinuation of the drug.82 Obviously, in this study it was not excluded that most sustained 
remissions could have occurred spontaneously. Most importantly, the data did not prove or 
even suggest that CsA would benefit patients with iMN in terms of attenuating development 
of renal failure. 
Cattran et al. have reported the results of a small RCT (including 18 patients total) with iMN 
and renal insufficiency.76 They observed that CsA attenuated RFD compared with placebo, 
with a decrease in the slope of ECC from 2.1 to 0.7 ml/min/month. Remarkably, treatment 
with CsA did not result in an improvement in renal function, and no patient developed a 
complete remission of proteinuria, in contrast to the observed effects of alkylating agents. To 
date, these data have not been confirmed. In fact, others have noted that CsA was not very 
effective in patients with renal insufficiency, and even often caused progression to ESRD.79 
Furthermore, the Cyclosporine in Membranous Nephropathy Study group (Cyclomen) 
compared CsA with conservative treatment in patients with iMN and RFD.97 In this controlled 
trial which was terminated too early, CsA failed to exert long term benefits. This and other 
observations have led Ponticelli to advise against the use of CsA in patients with a creatinine 
clearance < 60 ml/min and/or severe hypertension and/or severe tubulo-interstitial fibrosis and 
tubular atrophy at renal biopsy.98 
The situation may be different in patients without renal failure. The efficacy of CsA was 
studied in an RCT of patients with iMN and normal renal function.77  Eligible patients were 
steroid resistant as defined by non-responsiveness to 8 weeks prednisone. Obviously, this 
definition can be questioned because prednisone is not considered effective therapy and a 
period of 8 weeks is too short to document remissions in patients with iMN. Nonetheless, 
CsA significantly decreased proteinuria compared with placebo. At the end of the 26-week 
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treatment period of 28 CsA-treated patients, 2 patients were in complete remission and 19 
patients were in partial remission, significantly different from results in the 23 untreated 
patients (complete remission in 1 and partial remission in 4 patients). However, after ending 
treatment many relapses occurred, and at the end of follow-up the differences in remission 
rate were not very impressive (Table 4). The follow-up of this study was too short, only 18 
months, to allow conclusions with respect to renal function. Furthermore, 9 (30%) patients 
experienced a temporary increase of serum creatinine during treatment with CsA, 
necessitating dose reduction or even stopping of the drug, suggesting that CsA therapy might 
be difficult to handle in clinical practice.  
 
Mycophenolate mofetil (MMF) was introduced as an effective immunosuppressive agent in 
transplant patients. The drug caused few side effects. The efficacy has since been 
demonstrated in patients with SLE, and some studies have suggested equipotency compared 
with cyclophosphamide. Because cyclophosphamide and azathioprine are considered effective 
in patients with iMN it seems logical to consider MMF in these patients. Thus far, the 
experience with MMF in patients with iMN is limited. Briggs et al. were the first to report the 
experience with MMF in patients with iMN.99 They have treated 3 patients with iMN who had 
experienced a relapse of proteinuria after withdrawal of other agents. All three patients had 
normal renal function, and developed a partial remission of proteinuria. After this report the 
investigators have continued treatment with MMF in patients with iMN. Their experience has 
been published in detail.78 The study included 17 patients with iMN and proteinuria. Only 6 
patients had evidence of renal insufficiency. Treatment consisted of MMF 0.5 – 1.0 g twice 
daily for 12 (4 –25) months, combined with steroids in most patients. Overall, proteinuria 
decreased, and in 2 patients a complete remission ( < 0.2 g/day) and in 5 a partial remission    
( < 2 g/day) was noted. Renal function improved in 3 of 6 patients with renal failure. The 
heterogeneity of the patients precludes us to draw hard conclusions. In another study Miller et 
al. have treated 16 patients with iMN, the majority with evidence of renal failure, thus high-
risk patients.80 MMF was used in dosages of 500 - 2000 mg/day, and only 5 patients were 
administered steroids concomitantly. Therapy was continued for only 8 (2-10) months. A 
partial remission of proteinuria was achieved in 2 patients. 
We have also evaluated the effects of MMF in a pilot study in patients with iMN and renal 
insufficiency.100 Our treatment regimen consisted of MMF in a dosage of 1000 mg twice 
daily, combined with steroids as in our cyclophosphamide protocol.  
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We observed a significant decrease in serum creatinine and proteinuria, in contrast to the 
findings of Miller et al. (Figure 5). The differences in efficacy most likely are explained by 
the differences in dose and duration of MMF therapy (we have consistently used 2000 mg/day 
for one year) and the use of steroids (all our patients were administered methylprednisolone 
pulses and oral prednisone according to our schedule with cyclophosphamide). Although we 
consider our data as promising, data are too limited to advise the regular use of MMF as 
standard therapy in patients with iMN. 
 
Figure 5. Efficacy of Mycophenolate mofetil in patients with idiopathic membranous 
nephropathy. 
Serum creatinine at baseline and after 6 months are shown as reported by Miller et al.80 (dotted lines) 
and Du Buf et al. 100 (straight lines). The differences are significant, which are likely explained by the 
higher dose of MMF, the longer duration of therapy and the concomitant use of prednisone in all 
patients in the latter study. 
 
The anti-CD20 antibody rituximab has proved effective in the treatment of B cell lymphomas. 
The effectiveness of this agent in decreasing the number of B cells and attenuating antibody 
production has led to the introduction of this drug in such immune-mediated kidney diseases 
as iMN. Remuzzi et al. have described the results after one year of treatment.81;101 They have 
treated 8 patients (3M, 5F) with iMN and a nephrotic syndrome. Renal function was normal 
in 5 patients. During follow-up, creatinine remained stable and proteinuria decreased to some 
extent; however only 3 patients developed a partial remission and no patient developed a 
complete remission. Thus, this study has included low-risk patients (women and patients with 
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normal renal function) and follow-up has been too short to allow meaningful conclusions on 
the efficacy of the drug. Subsequent data published in abstract form even suggested that the 
efficacy may be very limited.102 In this abstract it was shown that rituximab was ineffective in 
patients with tubulo-interstitial injury; a decrease in proteinuria was only observed in patients 
without tubulo-interstitial injury. Because the latter patients usually develop spontaneous 
remissions these data suggest that rituximab is ineffective in patients at risk for ESRD. 
 
The potential use of ACTH (corticotropin) in patients with iMN has received little attention. 
Long-acting ACTH administered intramuscularly two to three times weekly decreased serum 
lipids and proteinuria within 8 weeks.87 Relapses occurred after ending treatment. However, 
continued treatment for one year in 5 patients resulted in improvement in renal function and 
remission of proteinuria. Unfortunately, these data have not been confirmed; effectiveness has 
only been evaluated in patients with recent-onset iMN, normal renal function and moderate 
proteinuria.88 
  
It generally is accepted that the complement system is involved in iMN. Activation of the 
complement system with the formation of the C5b-9 membrane attack complex is held 
responsible for the podocyte injury and proteinuria. The development of a monoclonal 
antibody directed at C5a held the promise of rational treatment targeting one of the effector 
molecules. A humanized antibody has allowed studies of patients with iMN. The first study 
demonstrated no obvious benefits.86 Admittedly, this may have been caused by the inability of 
the regimen used to continuously block complement generation. Thus, additional studies are 
needed to better define the adequate timing of drug administration. 
 
5. Which parameters can be used to identify patients at risk for  
disease progression? 
Ideally, immunosuppressive therapy should be restricted to patients with iMN who will 
develop ESRD. In such patients, treatment preferably should be started before severe renal 
insufficiency has developed. Admittedly, there is still no evidence that an early start of 
treatment will lead to a better preservation of renal function. However, early start of treatment 
will decrease the time patients spend in a nephrotic phase, with its associated risks for 
thrombo-embolic complications and premature vascular disease.29;30;35  
 
 
142 
Chapter 9 
To allow an early start of treatment it is necessary to be able to identify patients at risk for 
ESRD with high sensitivity and specificity. If a prognostic marker is used to guide treatment, 
its specificity must be high, preferably  > 90%. In such a case, less than 10% of patients will 
receive treatment unnecessarily. Furthermore, sensitivity also must be high to ensure that 
patients are indeed detected. 
In the literature, several risk markers have been identified that are associated with disease 
progression. We have reviewed the literature and calculated sensitivities and specificities for 
the various factors.49 Examples of risk factors are advanced age, male sex, white race, 
disturbed renal function at baseline, hypertension, higher glomerular stage and more extensive 
area of tubulo-interstitial fibrosis. Unfortunately, these parameters lack sufficient sensitivity 
and specificity and do not allow to guide treatment. In fact, as recent as 1994 Honkanen stated 
that ‘the prediction of renal outcome on clinical basis is hopeless in iMN patients showing a 
nephrotic syndrome at biopsy’.37 
Although proteinuria is a well-known predictor of progressive renal injury, the magnitude of 
proteinuria at baseline is not very discriminative.73 This is explained readily by the lack of an 
association between the level of proteinuria and the extent of tubulo-interstitial injury in renal 
biopsies.33 By combining the magnitude and the duration of proteinuria, the risk of renal 
function deterioration can be better estimated. Pei et al. observed a 47% risk of progression in 
patients with a proteinuria of  > 4 g for  > 18 months, and a 66% risk in patients with  > 8 g  
proteinuria for  > 6 months.103 Sensitivity and specificity improved when using a model that 
included the level of proteinuria during the 6-month period with greatest proteinuria, as well 
as serum creatinine at the start of this period and the change in creatinine clearance during this 
6-month period (Table 5).104 Some investigators have advocated measurement of urinary 
complement products, based on the hypothesis that renal injury in patients with iMN is 
mediated by complement.105 Initial studies have suggested a high sensitivity and specificity 
(Table 5).106 We and others have studied the predictive value of specific urinary proteins, such 
as IgG (as marker of glomerular size selectivity) and the low molecular weight proteins β2-
microglobulin (β2m) or α1-microglobulin (markers of tubulo-interstitial injury).11;12;107;108 Both 
urinary IgG excretion and urinary excretion of low molecular weight proteins proved valuable 
markers (Table 5). 
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Table 5. Overview of accuracy of predictors of ESRD in patients with idiopathic 
membranous nephropathy 
Original study 
Validation study 
Original study Validation study 
 
Parameter and threshold 
Sensitivity Specificity Sensitivity Specificity
Pei103 
Cattran104 
Proteinuria 
 > 8 g  > 6 months 
  66 88  
58 
 
93 
Cattran104 
  Italy104 
  Finland104 
Model proteinuria and 
serum creatinine 
  83 86  
60 
77 
 
92 
89 
Brenchley106 
 
UC3dg 
 > 25 U/mg creat 
  80 81  
NA 
 
NA 
Brenchley106 
Cattran110 
 
UC5b-9 
 > 7 U/mg creat 
  60 86  
Invalid 
See comments in text 
Reichert12 
Branten18 
 
UIgG 
 > 250 mg/24 h 
  89 85  
88 
 
88 
Bazzi107 
 
UIgG 
 > 110 mg/g creat 
100 58  
NA 
 
NA 
Reichert11 
Branten18 
Uβ2m 
 > 0.5 μg/min 
  85 82  
88 
 
91 
Bazzi107 Uα1m 
 > 33 mg/g creat 
100 84  
NA 
 
NA 
Branten18 Uα1m 
 > 40 μg/min 
  84 94  
NA 
 
NA 
Reichert49 
Honkanen37 
Serum creatinine 
 > 1.5 mg/dl* 
  52 90  
80 
 
92 
* threshold for renal insufficiency has varied from 1.2 to 1.8 mg/dl. NA, not available. 
 
It is important to realize that initial studies often provide a too optimistic view of the value of 
risk markers. To evaluate these risk markers, their accuracy at the predefined threshold values 
must be validated in a new patient cohort. To date, the accuracy of urinary complement C3d 
has not been validated. We have measured urinary C3d in patients with various renal 
diseases.109 We observed a good correlation between urinary C3d and the urinary excretion of 
IgG and β2m. We calculated that the urinary C3d level was determined by tubular 
reabsorption processes, as well as glomerular permeability of C3 and local production of C3 
and C3d. When corrected for proteinuria there were no differences between patients with iMN 
and patients with other glomerular diseases. We have not evaluated the prognostic accuracy of 
C3d, although we expect that urinary C3d will be predictive in view of the good correlation 
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with IgG and β2m. However, measurement of urinary C3d is difficult in routine clinical 
practice, and requires special sampling conditions (in EDTA-containing tubes, placed on ice, 
centrifuged in the cold and stored at –70 oC). Furthermore, C3 may interfere in the assay, and 
the coefficient of variation is 7 – 10%.  
The accuracy of the urinary C5b-9 membrane attack complex has not been formally validated. 
However, Cattran et al. measured urine C5b-9 in patients with iMN that had participated in 
the CsA controlled trial.110 Notably, urinary C5b-9 was not measurable in the majority of 
patients (11 out of 16). Furthermore, the absence or presence of the membrane attack complex 
did not predict outcome or treatment response in their patients. 
The change of serum creatinine over a period of 2 years proved a very specific marker   
(Table 5).37 Unfortunately, sensitivity is low, and the use of this parameter does not allow the 
start of treatment before the onset of renal failure.  
The model developed by Cattran’s group has been validated in a Finnish and Italian 
population.104 This validation study proved the high specificity and sensitivity of this model 
(Table 5). Of note, the validation cohort consisted of treated and untreated patients, and also 
included patients with non-nephrotic proteinuria (17 – 23%). It is unclear whether results 
would have been similar if the validation cohorts had only included untreated patients with a 
nephrotic syndrome. Furthermore, application of the model requires a period of follow-up to 
identify the 6-month period with the highest level of persistent proteinuria. In approximately 
one quarter of patients in the validation study, the period of maximal persistent proteinuria 
started  > 12 months after renal biopsy.  
We recently have validated the use of urinary IgG and β2m in a new cohort of patients with 
iMN.18 The data unequivocally proved that these markers predict prognosis, with sensitivities 
and specificities approximating 90%. Specificity approached 100% when combining urinary 
β2m and serum albumin. In Figure 6, renal survival is depicted for patients with urinary β2m 
and serum albumin levels less than or greater than the threshold.  
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Figure 6. Urinary β2-microglobulin excretion and serum albumin predict renal survival in 
patients with idiopathic membranous nephropathy, a nephrotic syndrome and normal renal 
function at biopsy.  
Data adapted from Branten et al.18  
Threshold values were 0.5 μg/min for urinary β2m and 2.2 g/dl for serum albumin. 
 
The use of the Toronto model or specific urinary protein analysis should allow us to restrict 
therapy to patients at greatest risk for disease progression. We prefer measurements of low 
molecular weight proteins rather than the duration and magnitude of proteinuria, because of 
the greater accuracy, its easy applicability (no need for 24-h urine collections) and its direct 
use (no need for a waiting period).  
 
In conclusion, our treatment strategy is intended to allow individualized treatment for patients 
with iMN. High-risk patients can be identified readily. Patients at risk for developing ESRD 
should receive immunosuppressive therapy. Currently, we prefer a combination of 
cyclophosphamide and steroids. Alternative agents include CsA and MMF, however their 
efficacy on long term remains to be proved.  
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Summary 
The use of immunosuppressive therapy in patients with idiopathic membranous nephropathy 
is heavily debated. We prefer treating only patients at highest risk for disease progression. 
From 1988 onward, we have applied a restrictive treatment strategy, limiting the use of 
immunosuppressive drugs to patients with evidence of progressive renal failure. In addition, 
we have continued the search for risk markers of disease progression and for better 
immunosuppressive agents. In Figure 1, we provide an overview with reference to the 
relevant chapters.  
 
We first evaluated the efficacy of immunosuppressive therapy in patients at highest risk for 
end-stage renal disease: patients with evidence of renal function deterioration (serum 
creatinine  > 135 μmol/l and/or a rise in serum creatinine of  > 50%). In Chapter 2 we report 
the prospective study of 65 patients with idiopathic membranous nephropathy and renal 
insufficiency, treated with cyclophosphamide and steroids. The treatment schedule consisted 
of oral cyclophosphamide, 1.5-2.0 mg/kg/day for 12 months and steroids, methylprednisolone 
pulses 3 x 1 g, i.v. at months 0, 2 and 4 and oral prednisone 0.5 mg/kg/48 h for 6 months. 
Median follow-up was 51 months. Renal function temporarily improved or stabilized in all 
patients. A partial remission (PR, proteinuria 0.21-2.0 g/10 mmol creatinine) occurred in 56 
patients; 17 patients improved into a complete remission (CR, proteinuria < 0.2 g/10 mmol 
creatinine). During follow-up, 11 patients relapsed (28% relapse rate after 5 years) to a 
nephrotic syndrome. Nine of them were re-treated because of renal function deterioration. At 
the end of follow-up, 16 patients were in CR, 31 in PR, eight had a persistent nephrotic 
syndrome, one had mild proteinuria, four had progressed to ESRD and five had died. Overall 
renal survival was 86% after 5 years and 74% after 7 years. To demonstrate the efficacy of 
immunosuppressive therapy in patients with renal function deterioration, we have compared 
renal survival in our treated patients with outcome in a group of historical control patients 
(n=24), who were either not treated or treated with ineffective immunosuppression. Renal 
survival in this historical control group was only 32% after 5 and 7 years. 
Unfortunately, immunosuppressive treatment was accompanied by complications in two-
thirds of patients. Side effects consisted mainly of bone marrow depression and infections. 
Furthermore, one patient has developed bladder cancer, a feared complication of 
cyclophosphamide therapy. 
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From this study we conclude that renal survival can be significantly improved by treating 
patients with idiopathic membranous nephropathy and renal insufficiency with 
cyclophosphamide and steroids. However, side effects occur frequently and the relapse rate is 
high during longer follow-up. 
 
In Chapter 3 we have prospectively studied the clinical course in 15 patients, who either did 
not respond to the first course of immunosuppression or had experienced a relapse of the 
nephrotic syndrome, accompanied with renal function deterioration. These patients were 
treated with a consecutive course of immunosuppression. Initial immunosuppression 
consisted of either chlorambucil or cyclophosphamide and was started 8 months (range: 0-143 
months) after renal biopsy. The second course of immunosuppression consisted of 
cyclophosphamide and steroids in all patients. The interval between the first and second 
course was 40 months (range: 7-112 months). Total follow-up was 110 months (range: 46-289 
months). Renal function and proteinuria improved at least temporarily in all patients after the 
second course. Four patients have needed an additional course of therapy. At the end of 
follow-up two patients were in complete remission, eight in partial remission, three patients 
experienced persistent proteinuria, one patient had progressed to end-stage renal disease and 
one patient had died. Renal survival was 86% at 5 and 10 years of follow-up. The repeated 
courses of immunosuppression have resulted in a gain of dialysis-free survival time of more 
than 93 months (range: 43-192 months). In conclusion, we think that a second course of 
immunosuppression should be advised to patients with persistent or relapsing nephrotic 
syndrome and renal insufficiency. 
 
Despite the efficacy of cyclophosphamide, the high rate of immunosuppressive therapy-
related side effects prompted us to search for newer treatment strategies, aiming at high 
efficacy and fewer complications. In Chapter 4 we report the interim results of an ongoing 
pilot study, which started in May 2002. In this study we have treated patients with renal 
insufficiency with mycophenolate mofetil (MMF), 1000 mg twice daily for 12 months in 
combination with steroids in the same schedule as mentioned previously. Thirteen patients 
have completed the treatment year and these results were compared with 13 matched 
historical controls treated with cyclophosphamide. MMF and cyclophosphamide were equally 
effective in improving renal function and reducing proteinuria. In the treatment year, eight 
(mycophenolate mofetil) and seven (cyclophosphamide) patients developed a partial 
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remission of proteinuria. Approximately 70% of patients experienced side effects with both 
treatment schedules. Patients on cyclophosphamide mainly experienced leucocytopenia, 
whereas patients on mycophenolate mofetil suffered from anemia. Both patient groups 
experienced infections. Although not less frequent, side effects on mycophenolate mofetil 
were less severe. Unfortunately, two patients treated with mycophenolate mofetil had a 
treatment failure. Therefore, the results of treatment of a larger group of patients with longer 
follow-up have to be awaited before firm conclusions on the efficacy of mycophenolate 
mofetil for this high-risk patient group can be drawn. 
 
In Chapter 5 we demonstrate the benefits of a restrictive treatment policy. We have 
prospectively studied a cohort of 69 patients with normal renal function and a nephrotic 
syndrome at the time of renal biopsy. Immunosuppressive treatment, mainly consisting of 
cyclophosphamide and steroids, was advised only in patients with renal insufficiency or 
severe intolerable nephrotic syndrome. At the time of biopsy average serum creatinine was 90 
μmol/l and proteinuria 6.7 g/day. After a follow-up of more than 5 years, 33 (48%) patients 
have received immunosuppressive therapy, mainly because of renal insufficiency (n=24). At 
the end of follow-up 22 patients were in complete remission (32%), 24 patients in partial 
remission (35%), 15 patients still had a nephrotic syndrome (22%), one patient experienced 
mild proteinuria (1.4%), six patients had developed end-stage renal disease (8.7%) and one 
patient had died. Renal survival was 94% at 5 years and 88% at 7 years. For comparison, 
Ponticelli et al. who treated 100% of patients reported a 10-year survival rate of 92%. We 
conclude that a restrictive treatment policy assures a favourable prognosis, while preventing 
exposure to immunosuppressive therapy in  > 50% of the patients. 
 
Nevertheless, we cannot exclude that prognosis can be improved by treating patients at high 
risk for renal function deterioration in an earlier phase, i.e. before serum creatinine rises 
significantly. To do so, we must be able to identify high-risk patients early in the course of the 
disease. In Chapter 6 we have validated the formerly suggested value of urinary β2-
microglobulin and IgG in predicting prognosis. In a prospective study, started in 1995, in 58 
patients with membranous nephropathy, normal renal function and a nephrotic syndrome, a 
standardized measurement was carried out to determine renal function and the excretion of 
low and high molecular weight proteins. The endpoint renal death was sharply defined as a 
serum creatinine exceeding 135 μmol/l (1.5 mg/dl), a rise of serum creatinine of  > 50%, or 
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need of immunosuppressive treatment. After a follow-up time of more than 4 years, 25 (43%) 
of the patients had reached the endpoint. Multivariate analysis by Cox proportional hazard 
confirmed urinary β2-microglobulin excretion, using the threshold value of 0.5 µg/min, as the 
strongest independent predictor for the development of renal insufficiency, with a sensitivity 
of 83% and a specificity of 88%. Sensitivity and specificity were 84% and 85% respectively 
for the urinary excretion of IgG, applying the threshold value of 250 mg/24 hours. When the 
excretions of both proteins were combined specificity improved to 94%. Therefore, urinary 
β2-microglobulin and IgG are useful markers to guide decisions on the start of 
immunosuppressive treatment. 
 
Unfortunately, β2-microglobulin in urine can only be accurately measured in alkaline urine. 
We therefore use sodium bicarbonate to alkalinize urine to levels of pH above 6.0. However, 
in 7% of patients, this value cannot be reached. We investigated if administration of 
acetazolamide, a carbonic anhydrase inhibitor, would sufficiently alkalinize urine, without 
influencing urinary protein excretion rates. In Chapter 7 we show, that the administration of 
acetazolamide adequately increased urinary pH, thus allowing measurement of urinary β2-
microglobulin, without influencing the urinary excretion of β2-microglobulin. However, side 
effects occurred frequently, mainly consisting of paresthesias (58%), changes in taste (32%) 
and dizziness (29%). Although these side effects were not severe, they prevent the routine use 
of acetazolamide. 
  
Given the value of the urinary β2-microglobulin and IgG excretion in predicting the 
occurrence of renal function deterioration in patients with normal renal function, we 
wondered what happened with the urinary excretion of the high and low molecular weight 
proteins during and after immunosuppressive therapy. In Chapter 8 we investigated the time-
course of the urinary excretion of these proteins after start of therapy and evaluated their value 
in predicting long-term outcome. Eleven patients underwent repeated standardized 
measurements of urinary IgG, β2-microglobulin and α1-microglobulin during the treatment 
year. We observed a rapid improvement in glomerular perm selectivity and tubular protein 
reabsorption within 2 months after start of therapy. Despite a partial remission of proteinuria 
within 12 months in most patients, evidence of tubulo-interstitial injury remained apparent. In 
order to investigate the predictive value of the urinary excretions of the high and low 
molecular weight proteins at the end of the treatment year, 25 patients had measurements at 
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12 months. However, the urinary levels of IgG, β2-microglobulin and α1-microglobulin 
neither at baseline nor at 12 months clearly predicted the occurrence of a remission or a 
relapse to nephrotic range proteinuria. Seventeen patients had measurements 2-5 years after 
the start of immunosuppressive treatment. In case of a persistent stable remission we observed 
a gradual decrease in urinary β2-microglobulin towards normal values, whereas in case of a 
relapse to nephrotic range proteinuria urinary β2-microglobulin excretion increased. The data 
of this study allowed us to investigate the relationship between the tubular reabsorption of β2-
microglobulin and the urinary excretion of IgG. We could conclude that the urinary excretion 
of β2-microglobulin is not the result of inhibition of its reabsorption by IgG, thus confirming 
the value of β2-microglobulin as a marker of tubulo-interstitial injury. 
 
In Chapter 9, we propose a rational treatment strategy for patients with idiopathic 
membranous nephropathy based on a review of the literature and our own experience. The 
proposed strategy is depicted in Figure 1. 
 
 
 
  
 
  
 
Chapter 11 
Samenvatting 
 
 
 
 
 
 
162 
Chapter 11 
Samenvatting 
Er is geen eenduidig beleid t.a.v. de immunosuppressieve behandeling van patiënten met een 
idiopathische membraneuze glomerulopathie. Wij geven er de voorkeur aan om alleen 
patiënten met het hoogste risico op progressie (achteruitgang) van de ziekte te behandelen. 
Sinds 1988 hebben wij dit terughoudende beleid gevoerd, waarbij we het gebruik van 
immunosuppressiva hebben beperkt tot die patiënten bij wie de nierfunctie duidelijk achteruit 
gaat. Daarnaast hebben wij gezocht naar risico factoren die het mogelijk maken patiënten ‘at 
risk’ voor progressieve ziekte in een vroege fase van de ziekte te identificeren. Ook hebben 
wij onderzoek gedaan naar betere immunosuppressieve medicijnen. In Figuur 1 geven we een 
overzicht van het verrichte onderzoek met verwijzing naar de relevante hoofdstukken. 
 
We hebben eerst de effectiviteit geëvalueerd van immunosuppressieve behandeling van 
patiënten die het hoogste risico lopen op eindstadium nierfalen: patiënten met een duidelijke 
achteruitgang van nierfunctie (serum creatinine  > 135 μmol/l en/of een stijging van het serum 
creatinine met  > 50%). In Hoofdstuk 2 rapporteren we de prospectieve studie bij 65 patiënten 
met idiopathische membraneuze glomerulopathie en nierinsufficiëntie, behandeld met 
cyclofosfamide en steroïden. Het behandelingsschema bestond uit oraal cyclofosfamide 1.5-
2.0 mg/kg/dag gedurende 12 maanden en steroïden, methylprednisolon pulsen 3 x 1 g, i.v. op 
maand 0, 2 en 4 en oraal prednison 0.5 mg/kg om de dag gedurende 6 maanden. De mediane 
duur van follow-up was 51 maanden. Bij alle patiënten bleek de nierfunctie tenminste tijdelijk 
te verbeteren of te stabiliseren. Een partiële remissie (PR, proteïnurie van 0.21-2.0 g/10 mmol 
creatinine) trad op bij 56 patiënten; 17 patiënten verbeterden tot een complete remissie (CR, 
proteïnurie < 0.2 g/10 mmol creatinine). Gedurende de follow-up trad bij 11 patiënten een 
recidief (terugkeer) op van het nefrotisch syndroom (dit komt overeen met een 
recidiefpercentage van 28% na 5 jaar). Negen patiënten werden opnieuw behandeld met 
immunosuppressie wegens achteruitgang van nierfunctie. Aan het eind van de follow-up 
waren 16 patiënten in CR, 31 in PR, acht patiënten hadden een aanhoudend nefrotisch 
syndroom, een patiënt had milde proteïnurie, vier patiënten hadden eindstadium nierfalen 
ontwikkeld en vijf patiënten waren overleden. De renale overleving (levende patiënt zonder 
eindstadium nierfalen) was 86% na 5 jaar en 74% na 7 jaar.  
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Om de effectiviteit van de immunosuppressieve therapie bij patiënten met achteruitgaande 
nierfunctie te illustreren, hebben we de renale overleving vergeleken van onze behandelde 
patiënten met die van een groep historische controle patiënten (n=24), die ofwel niet 
behandeld waren of behandeld waren met immunosuppressie waarvan we nu weten dat deze 
niet effectief is. De renale overleving in deze groep van historische controle patiënten was 
slechts 32% na 5 en 7 jaar. 
Helaas ging de behandeling met immunosuppressiva gepaard met complicaties in tweederde 
van de patiënten. De bijwerkingen bestonden met name uit beenmergdepressie en infecties. 
Bovendien ontwikkelde een patiënt blaaskanker, een gevreesde complicatie van behandeling 
met cyclofosfamide.  
Uit deze studie concluderen wij dat de renale overleving significant verbeterd kan worden 
door patiënten met idiopathische membraneuze glomerulopathie en nierinsufficiëntie te 
behandelen met cyclofosfamide en steroïden. Echter, er treden frequent bijwerkingen op en 
het aantal patiënten dat een recidief ontwikkelt neemt toe bij een langere follow-up. 
In Hoofdstuk 3 hebben we prospectief het klinische beloop bestudeerd in 15 patiënten, die 
ofwel niet hadden gereageerd op een eerste kuur met immunosuppressie dan wel een recidief 
van het nefrotisch syndroom hadden ontwikkeld gepaard gaande met achteruitgang van 
nierfunctie. Deze patiënten werden behandeld met een volgende kuur immunosuppressie. De 
eerste kuur immunosuppressie had bestaan uit chloorambucil of cyclofosfamide en was 8 
maanden (spreiding: 0 - 143 maanden) na het verrichten van de nierbiopsie gestart. De tweede 
kuur bestond bij alle patiënten uit cyclofosfamide en steroïden. Het interval tussen de eerste 
en tweede kuur was 40 maanden (spreiding: 7 - 112 maanden). De totale follow-up was 110 
maanden (spreiding: 46-289 maanden). Bij alle patiënten verbeterden de nierfunctie en de 
proteïnurie tenminste tijdelijk na de tweede kuur. Vier patiënten hadden nog een extra kuur 
nodig. Aan het eind van de follow-up waren twee patiënten in complete remissie, acht in 
partiële remissie, drie patiënten hadden aanhoudende proteïnurie, een patiënt was 
achteruitgegaan en ontwikkelde eindstadium nierfalen en een patiënt was overleden. De 
renale overleving kwam hiermee op 86% na 5 en 10 jaar follow-up. Het geven van herhaalde 
kuren immunosuppressie resulteerde in een winst in overlevingsduur zonder dialyse van meer 
dan 93 maanden (spreiding: 43-192 maanden). Concluderend denken wij dat een tweede kuur 
immunosuppressie geadviseerd zou moeten worden aan patiënten met een aanhoudend of 
recidiverend nefrotisch syndroom met nierinsufficiëntie.  
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Ondanks de effectiviteit van cyclofosfamide, noodzaakte het grote aantal bijwerkingen van de 
immunosuppressieve therapie ons tot het zoeken naar nieuwere behandelingsstrategieën, 
gericht op hoge effectiviteit met minder complicaties. 
In Hoofdstuk 4 rapporteren we de interim resultaten van een lopende pilot-studie, die gestart 
werd in mei 2002. In deze studie hebben we patiënten met nierinsufficiëntie behandeld met 
mycofenolaat mofetil (MMF), tweemaal daags 1000 mg gedurende 12 maanden in combinatie 
met steroïden volgens hetzelfde schema als hiervoor genoemd. Dertien patiënten hebben het 
behandelingsjaar afgerond en de resultaten van deze behandeling werden vergeleken met 13 
gematchte historische controle patiënten die behandeld waren met cyclofosfamide. Het bleek 
dat MMF en cyclofosfamide even effectief waren in het verbeteren van nierfunctie en het 
verminderen van de proteïnurie. In het behandelingsjaar bereikten acht (MMF) respectievelijk 
zeven (cyclofosfamide) patiënten een partiële remissie van de proteïnurie. Ongeveer 70% van 
de patiënten had bijwerkingen bij beide behandelingsschema’s. Patiënten die behandeld waren 
met cyclofosfamide hadden vooral last van leucopenie, terwijl de patiënten behandeld met 
mycofenolaat mofetil vooral leden aan anemie (bloedarmoede). In beide patiëntengroepen 
kwamen infecties voor. Hoewel aldus de frequentie van bijwerkingen niet minder hoog was, 
waren de bijwerkingen bij gebruik van mycofenolaat mofetil wel minder ernstig. Helaas 
ontwikkelden twee patiënten die behandeld waren met mycofenolaat mofetil een recidief 
nefrotisch syndroom nog tijdens of korte tijd na het staken van de behandeling. Derhalve 
moeten we de resultaten van behandeling van een grotere groep patiënten die langer vervolgd 
zijn afwachten, voordat we harde conclusies over de effectiviteit van mycofenolaat mofetil 
voor deze groep hoog-risico patiënten kunnen trekken.  
 
In Hoofdstuk 5 demonstreren we de voordelen van onze terughoudende 
behandelingsstrategie. Hiervoor hebben we prospectief een cohort van 69 patiënten 
bestudeerd, met een normale nierfunctie en een nefrotisch syndroom op het moment van de 
nierbiopsie. Immunosuppressieve therapie, die vooral bestond uit cyclofosfamide en 
steroïden, werd alleen geadviseerd aan patiënten met nierinsufficiëntie of een ernstig 
nefrotisch syndroom. Op het moment van de biopsie bedroeg het gemiddelde serum creatinine 
90 μmol/l en de proteïnurie 6.7 g/dag. Na een follow-up van meer dan 5 jaar hadden 33 (48%) 
patiënten immunosuppressieve therapie gekregen, vooral wegens nierinsufficiëntie (n=24). 
Aan het eind van de follow-up waren 22 patiënten in complete remissie (32%), 24 patiënten in 
partiële remissie (35%), 15 patiënten hadden nog steeds een nefrotisch syndroom (22%), een 
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patiënt vertoonde milde proteïnurie (1.4%), zes patiënten hadden progressie vertoond tot 
eindstadium nierfalen (8.7%) en een patiënt was overleden. De renale overleving bedroeg 
hiermee 94% na 5 jaar en 88% na 7 jaar follow-up. Ter vergelijking, Ponticelli et al., die 
100% van de patiënten behandelden, rapporteerden een 10 jaars overlevingspercentage van 
92%. Hieruit concluderen wij, dat een terughoudende behandelingsstrategie een gunstige 
prognose verzekert, terwijl in  > 50% van de patiënten de blootstelling aan immuno-
suppressieve therapie wordt voorkomen. 
 
Niettemin kunnen we niet uitsluiten, dat de prognose nog verder verbeterd kan worden door 
patiënten die een hoog risico hebben op achteruitgang van hun nierfunctie in een vroegere 
fase te behandelen, dat wil zeggen voordat het serum creatinine significant begint te stijgen. 
Om dit te kunnen doen moeten we echter in staat zijn hoog-risico patiënten vroeg in het 
beloop van de ziekte te identificeren. 
In Hoofdstuk 6 hebben we de waarde gevalideerd van de uitscheiding in de urine van β2-
microglobuline en IgG, de eerder door ons gesuggereerde prognostische factoren. In een 
prospectieve studie, die in 1995 van start ging, hebben we bij 58 patiënten met een 
membraneuze glomerulopathie, normale nierfunctie en een nefrotisch syndroom, een 
gestandaardiseerde meting uitgevoerd ter bepaling van nierfunctie en de uitscheiding van 
laag- en hoog-moleculaire eiwitten in de urine. Het eindpunt ‘nierdood’ werd scherp 
gedefinieerd als een serum creatinine boven de 135 μmol/l (1.5 mg/dl), een stijging in het 
serum creatinine van  > 50%, of de noodzaak tot het starten van immunosuppressieve 
behandeling. Na een follow-up tijd van meer dan 4 jaar, hadden 25 (43%) van de patiënten het 
eindpunt bereikt. In een multivariate analyse volgens het Cox proportional hazard model werd 
de β2-microglobuline excretie in de urine als de sterkste onafhankelijke voorspeller voor de 
ontwikkeling van nierinsufficiëntie bevestigd, gebruikmakend van een grenswaarde van      
0.5 µg/min, met een sensitiviteit van 83% en een specificiteit van 88%. De sensitiviteit en 
specificiteit waren resp. 84% en 85% voor de uitscheiding in de urine van IgG, bij toepassing 
van een grenswaarde van 250 mg/24 uur. Bij gebruik van de combinatie van beide eiwitten 
verbeterde de specificiteit naar 94%. Derhalve concluderen wij dat de uitscheiding in de urine 
van β2-microglobuline en IgG bruikbare markers zijn en een leidraad kunnen vormen bij de 
beslissing omtrent het starten van immunosuppressieve therapie. 
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Helaas kan de uitscheiding in de urine van β2-microglobuline alleen correct worden gemeten 
in alkalische urine. Om een urine pH boven de 6.0 te bewerkstelligen maken we gebruik van 
natriumbicarbonaat. Echter, in 7% van de gevallen wordt de pH-waarde van 6.0 niet bereikt. 
Wij onderzochten of het toedienen van acetazolamide, een carbo-anhydrase remmer, de urine 
voldoende zou kunnen alkaliniseren, zonder de uitscheiding in de urine van de diverse 
eiwitten te beïnvloeden. In Hoofdstuk 7 laten we zien, dat de toepassing van acetazolamide de 
urine pH adequaat verhoogde, zodat het meten van de β2-microglobuline excretie in de urine 
mogelijk bleek, zonder de hoogte van de excretie te beïnvloeden. Echter, er traden frequente 
bijwerkingen op, vooral bestaande uit paresthesiën (58%), smaakveranderingen (32%) en 
duizeligheid (29%). Hoewel deze bijwerkingen niet ernstig waren, belemmeren ze wel het 
routinematige gebruik van acetazolamide. 
  
In het perspectief van de waarde van de uitscheiding in de urine van β2-microglobuline en IgG 
ter voorspelling van het optreden van achteruitgang van nierfunctie bij patiënten met een 
normale nierfunctie, onderzochten we de veranderingen in de excretie van deze laag- en hoog-
moleculaire eiwitten gedurende en na behandeling met immunosuppressie. 
In Hoofdstuk 8 beschrijven we het tijdsbeloop van de excretie in de urine van deze eiwitten 
na het starten van therapie en de waarde in het voorspellen van de uitkomst op de lange 
termijn. Elf patiënten ondergingen herhaalde gestandaardiseerde metingen van de uitscheiding 
in de urine van IgG, β2-microglobuline en α1-microglobuline tijdens het jaar van behandeling. 
We zagen een snelle verbetering in de selectiviteit van de glomerulaire permeabiliteit en van 
de tubulaire eiwitresorptie in de eerste twee maanden na het starten van de therapie. Echter, 
ondanks het optreden van een partiële remissie van de proteïnurie in de eerste 12 maanden bij 
de meeste patiënten, bleven er duidelijke tekenen van tubulo-interstitiële schade bestaan. 
Teneinde de predictieve waarde van de uitscheiding in de urine van de hoog- en laag-
moleculaire eiwitten aan het eind van het behandelingsjaar te kunnen onderzoeken, werden bij 
25 patiënten metingen verricht op 12 maanden. Het bleek echter, dat de urinewaarden voor 
IgG, β2-microglobuline en α1-microglobuline noch aan het begin van de behandeling noch op 
12 maanden het optreden van een remissie of een recidief nefrotisch syndroom konden 
voorspellen. Zeventien patiënten ondergingen metingen 2-5 jaar na het starten van de 
immunosuppressieve behandeling. In het geval van een persisterende stabiele remissie zagen 
we een geleidelijke afname van het urine β2-microglobuline tot normale waarden, terwijl in 
geval van een recidief nefrotisch syndroom het β2-microglobuline in de urine steeg. De 
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verkregen waarden bij deze studie stelden ons in staat de relatie te onderzoeken tussen de 
tubulaire resorptie van β2-microglobuline en de uitscheiding in de urine van IgG. Hieruit 
konden we concluderen dat de uitscheiding in de urine van β2-microglobuline niet het gevolg 
is van het remmen van de resorptie ervan door IgG, waarmee de waarde van het β2-
microglobuline als marker voor tubulo-interstitiële schade werd bevestigd.  
 
In Hoofdstuk 9 stellen we een rationele behandelingsstrategie voor ter behandeling van 
patiënten met idiopathische membraneuze glomerulopathie, gebaseerd op een evaluatie van de 
literatuurgegevens hieromtrent en onze eigen ervaringen. De voorgestelde strategie wordt 
weergegeven in Figuur 1. 
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maandagen, zoals ik ze in de laatste jaren heb gekend, niet alleen efficiënt maar ook gezellig 
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